<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003155.pub3" GROUP_ID="DEMENTIA" ID="531701041300135475" MERGED_FROM="" MODIFIED="2008-03-19 16:30:18 +0100" MODIFIED_BY="Helen Collins" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-03-19 16:30:18 +0100" MODIFIED_BY="Helen Collins">
<TITLE>Metrifonate for Alzheimer's disease</TITLE>
<CONTACT MODIFIED="2008-03-19 16:30:18 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="8725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jess</FIRST_NAME><LAST_NAME>López-Arrieta</LAST_NAME><EMAIL_1>pdarrieta@wanadoo.es</EMAIL_1><EMAIL_2>jlopezar.hgugm@salud.madrid.org</EMAIL_2><ADDRESS><DEPARTMENT>Geriatric Department</DEPARTMENT><ORGANISATION>Hospital Universitario La Paz-Cantoblanco</ORGANISATION><ADDRESS_1>Ctra de Colmenar km 14,500</ADDRESS_1><CITY>Madrid</CITY><ZIP>28049</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 915 86 76 27</PHONE_1><PHONE_2>+ 34 610 926 479</PHONE_2><FAX_1>+34 915 86 75 82</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-03-19 16:30:18 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="8725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jess</FIRST_NAME><LAST_NAME>López-Arrieta</LAST_NAME><EMAIL_1>pdarrieta@wanadoo.es</EMAIL_1><EMAIL_2>jlopezar.hgugm@salud.madrid.org</EMAIL_2><ADDRESS><DEPARTMENT>Geriatric Department</DEPARTMENT><ORGANISATION>Hospital Universitario La Paz-Cantoblanco</ORGANISATION><ADDRESS_1>Ctra de Colmenar km 14,500</ADDRESS_1><CITY>Madrid</CITY><ZIP>28049</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 915 86 76 27</PHONE_1><PHONE_2>+ 34 610 926 479</PHONE_2><FAX_1>+34 915 86 75 82</FAX_1></ADDRESS></PERSON><PERSON ID="7068" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lon</FIRST_NAME><LAST_NAME>Schneider</LAST_NAME><POSITION>Professor of Psychiatry, Neurology, and Gerontology</POSITION><EMAIL_1>lschneid@usc.edu</EMAIL_1><ADDRESS><ORGANISATION>University of Southern California Keck School of Medicine</ORGANISATION><ADDRESS_1>1510 San Pablo St, HCC 600</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>90033</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 323 442 7600</PHONE_1><FAX_1>+1 323 442 7601</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-03-19 14:55:33 +0000" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="29" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="3" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-03-19 14:54:54 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-03-19 14:54:54 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="19" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>There are unlikely to be any further studies of metrifonate as Bayer stopped research when they found severe adverse effects in many patients</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-17 16:12:20 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>A new update search was done for this review on 29 February 2008. No new studies that met the inclusion criteria were retrieved by the search.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-03-17 14:31:12 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-17 14:31:12 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="22" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>New studies sought but none found: 12/5/05</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="16" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-03-19 15:06:55 +0000" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-03-17 14:46:17 +0000" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-03-17 14:44:52 +0000" MODIFIED_BY="Helen Collins">Metrifonate for Alzheimer's disease</TITLE>
<SUMMARY_BODY MODIFIED="2008-03-17 14:46:17 +0000" MODIFIED_BY="Helen Collins">
<P>Metrifonate cannot be recommended for the treatment of Alzheimer's disease.</P>
<P>Metrifonate is a long-acting irreversible cholinesterase inhibitor. We reviewed the evidence for its efficacy in Alzheimer's disease and assessed adverse events and tolerability. At various doses it was associated with significant cognitive improvement compared to placebo, improvement in clinical global impression, and activities of daily living.</P>
<P>Neuromuscular dysfunction with life-threatening respiratory failure and death was reported by the pharmaceutical company and FDA, and the drug will not be further developed.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-03-19 14:57:21 +0000" MODIFIED_BY="Helen Collins">
<ABS_BACKGROUND MODIFIED="2008-03-19 14:56:59 +0000" MODIFIED_BY="Helen Collins">
<P>Metrifonate is a long-acting irreversible cholinesterase inhibitor, originally used to treat schistosomiasis. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's disease (AD). Although low incidence of serious side effects occurred during short-term use as an antihelmintic, in studies of the treatment of AD extending over six months, 20 patients experienced respiratory paralysis and problems with neuromuscular transmission. These findings have led to a halt to trials of metrifonate for AD and Bayer, the pharmaceutical company, has withdrawn its FDA application.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-03-19 14:57:21 +0000" MODIFIED_BY="Helen Collins">
<P>1) To establish the efficacy of metrifonate for patients with Alzheimer's disease, in terms of cognition, global impression, functional activity, non cognitive symptoms, rate of institutionalization and mortality.<BR/>2) To assess the safety and tolerability of metrifonate.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-03-18 15:51:29 +0000" MODIFIED_BY="Helen Collins">
<P>The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched on 29 February 2008 using the term metrifonat*. The CDCIG Specialized Register contains records from all major health care databases (<I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources. One of the authors (LS), as member of the Metrifonate Study Group, has had the opportunity to contact other metrifonate trialists to obtain data from potentially non published data of metrifonate clinical trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All unconfounded, randomized double-blind clinical controlled trials comparing metrifonate to placebo in people with AD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted by the two reviewers, cross-checked, and pooled when appropriate and possible. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Most studies assessed changes in cognitive function, global function, activities of daily living, behavioural problems, severity of disease and adverse events. Occasionally the results were not reported in sufficient detail to allow extraction of data for the meta-analyses. The treatment regimens were varied: loading doses were used in some trials. The range of maintenance doses and studies were not pooled unless the treatment regimens were considered comparable. The lengths of treatment varied from 6 to 26 weeks and studies were not pooled unless the treatment duration was similar. The results are derived from the ITT populations.</P>
<P>Metrifonate at various doses, fixed and loading doses, was associated with significant cognitive improvement compared to placebo, except for weekly doses where there was no difference from placebo: MMSE (metrifonate 60-80 mg/day with initial loading at 26 weeks; metrifonate 50 mg/day fixed dose with no initial loading at 26 weeks MD 1.85, 95% CI 1.06 to 2.64, p&lt;0.00001); ADAS-Cog (metrifonate 60-80 mg/day with initial loading at 26 weeks MD -3.24, 95% CI -4.40 to -2.08, p&lt;0.00001)</P>
<P>In most trials, there was improvement in clinical global impression: CIBIC-Plus (metrifonate 30-55 mg/day, approximately 0.65 mg/kg body weight, with initial loading at 26 weeks MD -0.25, 95% CI -0.41 to -0.09 p=0.002; metrifonate 50 mg/day fixed dose with no initial loading at 26 weeks MD -0.20, 95% CI -0.39 to -0.01, p=0.04).</P>
<P>There were generally-significant drug-placebo differences in activities of daily living but this often depended on sample size and the characteristics of the instrument used: DAD (metrifonate 30-55 mg/day, 0.65 mg/kg body weight, with initial loading at 26 weeks MD 2.72, 95% CI 0.66 to 4.77, p=0.01; metrifonate 50 mg/day fixed dose with no initial loading at 26 weeks MD 4.07, 95% CI 0.29 to 7.85, p=0.03)</P>
<P>Also there were differences associated with metrifonate compared with placebo for different doses of metrifonate in scores on a behavioural symptom scale, caregiver burden scale, and severity of disease scale.<BR/>
<BR/>Adverse events occurring more often with metrifonate included abdominal pain, bloating, bradycardia, diarrhoea, leg cramps, nausea and rhinitis and were described as mostly mild and transient, but occasionally moderately severe, and infrequently severe and serious. Analysis of the number of patients suffering at least one mild, moderate, severe or serious adverse event before the end of treatment showed that there was usually no difference between placebo and metrifonate.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>
<BR/>Metrifonate given once per day appears to be related to clinical response in cognition, global improvement, and activities of daily living in patients with mild to moderate Alzheimer's disease.<BR/>Tolerability is good with adverse events as expected from a cholinesterase inhibitor, but with a low incidence of neuromuscular dysfunction and respiratory failure, too low to be detected in this review. It has been withdrawn from further development. <BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-03-19 15:04:15 +0000" MODIFIED_BY="Helen Collins">
<BACKGROUND MODIFIED="2008-03-19 15:01:13 +0000" MODIFIED_BY="Helen Collins">
<CONDITION MODIFIED="2008-03-19 14:59:43 +0000" MODIFIED_BY="Helen Collins">
<P>Alzheimer's disease (AD) is the most common form of dementia, affecting as many as 30 to 50% of individuals aged 85 and older (<LINK REF="REF-Evans-1989" TYPE="REFERENCE">Evans 1989</LINK>). It is characterized by gradual onset, with a progressive decline in intellectual function that causes a heavy emotional and financial burden on affected individuals and caregivers.</P>
<P>The cause of AD is unknown, although there has been considerable progress in knowledge of its pathophysiology. The development of treatments for Alzheimer's disease has been based on the cholinergic hypothesis, which postulates that cognitive impairment is caused by a deficit in cholinergic neurotransmission between neurons (<LINK REF="REF-Bartus-1982" TYPE="REFERENCE">Bartus 1982</LINK>). Several strategies have been used to enhance central cholinergic function in people with AD. ACh precursors, ACh release facilitators, and ACh receptor agonists have been employed, as have inhibitors of the enzyme acetylcholinesterase that breaks down ACh. Tacrine, donepezil, galantamine and rivastigmine, inhibitors of acetylcholinesterase (AChE), have been approved for the treatment of AD.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-03-19 15:00:15 +0000" MODIFIED_BY="Helen Collins">
<P>Metrifonate was introduced as a drug for the treatment of schistosomiasis in the 1960s. On the basis of a comparative pharmacological study with physostigmine, the first cholinesterase inhibitor to be tested clinically in AD, metrifonate was observed to possess a number of pharmacological properties suggesting its suitability for the treatment of AD (<LINK REF="REF-Hallak-1987" TYPE="REFERENCE">Hallak 1987</LINK>). By virtue of its in vitro and in vivo characteristics, it was suggested that metrifonate might be a drug suitable for the cholinergic approach to treating people with AD (<LINK REF="REF-Becker-1990" TYPE="REFERENCE">Becker 1990</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2008-03-19 15:00:34 +0000" MODIFIED_BY="Helen Collins">
<P>Metrifonate is unique as a cholinesterase inhibitor in that it is a prodrug that is non-enzymatically transformed into its active metabolite 2,2-dimethyl dichlorovinyl phosphate (<LINK REF="REF-Nordgren-1978" TYPE="REFERENCE">Nordgren 1978</LINK>). Metrifonate inhibits both AChE and butyrylcholinesterase (BuChE) activity in rodent and human brain cortex (<LINK REF="REF-Giovannini-1998" TYPE="REFERENCE">Giovannini 1998</LINK>). The non-selectivity of metrifonate for the ChE forms may offer a therapeutic advantage over other more selective compounds. By inhibiting both enzymes the drug may act throughout the disease process (<LINK REF="REF-Ogane-1992" TYPE="REFERENCE">Ogane 1992</LINK>). In addition to exerting its pharmacological actions through cholinesterase inhibition, metrifonate also inhibits other serine enzymes (esterases and phosphatases) which means it might regulate the amyloid precursor protein (APP) cleavage and APP release involved in the brain damage of Alzheimer's disease (<LINK REF="REF-Mori-1992" TYPE="REFERENCE">Mori 1992</LINK>).</P>
<P>Oral administration of metrifonate enhanced reference memory and passive avoidance behaviour in older rats but only passive avoidance in very aged rats (&gt;24 months) (<LINK REF="REF-Blokland-1995" TYPE="REFERENCE">Blokland 1995</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-03-19 15:01:58 +0000" MODIFIED_BY="Helen Collins">
<P>The first human trials reported a significantly improved cognitive and global function with few side effects (<LINK REF="REF-Becker-1990" TYPE="REFERENCE">Becker 1990</LINK>; <LINK REF="REF-Cummings-1998" TYPE="REFERENCE">Cummings 1998</LINK>). Later randomized controlled trials of metrifonate for people with AD followed FDA guidelines in looking for efficacy in cognitive, clinical global and functional measures. A pooled analysis of four RCTs showed metrifonate to improve behaviour, cognition, function in activities of daily living and global functional status of patients with mild to moderate AD (<LINK REF="REF-Farlow-2000" TYPE="REFERENCE">Farlow 2000</LINK>).</P>
<P>In the development of any new drug for a new indication, there must be concern for long-term toxicity, especially so for a medication, such as a cholinesterase inhibitor, that has multiple neurotransmitter effects. No signs of neurotoxicity from metrifonate were found in experiments with chickens in highly sensitive tests for organophosphate neurotoxicity (<LINK REF="REF-Sherman-1961" TYPE="REFERENCE">Sherman 1961</LINK>), nor in Rhesus monkeys treated with metrifonate at various doses for a period of 10 years (<LINK REF="REF-Scali-1997" TYPE="REFERENCE">Scali 1997</LINK>). An extensive review of metrifonate's toxicology and pharmacology during its use for schistosomiasis (<LINK REF="REF-Holmstedt-1978" TYPE="REFERENCE">Holmstedt 1978</LINK>) in Western Europe, the Americas or Australia, concluded that it had very few adverse effects and was at least as safe as other antihelmintics.</P>
<P>Of concern, however, was that approximately 20 patients out of 3000 in the metrifonate clinical studies for AD that were in the New Drug Application submitted to the FDA developed "asthenia, myasthenia, and malaise," and "four patients with muscular weakness received respiratory support" (Personal communication from Bayer Pharmaceuticals, September 18, 1998). Because of the seriousness of this neuromuscular dysfunction, metrifonate has been withdrawn from further clinical development for AD (<LINK REF="REF-Alz-Forum-2005" TYPE="REFERENCE">Alz Forum 2005</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness and safety of metrifonate for Alzheimer's disease, reviewing the literature on the use of metrifonate in the treatment of Alzheimer's disease, with an emphasis on the quality and quantity of the reported studies.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Relevant unconfounded, double-blind, randomized, placebo controlled studies were considered for inclusion. Studies in which the allocation to treatment was not random, or in which treatment allocation was not concealed were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies in which patients with AD have been treated with metrifonate were considered for inclusion. Patients with other dementias, major depression or delirium were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies in which metrifonate is given at any dose and for any time period were considered for inclusion. Studies must involve comparison of metrifonate with placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Outcomes of interest include: <BR/>1. Cognitive function<BR/>2. Functional performance<BR/>3. Global impression of change (of carer and/or health care professional)<BR/>4. Behavioural symptom measures<BR/>5. Quality of life and/or general well-being<BR/>6. Institutionalization<BR/>7. Effect on carer<BR/>8. Acceptability and safety of treatment (including withdrawal rates, incidence of adverse side effects and other measures)<BR/>9. Death</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-03-19 15:03:38 +0000" MODIFIED_BY="Helen Collins">
<ELECTRONIC_SEARCHES MODIFIED="2008-03-19 15:04:15 +0000" MODIFIED_BY="Helen Collins">
<P>The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 29 February 2008 using the search term: metrifonat*.</P>
<P>This register contains records from the following major healthcare databases <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS, and many ongoing trial databases and other grey literature sources. The following search terms were used:</P>
<P>
<I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO and CINAHL were searched separately on 29 February 2008 for records added to these databases after December 2005 to February 2008. The search terms used to identify relevant controlled trials on dementia, Alzheimer's disease and mild cognitive impairment for the Group's Specialized Register can be found in the Group's module on <I>The Cochrane Library</I>. These search terms were combined with the following search terms and adapted for each database, where appropriate:</P>
<P>On 29 February 2008, the Specialized Register consisted of records from the following databases:</P>
<P>
<B>Healthcare databases:</B>
</P>
<P>
<I>The Cochrane Library</I>: (2006, Issue 1);</P>
<P>MEDLINE (1966 to 2006/07, week 5);</P>
<P>EMBASE (1980 to 2006/07);</P>
<P>PsycINFO (1887 to 2006/08, week 1);</P>
<P>CINAHL (1982 to 2006/06);</P>
<P>SIGLE (Grey Literature in Europe) (1980 to 2005/03);</P>
<P>LILACS: Latin American and Caribbean Health Science Literature (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F) (last searched 29 August 2006).</P>
<P>
<B>Conference proceedings:</B>
</P>
<P>ISTP (http://portal.isiknowledge.com/portal.cgi) (Index to Scientific and Technical Proceedings) (to 29 August 2006);</P>
<P>INSIDE (BL database of Conference Proceedings and Journals) (to June 2000);.</P>
<P>
<B>Theses:</B>
</P>
<P>Index to Theses (formerly ASLIB) (http://www.theses.com/) (UK and Ireland theses) (1716 to 11 August 2006);</P>
<P>Australian Digital Theses Program (http://adt.caul.edu.au/): (last update 24 March 2006);</P>
<P>Canadian Theses and Dissertations (http://www.collectionscanada.ca/thesescanada/index-e.html): 1989 to 28 August 2006);</P>
<P>DATAD - Database of African Theses and Dissertations (http://www.aau.org/datad/backgrd.htm);</P>
<P>Dissertation Abstract Online (USA) (http://wwwlib.umi.com/dissertations/gateway) (1861 to 28 August 2006).</P>
<P>
<B>Ongoing trials:</B>
</P>
<P>
<I>UK</I>
</P>
<P>National Research Register (http://www.update-software.com/projects/nrr/) (last searched issue 3/2006);</P>
<P>ReFeR (http://www.refer.nhs.uk/ViewWebPage.asp?Page=Home) (last searched 30 August 2006);</P>
<P>Current Controlled trials: Meta Register of Controlled trials (mRCT) (http://www.controlled-trials.com/) (last searched 30 August 2006) :</P>
<P>ISRCTN Register - trials registered with a unique identifier</P>
<P>Action medical research</P>
<P>Kings College London</P>
<P>Laxdale Ltd</P>
<P>Medical Research Council (UK)</P>
<P>NHS Trusts Clinical Trials Register</P>
<P>National Health Service Research and Development Health Technology Assessment Programme (HTA)</P>
<P>National Health Service Research and Development Programme 'Time-Limited' National Programmes</P>
<P>National Health Service Research and Development Regional Programmes</P>
<P>The Wellcome Trust</P>
<P>Stroke Trials Registry (http://www.strokecenter.org/trials/index.aspx) (last searched 31 August 2006);</P>
<P>
<I>Netherlands</I>
</P>
<P>Nederlands Trial Register (http://www.trialregister.nl/trialreg/index.asp) (last searched 31 August 2006);</P>
<P>
<I>USA/International</I>
</P>
<P>ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last searched 31 August 2006)</P>
<P>(contains all records from http://clinicalstudies.info.nih.gov/);</P>
<P>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html. The Ongoing Trials database within this Register searches http://www.controlled-trials.com/isrctn, http://www.ClinicalTrials.gov and http://www.centerwatch.com/. The ISRCTN register and Clinicaltrials.gov are searched separately. Centerwatch is very difficult to search for our purposes and no update searches have been done since 2003.</P>
<P>The IFPMA Trial Results databases searches a wide variety of sources among which are:</P>
<P>http://www.astrazenecaclinicaltrials.com (seroquel, statins)</P>
<P>http://www.centerwatch.com</P>
<P>http://www.clinicalstudyresults.org</P>
<P>http://clinicaltrials.gov</P>
<P>http://www.controlled-trials.com</P>
<P>http://ctr.gsk.co.uk</P>
<P>http://www.lillytrials.com (zyprexa)</P>
<P>http://www.roche-trials.com (anti-abeta antibody)</P>
<P>http://www.organon.com</P>
<P>http://www.novartisclinicaltrials.com (rivastigmine)</P>
<P>http://www.bayerhealthcare.com</P>
<P>http://trials.boehringer-ingelheim.com</P>
<P>http://www.cmrinteract.com</P>
<P>http://www.esteve.es</P>
<P>http://www.clinicaltrials.jp</P>
<P>
<I>This part of the IPFMA database is searched and was last updated on 4 September 2006;</I>
</P>
<P>Lundbeck Clinical Trial Registry (http://www.lundbecktrials.com) (last searched 15 August 2006);</P>
<P>Forest Clinical trial Registry (http://www.forestclinicaltrials.com/) (last searched 15 August 2006). </P>
<P>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module on <I>The Cochrane Library</I>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-03-19 15:03:15 +0000" MODIFIED_BY="Helen Collins">
<P>In addition dementia organisations, drug manufacturer and lead investigators in this research area were contacted to request further studies, particularly unpublished evidence. One of the authors (LS), as member of the Metrifonate Study Group has had the opportunity to contact other metrifonate trialists to obtain data from potentially non published data of metrifonate clinical trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of trials</B>
<BR/>A single reviewer (JLA) eliminated irrelevant citations based on the title and abstract of the article. Articles that were relevant or possibly relevant were obtained for further assessment. Two reviewers (LS and JLA) independently selected trials for inclusion in the review from the culled citation list. Disagreements were resolved where possible by discussion. A third reviewer (JB) adjudicated persisting differences.</P>
<P>
<B>Quality Assessment </B>
<BR/>Two reviewers (LS and JLA) assessed the methodological quality of each trial, using the Cochrane Collaboration guidelines (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>). </P>
<P>Category A (adequate) is where the report describes allocation of treatment by: (i) some form of centralized randomized scheme, such as having to provide details of an enrolled participant to a centralized office by phone to receive the treatment group allocation; (ii) some form of randomization scheme run by a pharmacy; (iii) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administered sequentially to enrolled participants; (iv) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed opaque envelopes; (vi) other combinations of described elements of the process that provides assurance of adequate concealment. </P>
<P>Category B (intermediate) is where the report describes allocation of treatment by: (i) use of a 'list' or 'table' to allocate assignments; (ii) use of 'envelopes' or 'sealed envelopes'; (iii) stating the study as 'randomized' without further detail.</P>
<P>Category C (inadequate) is where the report describes allocation of treatments by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any other such approach; (iii) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments. </P>
<P>Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, but less pronounced than inadequately concealed trials (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Thus trials were included if they conformed to categories A or B, and those falling into category C were excluded. Other aspects of trial quality will not be assessed by a scoring system although details will be noted of blinding, whether intention-to-treat analyses were extractable from the published data, and the number of patients lost to follow-up.</P>
<P>
<B>Data Extraction</B>
<BR/>The data were extracted by the co-ordinating editor of CDCIG. Data were extracted from the published reports. The summary statistics required for each trial and each outcome for continuous data are the mean change from baseline, the standard error of the mean change, and the number of patients for each treatment group at each assessment. </P>
<P>For binary data the numbers in each treatment group and the numbers experiencing the outcome of interest were sought. </P>
<P>The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months prior. </P>
<P>For each outcome measure, data were sought on every patient randomized. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data were not available in the publications, "on-treatment" or the data of those who complete the trial was sought and indicated as such. </P>
<P>
<B>Data Analysis<BR/>
</B>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 6) the data are treated as continuous outcomes arising from a normal distribution.</P>
<P>Summary statistics (n, mean and standard deviation) are required for each rating scale at each assessment time for each treatment group in each trial for change from baseline. The meta-analysis requires the combination of data from the trials that may not use the same rating scale to assess an outcome. The measure of the treatment difference for any outcome is the weighted mean difference when the pooled trials use the same rating scale or test, and the standardized mean difference, which is the absolute mean difference divided by the standard deviation when they used different rating scales or tests. </P>
<P>The duration of the trials varies considerably. The range is considered too great to combine all trials into one meta-analysis and it is divided into smaller time periods and a separate meta-analysis conducted for each period. Some trials may contribute data to more than one time period if multiple assessments have been done.</P>
<P>For binary outcomes, such as clinical improvement or no clinical improvement, the odds ratio is used to measure treatment effect. A weighted estimate of the typical treatment effect across trials is calculated.</P>
<P>Overall estimates of the treatment difference are presented. In all cases the overall estimate from a fixed effects model is presented and a test for heterogeneity using a standard chi-square statistic or the I-squared statistic is performed. If, however, there is evidence of heterogeneity of the treatment effect between trials then either only homogeneous results are pooled, or a random-effects model is used (in which case the confidence intervals are broader than those of a fixed-effects model).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>There are eight included studies and four excluded studies. Most of the included studies were designed to assess the safety, tolerability and efficacy of metrifonate in patients with probable Alzheimer's disease of mild to moderate severity. One study investigated whether metrifonate slowed cognitive decline (<LINK REF="STD-Becker-1998" TYPE="STUDY">Becker 1998</LINK>). The studies have all been reported since 1996. Six studies were sponsored by the manufacturer of metrifonate, Bayer Corporation. Two studies, <LINK REF="STD-Becker-1996" TYPE="STUDY">Becker 1996</LINK> and <LINK REF="STD-Becker-1998" TYPE="STUDY">Becker 1998</LINK>, were supported by grants from the National Institute of Mental Health and the National Institute of Aging Alzheimer's Disease Center. 2285 patients were included in the eight studies, and the size of a study ranged from 39 to 599 patients. The average patient age within a study ranged from 71.4 to 74.6 years, the average MMSE from 18 to 20, and the percentage of patients who were men ranged from 34% to 51%. The characteristics of the studies are summarized in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. All studies were randomized, double-blind placebo-controlled parallel group studies, comparing metrifonate with placebo. Seven studies were carried out in North America and one in the UK and France (<LINK REF="STD-MALT-Study-Group" TYPE="STUDY">MALT Study Group</LINK>). The details of the studies at baseline are reported in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Diagnosis of probably Alzheimer's disease was made according to NINCDS-ADRDA criteria in 7 studies and by DSM-IV criteria in the eighth.</P>
<P>Six studies began the randomized phase with a loading dose of metrifonate, lasting between one and three weeks, that was designed to achieve the target erythrocyte acetylcholinesterase inhibition more rapidly and achieve efficacy as soon as possible, followed by a lower maintenance dose. One study used no loading dose (<LINK REF="STD-Raskind-1999" TYPE="STUDY">Raskind 1999</LINK>), and one study compared a regimen with a loading dose with a no-loading dose regimen (<LINK REF="STD-Jann-1999" TYPE="STUDY">Jann 1999</LINK>). Two older studies (<LINK REF="STD-Becker-1996" TYPE="STUDY">Becker 1996</LINK> and <LINK REF="STD-Becker-1998" TYPE="STUDY">Becker 1998</LINK>) used a weekly dose, the other studies used a daily dose. Most studies used a dose that depended on body weight, but two used a fixed dose. The daily dose varied between 13 and 190 mg/day, for a person of 65 kgs. The exact details of the dosing regimens are reported in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<P>Exclusion criteria were extensive for the 6 later studies. Patients were excluded with CNS disorders other than Alzheimer's disease, with current major depression, bipolar disorder, or schizophrenia, with significant medical conditions such as uncontrolled diabetes, neoplasm or respiratory disease. Concomitant medications with potential cognitive effects were not allowed.</P>
<P>The outcome measures used in the studies are described in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Cognitive tests include the Mini-mental test Examination (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog). Activities of daily living were assessed using the Disability Assessment for Dementia (DAD) and the Activities of Daily Living Checklist (ADCL). Behavioural problems were assessed using the Alzheimer's Disease Assessment Scale-Noncognitive (ADAS-Noncog) and the Neuropsychiatric Inventory (NPI). The burden on carers was assessed using the Abridged Relatives Stress Scale (aRSS), the Caregiver Activity Time Survey (CATS), the Poulshock and Deimling cognitive subscale (PD) and the Screen for Caregiver Burden (SCB). Clinical global impression was assessed using the Clinical Global Impression (CGI) or the Clinician's Interview-Based Impression of Change with carer input (CIBIC-plus. Severity of disease was assessed by the Global Deterioration Scale (GDS) or the Clinician's Interview-Based Impression of Severity (CIBIS).</P>
<P>The reported analyses were performed on an intention -to- treat basis (ITT), which included all patients who were randomized to treatment, assessed at baseline, received at least one dose of the study drug, and had at least one post baseline assessment. Patients were included in the safety analysis if they took at least one dose of the study medication and had any post baseline safety assessments. All efficacy variables were analysed as a change from baseline except for the CIBIC-Plus, for which the value itself was analysed. The variables were analysed using an ANOVA model with centre (if appropriate), centre by treatment interaction, and treatment in the model.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All the included studies were described as randomized, placebo-controlled and double-blind. <LINK REF="STD-Raskind-1999" TYPE="STUDY">Raskind 1999</LINK>, <LINK REF="STD-Morris-1998" TYPE="STUDY">Morris 1998</LINK> and <LINK REF="STD-Cummings-1996" TYPE="STUDY">Cummings 1996</LINK> described the randomization as taking place according to a computer generated randomization code, and <LINK REF="STD-Morris-1998" TYPE="STUDY">Morris 1998</LINK> further confirmed that only a statistician had access to the code, with investigators blinded until the study database was complete. The other studies offered no description of the method of randomization, but it is known that all studies except <LINK REF="STD-Becker-1996" TYPE="STUDY">Becker 1996</LINK> and <LINK REF="STD-Becker-1998" TYPE="STUDY">Becker 1998</LINK> were blinded and randomized according to GCP standards. <BR/>
<BR/>The number of non-completers was small in all studies, less than 12% in the shorter studies and less than 20% in the 6 month studies, and there was little difference between the groups. The main cause of non-completion was adverse events.<BR/>The design of <LINK REF="STD-Becker-1996" TYPE="STUDY">Becker 1996</LINK> was compromised by the replacement of non-completers by new patients until the desired number was achieved.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Of the eight included studies most assessed cognitive function, global function, activities of daily living, behavioural ratings, severity of disease and adverse events. Occasionally the results were not reported in sufficient detail to allow extraction of data for the meta-analyses. <LINK REF="STD-Blass-2000" TYPE="STUDY">Blass 2000</LINK> only contributed data on adverse events to the meta-analyses because of insufficient detail in the study report. Carer burden was only assessed by <LINK REF="STD-MALT-Study-Group" TYPE="STUDY">MALT Study Group</LINK>. The treatment regimens were varied due to the use of loading doses in some studies, and the range of maintenance doses and studies were not pooled unless the treatment regimens were considered comparable. The length of treatment also varied from 6 to 26 weeks and studies were not pooled unless the treatment duration was similar. </P>
<P>The results are derived from the ITT populations.</P>
<P>Cognitive function </P>
<P>MMSE: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks (MD 1.11, 95% CI 0.40 to 1.82, p=0.002)<BR/>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks (MD 1.37, 95% CI 0.66 to 2.08, p=0.0001)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD 1.19, 95% CI 0.48 to 1.90, p=0.0009)<BR/>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks (MD 1.85, 95% CI 1.06 to 2.64, p&lt;0.00001)</P>
<P>ADAS-Cog: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 50 mg/day with initial loading at 6 weeks (MD -1.50, 95% CI -2.64 to -0.36, p=0.01)<BR/>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks (MD -1.50, 95% CI -2.83 to -0.17, p=0.03)<BR/>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks (MD -1.30, 95% CI -2.61 to 0.01, p=0.05)<BR/>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks (MD -2.94, 95% CI -4.27 to -1.61, p&lt;0.0001)<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (MD -1.92, 95% CI -2.83 to -1.00, p&lt;0.0001)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -3.24, 95% CI -4.40 to -2.08, p&lt;0.00001)</P>
<P>
<BR/>Global Impression of Change</P>
<P>CIBIC-Plus: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 50mg/day with initial loading at 6 weeks (MD -0.2, 95% CI -0.36 to -0.04, p=0.02)<BR/>metrifonate 50mg/day with no initial loading at 6 weeks (MD -0.39, 95% CI -0.56 to -0.22, p&lt;0.00001)<BR/>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks (MD -0.29, 95% CI -0.49 to -0.09, p=0.004)<BR/>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks (MD -0.35, 95% CI -0.55 to -0.15, p=0.0005)<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (MD -0.25, 95% CI -0.41 to -0.09 p=0.002)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -0.35, 95% CI -0.58 to -0.12, p=0.003)<BR/>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks (MD -0.20, 95% CI -0.39 to -0.01, p=0.04)</P>
<P>Activities of Daily Living</P>
<P>DAD: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 26 weeks (MD 2.72, 95% CI 0.66 to 4.77, p=0.01)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD 5.45, 95% CI 2.39 to 8.51 p=0.0005)<BR/>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks (MD 4.07, 95% CI 0.29 to 7.85, p=0.03)</P>
<P>Behavioural ratings<BR/>NPI: There are benefits associated with metrifonate compared with placebo on total NPI score as shown by the following ITT analyses.<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (MD -1.81, 95% CI -3.41 to -0.20, p=0.03)<BR/>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks (MD -3.42, 95% CI -6.09 to -0.75, p=0.01)</P>
<P>ADAS-Noncog: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -1.37, 95% CI -2.17 to -0.57, p=0.0008)</P>
<P>
<BR/>Severity of disease</P>
<P>CIBIS-Plus: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (MD -0.20, 95% CI -0.30 to -0.10, p=0.0002)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -0.23, 95% CI -0.35 to -0.11, p=0.0001)</P>
<P>
<BR/>Carer burden</P>
<P>PD: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analyses.<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (MD -1.14, 95% CI -1.97 to -0.31, p=0.007)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -1.50, 95% CI -2.34 to -0.6611, p=0.0005)</P>
<P>aRSS: There are benefits associated with metrifonate compared with placebo as shown by the following ITT analysis.<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (MD -1.49, 95% CI -2.66 to -0.132, p=0.01)</P>
<P>Withdrawals before the end of treatment</P>
<P>The analysis of the numbers of withdrawals before the end of treatment, using the Peto odds ratio, showed that there was usually no difference between metrifonate and placebo, the two exceptions showing benefit for placebo.<BR/>metrifonate 50 mg/day with initial loading at 6 weeks (15/133 vs 4/134, OR=3.49, 95% CI 1.38 to 8.86, p=0.009) <BR/>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks (13/119 vs 5/120, OR 2.63, 95% CI 1.01 to 6.86, p=0.05 )</P>
<P>Withdrawals before the end of treatment due to adverse events</P>
<P>The analysis of the numbers of withdrawals before the end of treatment due to adverse events, using the Peto odds ratio, showed that there was usually no difference between metrifonate and placebo, the one exception showing benefit for placebo.<BR/>metrifonate 50 mg/day with initial loading at 6 weeks (8/132 vs 2/133, OR=3.49, 95% CI 0.99 to 12.32, p=0.05) </P>
<P>
<BR/>Adverse events</P>
<P>16 different types of adverse event were reported in the studies. These were qualitatively reported as mostly mild and transient, but occasionally moderately severe, and infrequently severe and serious.<BR/>The analysis of the number of patients suffering at least one mild, moderate, severe or serious adverse event before the end of treatment, using the Peto odds ratio, showed that there was usually no difference between placebo and metrifonate, the two exceptions showing benefit for placebo</P>
<P>Total number who suffered at least one moderately severe adverse event before the end of treatment<BR/>metrifonate 50 mg/day with no initial loading at 26 weeks (76/177 vs 20/87, OR=2.36, 95% CI 1.39 to 4.02, p=0.002) </P>
<P>Total number who suffered at least one severe adverse event before the end of treatment<BR/>metrifonate 50 mg/day with initial loading at 6 weeks (7/132 vs 0/133, OR=7.80, 95% CI 1.74 to 34.92, p=0.007) </P>
<P>There was a significant difference between metrifonate and placebo, in favour of placebo for several types of adverse events.<BR/>abdominal pain<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 12 weeks (14/119 vs 4/120, OR=3.34, 95% CI 1.28 to 8.71, p=0.01) <BR/>metrifonate 50 mg/day with no initial loading at 26 weeks (17/177 vs 2/87, OR=2.97, 95% CI 1.10 to 8.01, p=0.03) <BR/>bloating<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 12 weeks (7/119 vs 1/120, OR=4.73, 95% CI 1.16 to 19.31, p=0.03) <BR/>bradycardia<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (14/196 vs 4/206, OR=3.88, 95% CI 1.26 to 12.01, p=0.02) <BR/>diarrhoea<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 12 weeks (23/119 vs 10/120, OR=2.51, 95% CI 1.21 to 5.22, p=0.01) <BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (26/197 vs 10/206 OR=2.41, 95% CI 1.54 to 3.75, p=0.0001)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (22/196 vs 10/206, OR=2.38, 95% CI 1.16 to 4.90, p=0.02) <BR/>leg cramps<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (37/470 vs 2/340 OR=4.69, 95% CI 2.40 to 9.18, p&lt;0.00001)<BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (6/196 vs 1/206, OR=4.49, 95% CI 1.01 to 19.98, p=0.05) <BR/>metrifonate 60-80 mg/day with no initial loading at 26 weeks (18/177 vs 2/87, OR=3.06 95% CI 1.16 to 8.07, p=0.02) <BR/>nausea<BR/>metrifonate 50 mg/day with initial loading at 6 weeks (11/132 vs 3/133, OR=3.35, 95% CI 1.15 to 9.82, p=0.03) <BR/>metrifonate 60-80 mg/day with initial loading at 26 weeks (22/196 vs 8/206, OR=2.89, 95% CI 1.37 to 6.07, p=0.005) <BR/>rhinitis<BR/>metrifonate 30-55 mg/day (approximately 0.65 mg/kg body weight) with initial loading at 26 weeks (19/273 vs 2/134 OR=4.94, 95% CI 1.13 to 21.52, p=0.03)<BR/>metrifonate 60-80 mg/day with no initial loading at 26 weeks (17/177 vs 2/87, OR=4.52 95% CI 1.02 to 20.01, p=0.05) </P>
<P>There was a significant difference between metrifonate and placebo, in favour of metrifonate for two types of adverse events.<I>
<BR/>
</I>nausea<BR/>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks (3/121 vs 11/120, OR=0.30, 95% CI 0.10 to 0.87, p=0.03) <BR/>vomiting<BR/>metrifonate 95-180 mg/week (2.1 mg/kg body weight) with initial loading at 12 weeks (0/27 vs 4/23, OR=0.10 95% CI 0.01 to 0.75, p=0.03) </P>
<P>Six trials reported the change in heart rate (beats per minute as measured by ECG) from baseline (<LINK REF="STD-Blass-2000" TYPE="STUDY">Blass 2000</LINK>; <LINK REF="STD-Cummings-1996" TYPE="STUDY">Cummings 1996</LINK>; <LINK REF="STD-Jann-1999" TYPE="STUDY">Jann 1999</LINK>; <LINK REF="STD-MALT-Study-Group" TYPE="STUDY">MALT Study Group</LINK>; <LINK REF="STD-Morris-1998" TYPE="STUDY">Morris 1998</LINK>; <LINK REF="STD-Raskind-1999" TYPE="STUDY">Raskind 1999</LINK>). All reported a decrease in heart rate in the metrifonate group compared with placebo, and reported an effect size of between 4 and 7 bpm, except for the very lowest dose used in <LINK REF="STD-Cummings-1996" TYPE="STUDY">Cummings 1996</LINK> (reduction of 1). Only <LINK REF="STD-Raskind-1999" TYPE="STUDY">Raskind 1999</LINK> provided the standard error for the treatment effect, which showed a significant effect (MD -6.1, 95% CI -8.79 to -3.45, p&lt;0.00001, one study). <BR/>
<BR/>Only one study provided data on the number of deaths during treatment (<LINK REF="STD-MALT-Study-Group" TYPE="STUDY">MALT Study Group</LINK>), and there were no significant differences between metrifonate and placebo.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>2285 patients drawn from eight studies were included in this meta-analysis. All of the studies were published from 1996 or later, and most were sponsored by the manufacturer of metrifonate, Bayer Corporation. Patient populations were on average aged 73.5 years and suffered from mild to moderately severe AD; 38% of patients were men.</P>
<P>Early metrifonate trials and observations tended to use weekly doses; later trials used once-daily-doses to reduce fluctuation between peak and trough inhibition level. The earlier randomized controlled trials involved dose-ranging studies, followed by individualized dosage studies, both using a loading dose for the first few several weeks of treatment. The Phase III studies tended to use single individualized dosages or a fixed dose.</P>
<P>Metrifonate at various doses was associated with significant cognitive improvement compared to placebo, excepting for weekly doses where there was no difference. Higher doses were consistently more effective than lower doses. In addition, in most trials, there was improvement in clinical global impression, indicating not only a measurable cognitive improvement but also a clinically meaningful improvement which was clearly observable by a clinician.</P>
<P>There were generally-significant treatment effects in favour of metrifonate in activities of daily living but this often depended on sample size and the characteristics of the instrument used to measure the outcome. In assessment of behavioural symptoms, burden on carers, and severity of disease, metrifonate showed statistical differences in favour of metrifonate. The clinical significance of these changes are unclear however. </P>
<P>Critical review of the low-dose clinical trial results indicates that the level of cognitive improvement is comparable to that observed with other cholinesterase inhibitors, and reflects the expected deterioration in the placebo group combined with no change or a small cognitive improvement in the metrifonate group. The magnitude of improvement on the global impression is also similar to that observed in other cholinesterase inhibitor studies.</P>
<P>Metrifonate is generally well-tolerated in that the vast majority of metrifonate-treated patients enrolled in Phase III studies complete these clinical trials. Occurrence of significant side effects is rare and mainly affected patients receiving higher doses. Most adverse events are cholinergically mediated, and are described as mild in severity and short-lived, lasting only few days. Patients tend to rapidly become tolerant to the adverse events when they occur. The most commonly reported adverse events in the metrifonate groups include abdominal pain, diarrhoea, bloating, leg cramps, and rhinitis. For nausea and vomiting there were significantly more adverse events in the placebo groups. The modest decrease in heart rate at higher doses of medication is almost certainly due to vagotonic effects observed with this class of compound. The increased incidence of leg or muscle cramping also has been reported with other cholinesterase inhibitors. The most obvious reason for this is tonic stimulation of myoneural nicotinic receptors. </P>
<P>Metrifonate's association with myasthenia and respiratory failure may similarly be caused by tonic stimulation of the muscles of respiration. Notably, the neuromuscular dysfunction associated with metrifonate could not be detected in this review because adverse events at rates less than about 5% are usually not reported in clinical trials.<BR/>
<BR/>Because of the actions of cholinesterase inhibitors, these drugs require caution when used in patients with asthma, significant chronic obstructive pulmonary disease, cardiac conduction defects, or clinically significant bradycardia.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Relatively high and consistent levels of cholinesterase inhibition can be achieved with metrifonate given once per day, and appear to be related to clinical response in cognition, function activity, behaviour, severity of the disease, and caregiver burden of patients suffering mild to moderate Alzheimer's disease. With respect to efficacy it compares favourably with other cholinesterase inhibitors.</P>
<P>The ability to maintain constant levels of cholinesterase inhibition may also be responsible for the high degree of tolerability with respect to cholinergic side effects observed. </P>
<P>The clinical development of metrifonate has been terminated and metrifonate cannot be used for the treatment of Alzheimer's disease.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further research is needed to understand and to clarify the relationship between metrifonate treatment and neuromuscular dysfunction with life-threatening respiratory distress. Without this the drug cannot be further developed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Micheline Selmes for his contributions as consumer editor. Dr Arantxa Encinas-López (School of Chemistry, Universidad Autónoma de Madrid) and Dr Javier López (School of Psychology, Universidad San Pablo-CEU) for valuable comments on the manuscript. The reviewers would also like to thank Jacqueline Birks for her statistical assistance, Katherine Hicks and Dymphna Hermans of the CDCIG for all their help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-03-19 15:06:55 +0000" MODIFIED_BY="Helen Collins">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JLA: all correspondence; drafting of review versions, selection of trials, extraction of data; entry of data and interpretation of data analysis<BR/>LS: drafting of review versions, selection of trials, extraction of data and interpretation of data analysis</P>
<P>Contact editor: Mario Fioravanti<BR/>Consumer editor: Michelin Selmes</P>
<P>This review has been peer reviewed in January 2006</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-03-19 15:06:54 +0000" MODIFIED_BY="Helen Collins">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-03-19 15:18:51 +0000" MODIFIED_BY="Helen Collins">
<STUDIES MODIFIED="2008-03-19 15:17:53 +0000" MODIFIED_BY="Helen Collins">
<INCLUDED_STUDIES MODIFIED="2008-03-19 15:16:55 +0000" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1996" MODIFIED="2008-03-19 15:14:11 +0000" MODIFIED_BY="Helen Collins" NAME="Becker 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Becker R, Moriearty P, Unni L, Vicari S</AU>
<TI>Cholinesterase inhibition, the bad and good news</TI>
<SO>Fourth International Nice/Springfield Symposium in Alzheimer's Therapy</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:14:11 +0000" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE, Colliver JA, MArkwell SJ, Moriearty PL</AU>
<TI>Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease.</TI>
<SO>Alzheimer's Disease and Associated Disorders</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>124-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1998" MODIFIED="2008-03-19 15:14:44 +0000" MODIFIED_BY="Helen Collins" NAME="Becker 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-03-19 15:14:44 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE, Colliver JA, Moriearty PL, Unni LK, Vicari S</AU>
<TI>Effects of metrifonate on cognitive decline in Alzheimer's disease: a double-blind, placebo-controlled, 6-month study</TI>
<SO>Alzheimer's Disease and Associated Disorders</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blass-2000" NAME="Blass 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blass JP, Cyrus PA, Bieber F, Gulanski B, and Metrifonate Study Group</AU>
<TI>Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer's disease</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-1996" MODIFIED="2008-03-19 15:16:04 +0000" MODIFIED_BY="Helen Collins" NAME="Cummings 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-03-19 15:15:13 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ashford JW, Schmitt FA, Wermeling D, Bieber F, Orazem J, Gulanski B</AU>
<TI>Advantages of the "TIME-INDEX" method for measurement of Alzheimer dementia: assessment of metrifonate benefit</TI>
<SO>Alzheimer Disease: from Molecular Biology to Therapy</SO>
<YR>1996</YR>
<PG>431-4</PG>
<ED>Becker R and Giacobini E</ED>
<PB>Birkhauser</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bieber F, Mas J, Orazem J, Gulanski B</AU>
<TI>Results of a dose finding study with metrifonate in patients with Alzheimer's disease</TI>
<SO>Proceedings of the 4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy; 1996 April 10-14, Nice France</SO>
<YR>1996</YR>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings J, Bieber F, Mas J, Orazem J, Gulanski B</AU>
<TI>Metrifonate in Alzheimer's disease results of a dose finding study</TI>
<SO>Neurobiology of Aging</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S153-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:15:31 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Cummings J, Bieber F, Mas J, Orazem J, Gulanski B</AU>
<TI>Metrifonate in Alzheimer's disease: Results of a dose-finding study</TI>
<SO>Alzheimer's Disease: Biology, Diagnosis and Therapeutics</SO>
<YR>1997</YR>
<PG>665-669</PG>
<ED>Iqbal K, Winblad B, Nishimura T, Takeda M and Wisniewski HM</ED>
<PB>John Wiley and Sons</PB>
<CY>Chicester, New York, Weiheim, Brisbane, Singapore, Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Bulanski B and Metrifonate Study Group</AU>
<TI>Metrifonate treatment for the cognitive deficits of Alzheimer's disease: Correction</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>1</NO>
<PG>332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:15:54 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, and Metrifonate Study Group</AU>
<TI>Metrifonate treatment of the cognitive deficits of Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<PG>1214-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:16:04 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cyrus P, Orazem J, Ruzicka B, Mas J, Bieber F, Gulanski B</AU>
<TI>Metrifonate treatment of Alzheimer's disease: influence of demographic characteristics</TI>
<SO>Proceedings of the 1997 Annual Meeting, The Amercian Geriatrics Society and The American Federation for Aging Research , May 1997</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jann-1999" NAME="Jann 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jann MW, Cyrus PA, Eisner LS, Margolin DI, Griffin T, Gulanski B and the Metrifonate Study Group</AU>
<TI>Efficacy and safety of a loading-dose regimen versus a no-loading dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>1</NO>
<PG>88-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MALT-Study-Group" NAME="MALT Study Group" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien DR</AU>
<TI>A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: The MALT Study</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>973-982</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKeith IG</AU>
<TI>The clinical trial protocol of the Metrifonate in ALzheimer's Trial (MALT)</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>2-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, Dubois B</AU>
<TI>The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT Clinical Trial</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2000</YR>
<VL>48</VL>
<PG>268-274</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson D, Dubois B, Shakespeare A, McKeith I, Shikiar R, Dartiques F, Sagnier PP</AU>
<TI>The effect of metrifonate on the burden to caregivers of patients with alzheimer's disease</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>S67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-1998" NAME="Morris 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cummings JL, Cyrus PA, Bieber F, Orazem J, Mas J, Gulanski B</AU>
<TI>The effect of metrifonate on the cognitive, functional and behavioral symptoms of Alzheimer's disease patients</TI>
<SO>Conference proceedings 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 March 8-11, San Diego, California</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufer D</AU>
<TI>Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Morris JC, Cyrus P, Orazem J, Mas J, Ruzicka B, Bieber F, Gulanski B</AU>
<TI>Metrifonate: potential therapy for Alzheimer's disease</TI>
<SO>15th World Congress of Neurology, Buenos Aires, September 14-19, 1997</SO>
<YR>1997</YR>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B</AU>
<TI>Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<PG>1222-1230</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskind-1999" MODIFIED="2008-03-19 15:16:55 +0000" MODIFIED_BY="Helen Collins" NAME="Raskind 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luckmann R</AU>
<TI>Metrifonate was effective in mild-to-moderate Alzheimer's disease</TI>
<SO>ACP Journal Club</SO>
<YR>1999</YR>
<VL>131</VL>
<NO>3</NO>
<PG>72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:16:55 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskind MA, Cyrus PA, Ruzicka BB, Gulanski B and the Metrifonate Study Group</AU>
<TI>The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>5</NO>
<PG>318-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-03-19 15:17:53 +0000" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Bieber-1995" NAME="Bieber 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bieber F, Pettigrew C, Mas JC, Schmitt FA, Wermeling DP</AU>
<TI>Results of a phase IIa clinical study using metrifonate in patients with probable Alzheimer's disease of mild to moderate severity</TI>
<SO>35th Annual Meeting, Orlando, Florida, May 31st-June 3rd, 1995</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bieber F, Pettigrew C, Mas JC, Schmitt FA, Wermeling DP</AU>
<TI>Results of a phase IIa clinical study with metrifonate</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<PG>554</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bieber RF, Meulin D, Ouvry I, Collins O, Curram J, Gibbons F, Gleeson M</AU>
<TI>Clinical studies of metrifonate as a treatment for Alzheimer's disease: an overview</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1997</YR>
<VL>150[Suppl]</VL>
<PG>59-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heining-1997" MODIFIED="2008-03-19 15:17:25 +0000" MODIFIED_BY="Helen Collins" NAME="Heining 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinig R, Boettcher M, Herman-Gnjidic Z, Pierce CH</AU>
<TI>Effects of a magnesium/aluminium hydroxide-containing antacid, cimetidine or ranitidine on the pharmacokinetics of metrifonate and its metabolite DDVP</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>1</NO>
<PG>67-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-03-19 15:17:25 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heining R, Versavel M, Breuel HP, Kuhlmann J</AU>
<TI>Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily</TI>
<SO>Conference Proceedings Sixth World Congress of Biological Psychiatry</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mega-2001" NAME="Mega 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mega MS, Dinov ID, Manese M, Felix J, Tran N, O'Connor SM, Masterman DM, Toga AW, Cummings JL, and the Laboratory of Neuro Imaging and Alzheimer's Disease</AU>
<TI>Anterior cingulate activation occurs across cholinesterase inhibitor therapy in Alzheimer's disease</TI>
<SO>Proceedings of the 10th Congress of the International Psychogeriatric Association; 2001 Sep 9-14, Nice, France</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>S108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petttigrew-1998" MODIFIED="2008-03-19 15:17:53 +0000" MODIFIED_BY="Helen Collins" NAME="Petttigrew 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-03-19 15:17:53 +0000" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, et al</AU>
<TI>Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>3</NO>
<PG>236-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-03-19 15:18:51 +0000" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES MODIFIED="2008-03-19 15:18:51 +0000" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Alz-Forum-2005" NAME="Alz Forum 2005" TYPE="OTHER">
<AU>Alzheimer's Research Forum</AU>
<TI>Drugs in clinical trials: metrifonate</TI>
<SO>http://www.alzforum.org/dis/tre/drc/detail.asp?id=74</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bartus-1982" MODIFIED="2008-03-19 15:07:49 +0000" MODIFIED_BY="Helen Collins" NAME="Bartus 1982" TYPE="JOURNAL_ARTICLE">
<AU>Bartus RT, Dean RL, Beer B, Lippa AS</AU>
<TI>The cholinergic hypothesis of geriatric memory dysfunction</TI>
<SO>Science</SO>
<YR>1982</YR>
<VL>217</VL>
<PG>408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-1990" MODIFIED="2008-03-19 15:08:14 +0000" MODIFIED_BY="Helen Collins" NAME="Becker 1990" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE, Colliver J, Elble R</AU>
<TI>Effects of metrifonate, a long-acting cholinesterase inhibitor in Alzheimer's disease: Report of an open trial</TI>
<SO>Drug Development Research</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>425-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blokland-1995" MODIFIED="2008-03-19 15:08:50 +0000" MODIFIED_BY="Helen Collins" NAME="Blokland 1995" TYPE="JOURNAL_ARTICLE">
<AU>Blokland A, Hinz V, Schmidt B</AU>
<TI>Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin test: Evaluation of the efficacy/safety profile in rats</TI>
<SO>Drug Development Research</SO>
<YR>1995</YR>
<VL>36</VL>
<PG>166-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD</AU>
<TI>Cochrane Reviewers' Handbook 4.1</TI>
<SO>Cochrane Library CD Rom</SO>
<YR>2000</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummings-1998" MODIFIED="2008-03-19 15:09:12 +0000" MODIFIED_BY="Helen Collins" NAME="Cummings 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cummings JL</AU>
<TI>Metrifonate: overview of safety and efficacy</TI>
<SO>Pharmacotherapy</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>43-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1989" MODIFIED="2008-03-19 15:09:48 +0000" MODIFIED_BY="Helen Collins" NAME="Evans 1989" TYPE="JOURNAL_ARTICLE">
<AU>Evans DA, Funkenstein HH, Albert MS</AU>
<TI>Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported</TI>
<SO>JAMA</SO>
<YR>1989</YR>
<VL>262</VL>
<PG>2551-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farlow-2000" MODIFIED="2008-03-19 15:10:13 +0000" MODIFIED_BY="Helen Collins" NAME="Farlow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Farlow MR, Cyrus PA</AU>
<TI>Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>4</NO>
<PG>202-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giovannini-1998" MODIFIED="2008-03-19 15:10:36 +0000" MODIFIED_BY="Helen Collins" NAME="Giovannini 1998" TYPE="JOURNAL_ARTICLE">
<AU>Giovannini MG, Scali C, Bartolini L, Schmidt B, Pepeu G.</AU>
<TI>Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats.</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1998</YR>
<VL>354</VL>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallak-1987" MODIFIED="2008-03-19 15:10:49 +0000" MODIFIED_BY="Helen Collins" NAME="Hallak 1987" TYPE="JOURNAL_ARTICLE">
<AU>Hallak M, Giacobini E</AU>
<TI>A comparison of the effects of two inhibitors on brain cholinesterase</TI>
<SO>Neuropharmacology</SO>
<YR>1987</YR>
<VL>26</VL>
<PG>521-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmstedt-1978" MODIFIED="2008-03-19 15:11:03 +0000" MODIFIED_BY="Helen Collins" NAME="Holmstedt 1978" TYPE="JOURNAL_ARTICLE">
<AU>Holmstedt B, Nordgren I, Sandoz M, Sundwall A</AU>
<TI>Metrifonate: Summary of toxicological and pharmacological information available.</TI>
<SO>Archives of Toxicology</SO>
<YR>1978</YR>
<VL>41</VL>
<PG>3-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mori-1992" MODIFIED="2008-03-19 15:11:44 +0000" MODIFIED_BY="Helen Collins" NAME="Mori 1992" TYPE="JOURNAL_ARTICLE">
<AU>Mori F, Lai CC, Fusi F, Giacobini E</AU>
<TI>Cholinesterase inhibitors increase secretion of APPs in rat brain cortex</TI>
<SO>Neuroreport</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>633-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nordgren-1978" MODIFIED="2008-03-19 15:12:00 +0000" MODIFIED_BY="Helen Collins" NAME="Nordgren 1978" TYPE="JOURNAL_ARTICLE">
<AU>Nordgren I, Bergstrom M, Holmstedt B, Sandoz M</AU>
<TI>Transformation and action of metrifonate.</TI>
<SO>Archives of Toxicology</SO>
<YR>1978</YR>
<VL>41</VL>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ogane-1992" MODIFIED="2008-03-19 15:12:19 +0000" MODIFIED_BY="Helen Collins" NAME="Ogane 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ogane N, Giacobini E, Messamore E</AU>
<TI>Preferential inhibition of acetylcholinesterase molecular forms in rat brain</TI>
<SO>Neurochemical Research</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>489-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scali-1997" MODIFIED="2008-03-19 15:12:44 +0000" MODIFIED_BY="Helen Collins" NAME="Scali 1997" TYPE="JOURNAL_ARTICLE">
<AU>Scali C, Giovannini MG, Bartolini L, et al</AU>
<TI>Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1997</YR>
<VL>325</VL>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-03-19 15:13:05 +0000" MODIFIED_BY="Helen Collins" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1961" MODIFIED="2008-03-19 15:13:26 +0000" MODIFIED_BY="Helen Collins" NAME="Sherman 1961" TYPE="JOURNAL_ARTICLE">
<AU>Sherman M, Ross E, Chang MT</AU>
<TI>Acute and subacute toxicity of insecticides to chicks</TI>
<SO>Toxicology and Applied Pharmacology</SO>
<YR>1961</YR>
<VL>7</VL>
<PG>606-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-03-18 16:00:41 +0000" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-L_x00f3_pez-Arrieta-2006" MODIFIED="2008-03-18 16:00:41 +0000" MODIFIED_BY="Helen Collins" NAME="López Arrieta 2006" TYPE="COCHRANE_REVIEW">
<AU>López-Arrieta JM, Schneider L</AU>
<TI>Metrifonate for Alzheimer's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-03-18 16:00:41 +0000" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-03-18 16:00:41 +0000" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD003155.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Becker-1996">
<CHAR_METHODS>
<P>Duration: 3 months<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US<BR/>Population: 53 AD patients (NINCDS-ADRDA). Patients who did not complete the double blind phase were replaced in order to obtain data from 50 patients<BR/>Selection criteria: MMSE: &gt;8, Rosen modified HIS: &lt;4, age: &lt;90 years<BR/>Exclusion criteria: used of concomitant medications with potential cognitive effects<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: Loading dose: 5mg/kg body weight /week for 2 weeks, 4.9 mg/kg body weight /week for 1 week<BR/>Maintenance dose: 2.1 mg/kg body weight/week<BR/>2. placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: ADAScog<BR/>Secondary: MMSE, ADASnoncog, Global Improvement Scale, ADL Checklist<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients who completed the double-blind phase were discontinued from treatment for 1 month, and then offered the chance of open label metrifonate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Becker-1998">
<CHAR_METHODS>
<P>Duration: 6 months<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US<BR/>Population: 47 AD patients (NINCDS-ADRDA)<BR/>Selection criteria: MMSE &gt;10, mod HIS &lt;4, age &lt;90 years, and were not taking concomitant medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: Loading dose: 2 mg/kg body weight /day for 5 days, 0.95 mg/kg body weight /day forday 6, followed by <BR/>Maintenance dose: 2.9 mg/kg body weight /week<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-Cog<BR/>MMSE<BR/>ADAS-Noncog<BR/>GIS<BR/>ADLC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The randomized phase of the study was immediately proceeded by a one month, patient blind, baseline phase during which all patients received metrifonate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blass-2000">
<CHAR_METHODS>
<P>Duration: 6 weeks (2 week loading dose plus 4 weeks maintainance dose)<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: USA<BR/>Population: 39 probable mild to moderate Alzheimer's disease (NINCDS-ADRDA)<BR/>Age: 45 to 85 years<BR/>Selection criteria: MMSE: 10-26, Rosen Hachinski Ischaemic Scale: &lt;4, Weight: 45-98 kg, caregiver available<BR/>Exclusion criteria: CNS disorder other than AD (eg vascular dementia, toxic or alcoholic origin, mass lesions, normal pressure hydrocephalus, intracranial haemorrhage), current major depressive disorder, bipolar disorder, schizophrenia disorder, mental retardation, history of seizures, encephalitis, or other medical problems known to cause dementia or to interfere with cognition; evidence of unstable significant medical illnesses<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: Loading dose 2.5 mg/kg body weight /day for 2 weeks, maintenance dose: 1 mg/kg body weight /day for 4 weeks<BR/>2. placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Safety: complete physical examination, chest roentgrams, ECG, stress ECG, pulmonary function tests, complete neurologic examination, and laboratory tests. Adverse events were rated as mild, moderate, or severe</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients who completed the 6 week double blind phase has the option of entering a 56 week open label extension study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cummings-1996">
<CHAR_METHODS>
<P>Duration: 12 weeks including a 2-week loading dose period<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US Multicentre study<BR/>Population: 480 AD patients <BR/>Selection criteria: NINCDS-ADRDA criteria for Alzheimer's disease, MMSE: 10-26, modified Ischemic Scale &lt;4, GDS stages of 3 to 6; weight between 45 to 94 kg; caregiver essential<BR/>Exclusion criteria: major depression, bipolar disorder, schizophrenia or mental retardation, CNS disorder (e.g. vascular dementia, intracranial mass lesions; normal pressure hydrocephalus; non-Alzheimer's dementias or another neurologic disease(e.g. Parkinson's, Huntington's, or seizures); patients with significant medical condition such as poor controlled diabetes, systolic blood pressure (&lt;100 mmHg, &gt;180 mmHg), neoplasm or respiratory disease; hepatic or renal insufficiency, cardiac disease, patients taken psychotropic agents, antidementia drugs, cholinergic or anticholinergic agents, anticonvulsivants, antacids or cimetidine<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: Loading dose 0.5 mg/kg body weighgt /day for 2 weeks, maintenance dose: 0.2mg/kg body weight /day for 10 weeks<BR/>2. metrifonate: Loading dose 0.9 mg/kg body weight /day for 2 weeks, maintenance dose: 0.3mg/kg body weight /day for 10 weeks<BR/>3. metrifonate: Loading dose 2.0 mg/kg body weight /day for 2 weeks, maintenance dose: 0.65 mg/kg body weight /day for 10 weeks<BR/>4. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: ADAScog, CIBIC-plus<BR/>Secondary: MMSE, CIBIS-plus, GERRRI, PSMS<BR/>Safety: Mortality, emergent events, laboratory abnormalities, changes in vital signs, ECGs, and neurologic examinations<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jann-1999">
<CHAR_METHODS>
<P>Duration: 6 weeks, 2-week screening phase.<BR/>Randomized, double-blind, placebo-controlled, parallel-group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US multicentre study<BR/>Population:395 AD patients (NINCDS-ADRDA), (placebo 134; loading MTF dose 133; non-loading MTF 128)<BR/>Age: 45-90 years<BR/>Selection criteria: MMSE: 10-26, Rosen modified HIS: &lt;4<BR/>Exclusion criteria: CNS disorder (e.g. dementia of vascular, toxic, or alcoholic aetiology; mass lesions; normal pressure hydrocephalus; or intracraneal haemorrage), major depression, bipolar disorder, schizophrenia or mental retardation; history of fits, encephalitis, other dementia disorders (e.g. Parkinson's, Huntington's, Pick's disease) or interfere with cognition (e.g.syphilis, severe anemia, alcoholism); significant medical condition not limited to hepatic or renal insufficiency, cardiac disease, neoplasm or respiratory disease; known hypersensitivity to AchE inhibitors or physical deficits that could interfere with the study completion<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: loading dose 100 mg/day (body weight &lt; 65 kg) or 150 mg/day (body weight &gt;= 65 kg) for 2 weeks, maintenance 50 mg/day for 4 weeks<BR/>2. metrifonate 50 mg/day for 6 weeks<BR/>3. placebo<BR/> mg/day (by weight) for 2 weeks followed by 50 mg/day for 4 weeks: non-loading MTF: 50 mg/day for 6 weeks <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: ADAScog;<BR/>Secondary: MMSE, CIBIC-plus, CIBIS-plus, ADASnoncog<BR/>Safety: Emergent adverse events, changes in vital signs and laboratory variables, ECG and neurologic examination<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MALT-Study-Group">
<CHAR_METHODS>
<P>Duration: 24 weeks, 2-week screening phase<BR/>Randomized, double-blind, placebo-controlled, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Multicentre (71 sites from France and UK )<BR/>Population: 605 randomized AD patients (DSM-IV), 594 were included in the ITT analysis.<BR/>Selection criteria: MMSE: 10-26, Rosen modified HIS: &lt;4, and a body mass 45-94 kg and a caregiver essential.<BR/>Exclusion criteria: medical problems that might interfere with cognition (eg alcoholism, CNS syphilis, severe anaemia, thyroid disease, structural cerebral pathology, hypersensitivity to ChE inhibitors, administration of drugs with potential cognitive properties or with effect on the cholinergic system (e.g. cimetidine, antacids, anticonvulsivants, or clonidine)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: loading dose 80 mg/day (body weight &lt; 65 kg) or 120 mg/day (body weight &gt;= 65 kg) for 2 weeks, maintenance 40 mg/day (body weight &lt; 65 kg) or 60 mg/day (body weight &gt;= 65 kg) for 24 weeks<BR/>2. metrifonate: loading dose 80 mg/day (body weight &lt; 65 kg) or 120 mg/day (body weight &gt;= 65 kg) for 2 weeks, maintenance 60 mg/day (body weight &lt; 65 kg) or 80 mg/day (body weight &gt;= 65 kg) for 24 weeks<BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: ADAS-cog, CIBIC-plus<BR/>Secondary: MMSE, NPI, and ADAS-noncog, DAD, CIBIS-plus, Caregiver Burden Assessment which includes: the Screen for Caregiver Burden, the Poulshock and Deimling cognitive subscale, the abridge Relatives Stress Scale and the CATS<BR/>Safety: Mortality, adverse events, assessment of vital signs and laboratory variables and ECG and physical examination<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Morris-1998">
<CHAR_METHODS>
<P>Duration: 26 weeks, including a 2-week loading dose period<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US Multicentre study<BR/>Population: 408 AD patients<BR/>Selection criteria: NINCDS-ADRDA criteria for Alzheimer's disease, MMSE: 10-26, modified Ischemic Scale &lt;4, GDS stages of 3 to 6; weight between 45 to 94 kg; caregiver disposal.<BR/>Exclusion criteria: major depression, bipolar disorder, schizophrenia or mental retardation, CNS disorder (e.g. vascular dementia, intracranial mass lesions; normal pressure hydrocephalus; non-Alzheimer's dementias or another neurologic disease (e.g. Parkinson's, Huntington's, or seizures); patients with significant medical condition such as poor controlled diabetes, systolic blood pressure (&lt;100 mmHg, &gt;180 mmHg), neoplasm or respiratory disease; hepatic or renal insufficiency, cardiac disease, patients taken psychotropic agents, antidementia drugs, cholinergic or anticholinergic agents, anticonvulsivants, antacids or cimetidine<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. metrifonate: Loading dose 2.0 mg/kg body weighgt /day for 2 weeks, maintenance dose: 0.65 mg/kg body weight /day for 24 weeks<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: ADAS-cog, CIBIC-plus<BR/>Secondary: NPI, DAD, GDS, ADAS-noncog, MMSE, CIBISplus<BR/>Safety: Mortality, emergent events, laboratory abnormalities, changs in vital signs, ECGs, and neurologic examinations<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raskind-1999">
<CHAR_METHODS>
<P>Duration: 26 weeks<BR/>Randomized, double blind, placebo controlled, parallel study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: US multicentre study<BR/>Population: 264 AD patients (NINCDS-ADRDA), (placebo: 87; MTF: 177)<BR/>Selection criteria: NINCDS-ADRDA criteria for Alzheimer's disease, MMSE: 10-26, modified Ischemic Scale &lt; 4, weight between 43 to 98 kg; caregiver essential.<BR/>Exclusion criteria: major depression, bipolar disorder, schizophrenia or mental retardation, CNS disorder (e.g. vascular dementia, intracranial mass lesions; normal pressure hydrocephalus; non-Alzheimer's dementias or another neurologic disease (e.g. Parkinson's, Huntington's, or seizures); patients with significant medical condition such as poor controlled diabetes, systolic blood pressure (&lt;100 mmHg, &gt;180 mmHg), neoplasm or respiratory disease; hepatic or renal insufficiency, cardiac disease, patients taken psychotropic agents, antidementia drugs, cholinergic or anticholinergic agents, anticonvulsivants, antacids or cimetidine.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Metrifonate 50 mg/day <BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS-cog, MMSE, CIBIC-plus, CIBIS-plus, ADAS-noncog, NPI, DAD, GDS<BR/>Safety: Emergent adverse events, changes in vital signs and laboratory variables, ECG and neurologic examination<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bieber-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized double-blind, placebo controlled 3 week study to assess 4 dosing regimens of metrifonate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heining-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Metrifonate was tested on healthy elderly volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mega-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised placebo-controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petttigrew-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a randomized, placebo controlled, double-blind trial that evaluates the pharmacokinetics, pharmacodynamics and safety of metrifonate. Cognition was assessed. Blinding was inadequate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Becker-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Becker-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Blass-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cummings-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Jann-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-MALT-Study-Group">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Morris-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Raskind-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Description of rating scales and cognitive tests used in the trials</TITLE>
<TABLE COLS="4" ROWS="15">
<TR>
<TH>
<P>Name</P>
</TH>
<TH>
<P>Abbreviation</P>
</TH>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Reference</P>
</TH>
</TR>
<TR>
<TD>
<P>Abridged Relatives Stress Scale</P>
</TD>
<TD>
<P>aRSS</P>
</TD>
<TD>
<P>Assesses the overall psychological impact of the situation on the carer. 10 items corresponding to 2 dimensions, personal distress and negative feelings. Each item is scored from 0=not at all, to 4=considerably. Range is 0 (good) to 40.</P>
</TD>
<TD>
<P>Kaufer 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>Activities of Daily Living Checklist</P>
</TD>
<TD>
<P>ADLC</P>
</TD>
<TD>
<P>50 item list of common daily living activities, each assessed on a scale of 1-7 (1=very much improved) to 7 =very much worse).</P>
</TD>
<TD>
<P>Becker 1990</P>
</TD>
</TR>
<TR>
<TD>
<P>Alzheimer's Disease Assessment Scale - Cognitive</P>
</TD>
<TD>
<P>ADAS-Cog</P>
</TD>
<TD>
<P>The ADAS scale is divided into cognitive and noncognitive sections. It was designed specifically to evaluate the severity of dysfunction characteristic of persons with Alzheimer's disease. The cognitive test consists of 11 subsets, language, comprehension, recall of test instructions, word finding difficulty, following commands, naming, construction, ideational praxis, orientation, word recall, and word recognition. The maximum score of 70 indicates severe impairment.</P>
</TD>
<TD>
<P>Rosen 1984</P>
</TD>
</TR>
<TR>
<TD>
<P>Alzheimer's Disease Assessment Scale - Noncognitive</P>
</TD>
<TD>
<P>ADAS-Noncog</P>
</TD>
<TD>
<P>Information from the patient and an informant provides an asssessment of the severity (0=not present, 5=severe) of these 10 problems : tearfulness, depression, delusions, distractability,hallucinations, pacing, increased motor activity, tremors, change in appetite, uncooperativeness in testing</P>
</TD>
<TD>
<P>Rosen 1984</P>
</TD>
</TR>
<TR>
<TD>
<P>Caregiver Activity Time Survey</P>
</TD>
<TD>
<P>CATS</P>
</TD>
<TD>
<P>The CATS assesses the amount of time spent in providing unpaid and paid care on 9 activities.</P>
</TD>
<TD>
<P>Clipp 1995</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Impression</P>
</TD>
<TD>
<P>CGI</P>
</TD>
<TD>
<P>The CGI consists of 3 global scales. Severity of illness is rated from 1 (normal) to 7 (extremely ill) and global improvement is rated from 1 (very much improved) to 7 (very much worse), with 0 denoting not assessed in both scales. The efficacy index requires a rating of the interaction of therapeutic effectiveness and adverse reactions. <BR/>
</P>
</TD>
<TD>
<P>Guy 1976</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinician's Interview-Based Impression of Change with Carer Input</P>
</TD>
<TD>
<P>CIBIC-plus</P>
</TD>
<TD>
<P>The global clinical status is assessed relative to baseline, based on inforamtion from semi-structured interviews with the patient and the carer with reference to cognitive test performance. It is scored on a scale of 1 - 7 (1=very much improved, 4=no change, 7=very much worse).</P>
</TD>
<TD>
<P>FDC-Report, 1992</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinician's Interview-Based Impression of Severity</P>
</TD>
<TD>
<P>CIBIS</P>
</TD>
<TD>
<P>The global clinical status is assessed relative to baseline, based on inforamtion from semi-structured interviews with the patient and the carer with reference to cognitive test performance. It is scored on a scale of 1 - 7 (1=very much improved, 4=no change, 7=very much worse).</P>
</TD>
<TD>
<P>Knopman 1994</P>
</TD>
</TR>
<TR>
<TD>
<P>Disability Assessment for Dementia</P>
</TD>
<TD>
<P>DAD</P>
</TD>
<TD>
<P>To measure functional abilities in activities of daily living including, personal hygiene, dressing, continence, eating, meal preparation, use of telephone, outdoor ability, finance/correspondence, and leisure.</P>
</TD>
<TD>
<P>Gélinas 1996</P>
</TD>
</TR>
<TR>
<TD>
<P>Global Deterioration Scale</P>
</TD>
<TD>
<P>GDS</P>
</TD>
<TD>
<P>The GDS was developed for the assessment of primary degenerative dementia and the delineation of its stages. The stages are scored from 1 (no cognitive decline) to 7 (very severe cognitive decline). This scale is often used to assess the degree of severity of disease at baseline<BR/>
</P>
</TD>
<TD>
<P>Reisberg 1982</P>
</TD>
</TR>
<TR>
<TD>
<P>Mini Mental State Examination</P>
</TD>
<TD>
<P>MMSE</P>
</TD>
<TD>
<P>The MMSE was developed as a short test suitable for the elderly with dementia. It concentrates on the cognitive aspects of mental function, the five sections cover orientation, immediate recall, attention and calculation, delayed recall and language. A maximum score of 30 indicates no impairment.</P>
</TD>
<TD>
<P>Folstein 1975</P>
</TD>
</TR>
<TR>
<TD>
<P>Neuropsychiatric Inventory</P>
</TD>
<TD>
<P>NPI</P>
</TD>
<TD>
<P>The NPI evaluates changes in behaviour that have occurred since the onset of cognitive impairment and that have been present in the preceding 4 weeks using information from the carer. It assesses 10 symptom domains: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, abberrant motor behaviours. If the behaviour is present the frequency (1=less than once a week, 2=once a week, 3=several times a week, 4=every day) and severity (1=mild, 2=moderate, 3=severe) are rated. The symptoms score is the product of frequency and severity . The total NPI is the sum of the symptom scores.</P>
</TD>
<TD>
<P>Cummings 1994</P>
</TD>
</TR>
<TR>
<TD>
<P>Poulshock and Deimling</P>
</TD>
<TD>
<P>PD</P>
</TD>
<TD>
<P>The cognitive subscale measures the distress associated with cognitive impairment in the patient. This scale yields a subjective and an objective measure. It consists of 8 items. Respondents indicate whether an item has occurred in the previous 4 weeks, and how much distress it had caused (from 1=did not occur, or occurred but did not cause distress, - 4=severe distress). The objective score is the number of items that occurred (0-8), and the subjective score is the sum of the amount os distress (8-32).</P>
</TD>
<TD>
<P>Poulshock 1984</P>
</TD>
</TR>
<TR>
<TD>
<P>Screen for Caregiver Burden</P>
</TD>
<TD>
<P>SCB</P>
</TD>
<TD>
<P>This scale yields a subjective (distress) and an objective (prevalence) measure of burden. It consists of 25 items corresponding to the most frequently cited upsetting experiences cited by carers. Respondents indicate whether an item has occurred in the previous 4 weeks, and how mush distress it had caused (from 1=did not occur, or occurred but did not cause distress, - 4=severe distress). The objective score is the number of items that occurred (0-25), and the subjective score is the sum of the amount os distress (0-100).</P>
</TD>
<TD>
<P>Vitaliano 1991</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Metrifonate regimen used in the included studies</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Loading dose weeks</P>
</TH>
<TH>
<P>loading dose frequen</P>
</TH>
<TH>
<P>loading dose</P>
</TH>
<TH>
<P>maintenance dose</P>
</TH>
<TH>
<P>equivalent dose</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Becker 1996</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>weekly</P>
</TD>
<TD>
<P>5 mg/kg body weight for 2 weeks, 4.9 mg/kg body weight for 1 week</P>
</TD>
<TD>
<P>2.1mg/kg body weight/week</P>
</TD>
<TD>
<P>95-180 mg / week</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Becker 1998</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>2 mg/kg body weight for 5 days, 0.95 mg/kg body weight for day 6</P>
</TD>
<TD>
<P>2.9 mg/kg body weight /week</P>
</TD>
<TD>
<P>130-250 mg/week</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Blass 2000</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>0.5 mg/kg body weight</P>
</TD>
<TD>
<P>1.0 mg/kg body weight /day</P>
</TD>
<TD>
<P>45-85 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cummings 1998</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>0.5 mg/kg body weight</P>
</TD>
<TD>
<P>0.2 mg/kg body weight /day</P>
</TD>
<TD>
<P>9-17 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>0.9 mg/kg body weight</P>
</TD>
<TD>
<P>0.3 mg/kg body weight /day</P>
</TD>
<TD>
<P>13-26 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>2.0 mg/kg body weight</P>
</TD>
<TD>
<P>0.65 mg/kg body weight /day</P>
</TD>
<TD>
<P>30-55 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jann 1999</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>100mg/day if &lt;65 kg 150 mg/day if &gt;= 65 kg</P>
</TD>
<TD>
<P>50mg/day</P>
</TD>
<TD>
<P>50 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>no loading</P>
</TD>
<TD>
<P>50mg/day</P>
</TD>
<TD>
<P>50 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MALT</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>80 mg/day if &lt;65 kg 120 mg/day if &gt;= 65 kg</P>
</TD>
<TD>
<P>40 mg/day if &lt;65 kg 50 mg/day if &gt;= 65 kg</P>
</TD>
<TD>
<P>40-50 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>80 mg/day if &lt;65 kg 120 mg/day if &gt;= 65 kg</P>
</TD>
<TD>
<P>60 mg/day if &lt;65 kg 80 mg/day if &gt;= 65 kg</P>
</TD>
<TD>
<P>60-80 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Morris 1998</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>daily</P>
</TD>
<TD>
<P>2 mg/kg body weight</P>
</TD>
<TD>
<P>0.65 mg/kg body weight /day</P>
</TD>
<TD>
<P>30-55 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Raskind 1999</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>no loading</P>
</TD>
<TD>
<P>50mg/day</P>
</TD>
<TD>
<P>50 mg/day</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Description of included studies at baseline</TITLE>
<TABLE COLS="8" ROWS="9">
<TR>
<TH>
<P>study</P>
</TH>
<TH>
<P>duration weeks</P>
</TH>
<TH>
<P>number of patients</P>
</TH>
<TH>
<P>mean age</P>
</TH>
<TH>
<P>% men</P>
</TH>
<TH>
<P>mean MMSE</P>
</TH>
<TH>
<P>mean ADAS-Cog</P>
</TH>
<TH>
<P>country</P>
</TH>
</TR>
<TR>
<TD>
<P>Becker 1996</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>71.4</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>19.4</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Becker 1998</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>73.0</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>20.2</P>
</TD>
<TD>
<P>21.2</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Blass 2000</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>74.6</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>18.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Cummings 1996</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>480</P>
</TD>
<TD>
<P>73.5</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Jann 1999</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>395</P>
</TD>
<TD>
<P>75.0</P>
</TD>
<TD>
<P>42.5</P>
</TD>
<TD>
<P>19.1</P>
</TD>
<TD>
<P>21.4</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>MALT</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>599</P>
</TD>
<TD>
<P>72.1</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>18.5</P>
</TD>
<TD>
<P>25.2</P>
</TD>
<TD>
<P>UK and France</P>
</TD>
</TR>
<TR>
<TD>
<P>Morris 1998</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>408</P>
</TD>
<TD>
<P>73.6</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>22.1</P>
</TD>
<TD>
<P>USA</P>
</TD>
</TR>
<TR>
<TD>
<P>Raskind 1999</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>264</P>
</TD>
<TD>
<P>74.6</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>18.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Canada and USA</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Metrifonate vs placebo</NAME>
<IV_OUTCOME CHI2="11.688646178637647" CI_END="1.2603360251328644" CI_START="0.7147457965573074" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.9875409108450859" ESTIMABLE="YES" I2="31.557514208780436" I2_Q="40.09896601553811" ID="CMP-001.01" LOG_CI_END="0.10048635020100673" LOG_CI_START="-0.1458483900620818" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.005444903816700402" NO="1" P_CHI2="0.1656457310865065" P_Q="0.1113715724268236" P_Z="1.2913468999871799E-12" Q="11.68594185171457" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="9" TOTAL_2="9" WEIGHT="800.0" Z="7.095231978657776">
<NAME>MMSE (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="5.289118244905923" CI_START="-3.6091182449059236" DF="0.0" EFFECT_SIZE="0.84" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.7233832763281393" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.07572071393811836" NO="1" P_CHI2="1.0" P_Z="0.711349667797485" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="99.99999999999999" Z="0.3700440528634361">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="5.289118244905923" CI_START="-3.6091182449059236" EFFECT_SIZE="0.84" ESTIMABLE="YES" ESTIMATE="0.84" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="619" SE="2.27" STUDY_ID="STD-Becker-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="99.99999999999999"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.8155870344344196" CI_START="0.4044129655655806" DF="0.0" EFFECT_SIZE="1.11" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.2590170726752993" LOG_CI_START="-0.39317492928449366" LOG_EFFECT_SIZE="0.04532297878665747" NO="2" P_CHI2="1.0" P_Z="0.0020469573285999505" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.083333333333334">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="1.8155870344344196" CI_START="0.4044129655655806" EFFECT_SIZE="1.11" ESTIMABLE="YES" ESTIMATE="1.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="620" SE="0.36" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.3355870344344196" CI_START="-0.0755870344344195" DF="0.0" EFFECT_SIZE="0.63" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.12567219437385918" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.2006594505464183" NO="3" P_CHI2="1.0" P_Z="0.08011831372775254" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.75">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="1.3355870344344196" CI_START="-0.0755870344344195" EFFECT_SIZE="0.63" ESTIMABLE="YES" ESTIMATE="0.63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="621" SE="0.36" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.0755870344344194" CI_START="0.6644129655655806" DF="0.0" EFFECT_SIZE="1.37" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.3171409491248488" LOG_CI_START="-0.17756190117752946" LOG_EFFECT_SIZE="0.1367205671564068" NO="4" P_CHI2="1.0" P_Z="1.4148625054982597E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.805555555555556">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="2.0755870344344194" CI_START="0.6644129655655806" EFFECT_SIZE="1.37" ESTIMABLE="YES" ESTIMATE="1.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="622" SE="0.36" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="4.722730490162305" CI_START="-2.842730490162305" DF="0.0" EFFECT_SIZE="0.94" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.6741931626050741" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.026872146400301365" NO="5" P_CHI2="1.0" P_Z="0.6262252866111431" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.4870466321243523">
<NAME>metrifonate 130-250 mg/week (2.9 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="4.722730490162304" CI_START="-2.8427304901623045" EFFECT_SIZE="0.94" ESTIMABLE="YES" ESTIMATE="0.94" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="623" SE="1.93" STUDY_ID="STD-Becker-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.002704326923076918" CI_END="0.9426215860422307" CI_START="-0.10108312450376927" DF="1.0" EFFECT_SIZE="0.42076923076923073" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="-0.025662619115226926" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.37595602597340605" NO="6" P_CHI2="0.9585262089475444" P_Z="0.11403411772750764" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.5803177465375016">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="1.340782712579226" CI_START="-0.5407827125792259" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="624" SE="0.48" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="30.769230769230766"/>
<IV_DATA CI_END="1.0571884750528173" CI_START="-0.1971884750528174" EFFECT_SIZE="0.43" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="625" SE="0.32" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="69.23076923076923"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.8955870344344194" CI_START="0.48441296556558044" DF="0.0" EFFECT_SIZE="1.19" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="0.2777437295204826" LOG_CI_START="-0.3147842412551847" LOG_EFFECT_SIZE="0.07554696139253074" NO="7" P_CHI2="1.0" P_Z="9.478831065849044E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.3055555555555554">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="1.8955870344344194" CI_START="0.48441296556558044" EFFECT_SIZE="1.19" ESTIMABLE="YES" ESTIMATE="1.19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="626" SE="0.36" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.637905521785102" CI_START="1.0620944782148982" DF="0.0" EFFECT_SIZE="1.85" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.4212592369638858" LOG_CI_START="0.026163150966138887" LOG_EFFECT_SIZE="0.2671717284030138" NO="8" P_CHI2="1.0" P_Z="4.1847320083090594E-6" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.601990049751244">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<IV_DATA CI_END="2.637905521785102" CI_START="1.0620944782148982" EFFECT_SIZE="1.85" ESTIMABLE="YES" ESTIMATE="1.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="627" SE="0.402" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="20.121636096216715" CI_END="-1.3484461194158972" CI_START="-2.2273798817736474" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7879130005947723" ESTIMABLE="YES" I2="55.27202680257105" I2_Q="54.1685562939688" ID="CMP-001.02" NO="2" P_CHI2="0.01717641936468517" P_Q="0.025702593738443302" P_Z="1.5380025620871053E-15" Q="17.455265104265607" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1312" TOTAL_2="1197" UNITS="" WEIGHT="900.0" Z="7.973854774349584">
<NAME>ADAS-Cog (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.35860992299302086" CI_START="-2.641390077006979" DF="0.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.010002027917052337" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="2.575759187007638">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<CONT_DATA CI_END="-0.35860992299302086" CI_START="-2.641390077006979" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-0.92" MEAN_2="0.58" ORDER="628" SD_1="4.73" SD_2="4.75" SE="0.5823525768892277" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0164189827787358" CI_START="-1.3164189827787356" DF="0.0" EFFECT_SIZE="-0.14999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.8010032829290528" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="0.2520488795378063">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<CONT_DATA CI_END="1.0164189827787358" CI_START="-1.3164189827787356" EFFECT_SIZE="-0.14999999999999997" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="0.58" ORDER="629" SD_1="4.86" SD_2="4.75" SE="0.5951226614260771" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.95636529344474" CI_START="-10.65636529344474" DF="0.0" EFFECT_SIZE="-1.85" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.6805299605034542" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="0.4117400596700393">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<CONT_DATA CI_END="6.95636529344474" CI_START="-10.65636529344474" EFFECT_SIZE="-1.85" ESTIMABLE="YES" MEAN_1="-0.75" MEAN_2="1.1" ORDER="630" SD_1="16.73" SD_2="15.03" SE="4.493126079309735" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1733747082829289" CI_START="-2.826625291717071" DF="0.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="1.0" P_Z="0.026684052049640503" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0" Z="2.2161087951254608">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<CONT_DATA CI_END="-0.1733747082829289" CI_START="-2.826625291717071" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-0.94" MEAN_2="0.56" ORDER="631" SD_1="5.11" SD_2="5.11" SE="0.6768620761306443" STUDY_ID="STD-Cummings-1996" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.009647803788488174" CI_START="-2.609647803788488" DF="0.0" EFFECT_SIZE="-1.3" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" NO="5" P_CHI2="1.0" P_Z="0.05171176539972151" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="115" WEIGHT="100.0" Z="1.9455254859600195">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<CONT_DATA CI_END="0.009647803788488174" CI_START="-2.609647803788488" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-0.74" MEAN_2="0.56" ORDER="632" SD_1="5.11" SD_2="5.11" SE="0.6681999333247054" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.6073601337330776" CI_START="-4.272639866266922" DF="0.0" EFFECT_SIZE="-2.94" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" NO="6" P_CHI2="1.0" P_Z="1.5324650371670138E-5" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="115" WEIGHT="100.0" Z="4.323969483735673">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<CONT_DATA CI_END="-1.6073601337330776" CI_START="-4.272639866266922" EFFECT_SIZE="-2.94" ESTIMABLE="YES" MEAN_1="-2.38" MEAN_2="0.56" ORDER="633" SD_1="5.11" SD_2="5.11" SE="0.6799307930036549" STUDY_ID="STD-Cummings-1996" TOTAL_1="111" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.737677313735165" CI_START="-9.077677313735165" DF="0.0" EFFECT_SIZE="-1.67" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.07" NO="7" P_CHI2="1.0" P_Z="0.65859212516204" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.4418577801860917">
<NAME>metrifonate 130-250 mg/week (2.9 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="5.737677313735165" CI_START="-9.077677313735165" EFFECT_SIZE="-1.67" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="1.67" ORDER="634" SD_1="13.19" SD_2="12.7" SE="3.779496650023152" STUDY_ID="STD-Becker-1998" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6663709919511103" CI_END="-1.0020254100738284" CI_START="-2.8335446710975494" DF="1.0" EFFECT_SIZE="-1.9177850405856889" ESTIMABLE="YES" I2="62.49584161323881" ID="CMP-001.02.08" NO="8" P_CHI2="0.10248953621768375" P_Z="4.0508654448818765E-5" STUDIES="2" TAU2="0.0" TOTAL_1="465" TOTAL_2="336" WEIGHT="100.0" Z="4.104559192608955">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="-0.12166494987299048" CI_START="-2.4783350501270096" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="1.54" ORDER="635" SD_1="6.29" SD_2="5.71" SE="0.6012023993407869" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="203" WEIGHT="60.3983948342507"/>
<CONT_DATA CI_END="-1.4047919120349317" CI_START="-4.315208087965068" EFFECT_SIZE="-2.86" ESTIMABLE="YES" MEAN_1="-0.35" MEAN_2="2.51" ORDER="636" SD_1="7.0" SD_2="7.0" SE="0.7424667491053732" STUDY_ID="STD-Morris-1998" TOTAL_1="268" TOTAL_2="133" WEIGHT="39.60160516574929"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.0754369075509365" CI_START="-4.404563092449064" DF="0.0" EFFECT_SIZE="-3.24" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.09" NO="9" P_CHI2="1.0" P_Z="4.954602955847907E-8" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="203" WEIGHT="100.0" Z="5.452931963140956">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="-2.0754369075509365" CI_START="-4.404563092449064" EFFECT_SIZE="-3.24" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="1.54" ORDER="637" SD_1="6.11" SD_2="5.71" SE="0.5941757612053021" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="194" TOTAL_2="203" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="2.231196027518985" CI_END="5.209393441126465" CI_START="2.0969910802508" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="3.6531922606886322" ESTIMABLE="YES" I2="0.0" I2_Q="7.852445224887978" ID="CMP-001.03" LOG_CI_END="0.7167871589027557" LOG_CI_START="0.3215965831567619" LOG_DATA="NO" LOG_EFFECT_SIZE="0.5626725289211847" NO="3" P_CHI2="0.5258299896355787" P_Q="0.33782904370283295" P_Z="4.204108326025074E-6" Q="2.170431982575165" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4" TOTAL_2="4" WEIGHT="300.0" Z="4.6010280351642585">
<NAME>Disability Assessment in Dementia (DAD) (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.06076404494382022" CI_END="4.773793249127436" CI_START="0.6574552901984059" DF="1.0" EFFECT_SIZE="2.7156242696629214" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.6788636059762544" LOG_CI_START="-0.18213377573604755" LOG_EFFECT_SIZE="0.43386968133008397" NO="1" P_CHI2="0.8052923891722334" P_Z="0.009708313718511196" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="2.5860489674015996">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="6.057543815882484" CI_START="-0.057543815882484584" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="638" SE="1.56" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="45.312359550561794"/>
<IV_DATA CI_END="5.263148858046877" CI_START="-0.30314885804687686" EFFECT_SIZE="2.48" ESTIMABLE="YES" ESTIMATE="2.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="639" SE="1.42" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="54.687640449438206"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.507543815882485" CI_START="2.3924561841175156" DF="0.0" EFFECT_SIZE="5.45" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.92980419449391" LOG_CI_START="0.3788439927727132" LOG_EFFECT_SIZE="0.7363965022766424" NO="2" P_CHI2="1.0" P_Z="4.7657277286867447E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.4935897435897436">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="8.507543815882485" CI_START="2.3924561841175156" EFFECT_SIZE="5.45" ESTIMABLE="YES" ESTIMATE="5.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="640" SE="1.56" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="7.852730490162305" CI_START="0.2872695098376954" DF="0.0" EFFECT_SIZE="4.07" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.8950206924932169" LOG_CI_START="-0.5417104666357571" LOG_EFFECT_SIZE="0.6095944092252201" NO="3" P_CHI2="1.0" P_Z="0.034961132746079905" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.1088082901554404">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<IV_DATA CI_END="7.852730490162305" CI_START="0.28726950983769584" EFFECT_SIZE="4.07" ESTIMABLE="YES" ESTIMATE="4.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="641" SE="1.93" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.6218356923205723" CI_END="5.904259120177136" CI_START="-6.166127802191151" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1309343410070074" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.4303661539242999" P_Q="0.4303661539242999" P_Z="0.9660828255874881" Q="0.6218356923205723" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="47" UNITS="" WEIGHT="200.0" Z="0.042521684576266865">
<NAME>Activities of Daily living Checklist (ADLC) (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.973266272396259" CI_START="-7.573266272396258" DF="0.0" EFFECT_SIZE="3.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.520042434361696" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="0.6432800013386658">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<CONT_DATA CI_END="14.973266272396259" CI_START="-7.573266272396258" EFFECT_SIZE="3.7" ESTIMABLE="YES" MEAN_1="3.98" MEAN_2="0.28" ORDER="642" SD_1="24.19" SD_2="16.2" SE="5.751772155671402" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.475390771416667" CI_START="-8.815390771416666" DF="0.0" EFFECT_SIZE="-1.67" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.6468970548725539" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.00000000000001" Z="0.45807709597566876">
<NAME>metrifonate 130-250 mg/week (2.9 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="5.475390771416667" CI_START="-8.815390771416666" EFFECT_SIZE="-1.67" ESTIMABLE="YES" MEAN_1="4.01" MEAN_2="5.68" ORDER="643" SD_1="10.93" SD_2="13.94" SE="3.645674526562017" STUDY_ID="STD-Becker-1998" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="2.730230888495542" CI_END="-0.8455080646923165" CI_START="-3.221545313266416" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-2.033526688979366" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="0.43511436895744693" P_Q="0.5064815828445205" P_Z="7.940445636695158E-4" Q="1.3605348195351497" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4" TOTAL_2="4" WEIGHT="300.0" Z="3.3548624495616743">
<NAME>Neuropsychiactric Inventory NPI (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.3696960689603925" CI_END="-0.1990812618538198" CI_START="-3.41401972647939" DF="1.0" EFFECT_SIZE="-1.8065504941666048" ESTIMABLE="YES" I2="26.991102430555564" ID="CMP-001.05.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.24186429240844387" P_Z="0.02761583767232687" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="2.2027008876090335">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="1.4631578619118635" CI_START="-3.1231578619118636" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="644" SE="1.17" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="49.13799509548933"/>
<IV_DATA CI_END="-0.4960414177789376" CI_START="-5.003958582221062" EFFECT_SIZE="-2.75" ESTIMABLE="YES" ESTIMATE="-2.75" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="645" SE="1.15" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="50.86200490451066"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.9119567814480649" CI_START="-3.791956781448065" DF="0.0" EFFECT_SIZE="-1.44" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.040025742837558456" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.23013936226878062" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.2">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="0.9119567814480649" CI_START="-3.791956781448065" EFFECT_SIZE="-1.44" ESTIMABLE="YES" ESTIMATE="-1.44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="646" SE="1.2" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.7544489810255257" CI_START="-6.085551018974474" DF="0.0" EFFECT_SIZE="-3.42" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Z="0.011913172206124908" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.514705882352941">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.7544489810255257" CI_START="-6.085551018974474" EFFECT_SIZE="-3.42" ESTIMABLE="YES" ESTIMATE="-3.42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="647" SE="1.36" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.345750499654217" CI_END="-0.4035292166125235" CI_START="-1.320961660825858" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-0.8622454387191908" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="6" P_CHI2="0.6724524437471734" P_Q="0.507357847103224" P_Z="2.2948547677779818E-4" Q="2.327055034180944" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="400.0" Z="3.6841295866152652">
<NAME>ADAS-Noncog (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="3.534322926915716" CI_START="-4.854322926915716" DF="0.0" EFFECT_SIZE="-0.66" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.548306227958049" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.7577694497699614" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.308411214953271">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="3.534322926915716" CI_START="-4.854322926915716" EFFECT_SIZE="-0.66" ESTIMABLE="YES" ESTIMATE="-0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="648" SE="2.14" STUDY_ID="STD-Becker-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.052739494027291" CI_START="-3.5327394940272914" DF="0.0" EFFECT_SIZE="-0.24" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.48468974529651154" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.8864030064041377" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.14285714285714285">
<NAME>metrifonate 130-250 mg/week (2.9 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="3.052739494027291" CI_START="-3.5327394940272914" EFFECT_SIZE="-0.24" ESTIMABLE="YES" ESTIMATE="-0.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="649" SE="1.68" STUDY_ID="STD-Becker-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.018695465473272818" CI_END="-0.05523538538754702" CI_START="-1.1995464765055441" DF="1.0" EFFECT_SIZE="-0.6273909309465456" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.8912431454409656" P_Z="0.03162035931607865" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.00000000000001" Z="2.149177157202765">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="0.19398559381602176" CI_START="-1.3739855938160217" EFFECT_SIZE="-0.59" ESTIMABLE="YES" ESTIMATE="-0.59" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="650" SE="0.4" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="53.26133631681803"/>
<IV_DATA CI_END="0.16690462139860307" CI_START="-1.5069046213986033" EFFECT_SIZE="-0.67" ESTIMABLE="YES" ESTIMATE="-0.67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="651" SE="0.427" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="46.73866368318198"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.5664147663385779" CI_START="-2.1735852336614223" DF="0.0" EFFECT_SIZE="-1.37" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="1.0" P_Z="8.33379987272446E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="3.3414634146341466">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.5664147663385779" CI_START="-2.1735852336614223" EFFECT_SIZE="-1.37" ESTIMABLE="YES" ESTIMATE="-1.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="652" SE="0.41" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="12.627091076105422" CI_END="-0.19147645002299557" CI_START="-0.3194254782225581" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_SIZE="-0.25545096412277685" ESTIMABLE="YES" I2="20.80519622668071" I2_Q="27.645773047768568" ID="CMP-001.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="7" P_CHI2="0.24527518501726508" P_Q="0.18968649429284823" P_Z="5.03002978064238E-15" Q="12.438803341706405" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="11" TOTAL_2="11" WEIGHT="1000.0" Z="7.826158534252752">
<NAME>CIBIC-plus or CGI (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.03536302529863544" CI_START="-0.3646369747013646" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.017267943995728972" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.380952380952381">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<IV_DATA CI_END="-0.03536302529863544" CI_START="-0.3646369747013646" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="653" SE="0.084" STUDY_ID="STD-Jann-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.22340306131409537" CI_START="-0.5565969386859047" DF="0.0" EFFECT_SIZE="-0.39" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="4.470086478224988E-6" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.588235294117647">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<IV_DATA CI_END="-0.22340306131409537" CI_START="-0.5565969386859047" EFFECT_SIZE="-0.39" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="654" SE="0.085" STUDY_ID="STD-Jann-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.029990996135013548" CI_START="-0.9499909961350136" DF="0.0" EFFECT_SIZE="-0.46" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-1.5230091091402735" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Z="0.06576823732000014" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.84">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="0.029990996135013548" CI_START="-0.9499909961350136" EFFECT_SIZE="-0.46" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="655" SE="0.25" STUDY_ID="STD-Becker-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.15599639845400542" CI_START="-0.23599639845400544" DF="0.0" EFFECT_SIZE="-0.04" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="-0.8068854282455862" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="1.0" P_Z="0.6891565177502668" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="0.39999999999999997">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="0.15599639845400542" CI_START="-0.23599639845400544" EFFECT_SIZE="-0.04" ESTIMABLE="YES" ESTIMATE="-0.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="656" SE="0.1" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.09400360154599455" CI_START="-0.48599639845400544" DF="0.0" EFFECT_SIZE="-0.29" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="1.0" P_Z="0.0037316266007070818" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="2.8999999999999995">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="-0.09400360154599455" CI_START="-0.48599639845400544" EFFECT_SIZE="-0.29" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="657" SE="0.1" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.15400360154599455" CI_START="-0.5459963984540054" DF="0.0" EFFECT_SIZE="-0.35" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="6" P_CHI2="1.0" P_Z="4.652581580881997E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="3.4999999999999996">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<IV_DATA CI_END="-0.15400360154599455" CI_START="-0.5459963984540054" EFFECT_SIZE="-0.35" ESTIMABLE="YES" ESTIMATE="-0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="658" SE="0.1" STUDY_ID="STD-Cummings-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.7779891953620162" CI_START="-0.3979891953620162" DF="0.0" EFFECT_SIZE="0.19" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="-0.10902643440779043" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.721246399047171" NO="7" P_CHI2="1.0" P_Z="0.5265159937776662" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.6333333333333334">
<NAME>metrifonate 130-250 mg/week (2.9 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="0.7779891953620162" CI_START="-0.3979891953620162" EFFECT_SIZE="0.19" ESTIMABLE="YES" ESTIMATE="0.19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="659" SE="0.3" STUDY_ID="STD-Becker-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.18828773439901647" CI_END="-0.08975164410972325" CI_START="-0.40515459628375977" DF="1.0" EFFECT_SIZE="-0.2474531201967415" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="8" P_CHI2="0.6643455656798788" P_Z="0.0021020215589894007" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="3.0754258963312195">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="0.021275750175726388" CI_START="-0.4412757501757264" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="660" SE="0.118" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="46.495542576083615"/>
<IV_DATA CI_END="-0.06440396170059406" CI_START="-0.495596038299406" EFFECT_SIZE="-0.28" ESTIMABLE="YES" ESTIMATE="-0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="661" SE="0.11" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="53.50445742391639"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.11676428583973353" CI_START="-0.5832357141602664" DF="0.0" EFFECT_SIZE="-0.35" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.09" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="9" P_CHI2="1.0" P_Z="0.003269682012657571" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.941176470588235">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.11676428583973353" CI_START="-0.5832357141602664" EFFECT_SIZE="-0.35" ESTIMABLE="YES" ESTIMATE="-0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="662" SE="0.119" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.009883493499614732" CI_START="-0.3901165065003853" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.10" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="10" P_CHI2="1.0" P_Z="0.03922147907844517" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.061855670103093">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.009883493499614732" CI_START="-0.3901165065003853" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="663" SE="0.097" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.14042752379466375" CI_END="-0.13529485051372742" CI_START="-0.29100254377555335" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="-0.21314869714464038" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="8" P_CHI2="0.7078564813857675" P_Q="0.7078564813857675" P_Z="8.050177655454019E-8" Q="0.14042752379466375" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="2" WEIGHT="200.0" Z="5.366000369071701">
<NAME>CIBIS-plus (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.742513270754341E-31" CI_END="-0.09612190881937711" CI_START="-0.30387809118062287" DF="0.0" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-001.08.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.0" P_Z="1.6091841925831567E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.773584905660377">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.09612190881937714" CI_START="-0.30387809118062287" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="664" SE="0.053" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.11240216092759676" CI_START="-0.34759783907240327" DF="0.0" EFFECT_SIZE="-0.23" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="1.2641846374015077E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.8333333333333335">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-0.11240216092759676" CI_START="-0.34759783907240327" EFFECT_SIZE="-0.23" ESTIMABLE="YES" ESTIMATE="-0.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="665" SE="0.06" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="3.298086525957036E-4" CI_END="-0.27073896849952517" CI_START="-2.4289454521066864" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3498422103031058" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.9855107065194377" P_Q="0.9855107065194377" P_Z="0.014218142712372333" Q="3.298086525957036E-4" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="355" TOTAL_2="368" UNITS="" WEIGHT="200.0" Z="2.4517043546122452">
<NAME>Screen for Caregiver Burden SCB subjective (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17418307158706314" CI_START="-2.854183071587063" DF="0.0" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.08282926506991947" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="184" WEIGHT="100.0" Z="1.7345007935737324">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="0.17418307158706314" CI_START="-2.854183071587063" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="1.42" ORDER="666" SD_1="7.4" SD_2="7.4" SE="0.7725565793712261" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="183" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17826682797080262" CI_START="-2.8982668279708026" DF="0.0" EFFECT_SIZE="-1.3599999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="1.0" P_Z="0.08312633840771383" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0" Z="1.7328274721302563">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="0.17826682797080262" CI_START="-2.8982668279708026" EFFECT_SIZE="-1.3599999999999999" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="1.42" ORDER="667" SD_1="7.4" SD_2="7.4" SE="0.784844435971505" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4627718466181636" CI_END="0.08465769761840947" CI_START="-1.3269260024705984" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6211341524260945" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.49633142054860635" P_Q="0.49633142054860635" P_Z="0.08455055068406016" Q="0.4627718466181636" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="355" TOTAL_2="368" UNITS="" WEIGHT="200.0" Z="1.7248719551609923">
<NAME>Screen for Caregiver Burden SCB objective(change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6103575765515383" CI_START="-1.3703575765515383" DF="0.0" EFFECT_SIZE="-0.37999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="1.0" P_Z="0.4520283448555896" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="184" WEIGHT="100.0" Z="0.7520377808574898">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="0.6103575765515383" CI_START="-1.3703575765515383" EFFECT_SIZE="-0.37999999999999995" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.57" ORDER="668" SD_1="4.84" SD_2="4.84" SE="0.5052937627238829" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="183" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.677631530354364E-32" CI_END="0.13610965505117345" CI_START="-1.8761096550511733" DF="0.0" EFFECT_SIZE="-0.87" ESTIMABLE="YES" I2="100.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.0" P_Z="0.09011072257225133" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0" Z="1.6948139380126688">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="0.13610965505117356" CI_START="-1.8761096550511733" EFFECT_SIZE="-0.8699999999999999" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.57" ORDER="669" SD_1="4.84" SD_2="4.84" SE="0.5133306851489303" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3585153580794524" CI_END="-0.7280277453361137" CI_START="-1.9062918255756989" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3171597854559063" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.5493321598747134" P_Q="0.5493321598747134" P_Z="1.1758643225165598E-5" Q="0.3585153580794524" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="355" TOTAL_2="368" UNITS="" WEIGHT="200.0" Z="4.382015517019153">
<NAME>Cognitive subscale of Poulshock and Deimling PD (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.31333789064706286" CI_START="-1.9666621093529368" DF="0.0" EFFECT_SIZE="-1.14" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="0.006874394532345184" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="184" WEIGHT="99.99999999999999" Z="2.702868459913552">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="-0.31333789064706286" CI_START="-1.9666621093529368" EFFECT_SIZE="-1.14" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="0.98" ORDER="670" SD_1="4.04" SD_2="4.04" SE="0.4217741325215883" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="183" TOTAL_2="184" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.685430967000029E-31" CI_END="-0.6601894614862108" CI_START="-2.3398105385137895" DF="0.0" EFFECT_SIZE="-1.5000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.0" P_Z="4.639938969067141E-4" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0" Z="3.500725273122789">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="-0.6601894614862106" CI_START="-2.3398105385137895" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-0.52" MEAN_2="0.98" ORDER="671" SD_1="4.04" SD_2="4.04" SE="0.4284826380168757" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9406167788146287" CI_END="-0.26074468013386287" CI_START="-1.8974893137084043" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0791169969211336" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.33211943683128264" P_Q="0.33211943683128264" P_Z="0.009753855287962838" Q="0.9406167788146287" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="352" TOTAL_2="368" UNITS="" WEIGHT="200.0" Z="2.5844354772086304">
<NAME>Abridged Relatives Stress Scale aRSS (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4690378935731234" CI_START="-1.8290378935731233" DF="0.0" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="1.0" P_Z="0.24608725460584369" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="184" WEIGHT="100.0" Z="1.1599056192505113">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="0.4690378935731234" CI_START="-1.8290378935731233" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="1.22" ORDER="672" SD_1="5.6" SD_2="5.6" SE="0.5862545958173658" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="181" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.32414825291527305" CI_START="-2.6558517470847267" DF="0.0" EFFECT_SIZE="-1.49" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="1.0" P_Z="0.012248474245890494" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="184" WEIGHT="100.0" Z="2.504903684595541">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="-0.32414825291527305" CI_START="-2.6558517470847267" EFFECT_SIZE="-1.49" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="1.22" ORDER="673" SD_1="5.6" SD_2="5.6" SE="0.5948332501417458" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="171" TOTAL_2="184" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00971569929078015" CI_END="0.6292514025243175" CI_START="-1.5578471472051687" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4642978723404255" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.9214810832233604" P_Q="0.9214810832233604" P_Z="0.4053190886999183" Q="0.00971569929078015" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="357" TOTAL_2="366" UNITS="" WEIGHT="200.0" Z="0.8321592166007931">
<NAME>Caregiver Activity Time Survey CATS (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1267343796848581" CI_START="-1.946734379684858" DF="0.0" EFFECT_SIZE="-0.41" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="1.0" P_Z="0.601031698021268" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0" Z="0.5229174568387124">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="1.1267343796848581" CI_START="-1.946734379684858" EFFECT_SIZE="-0.41" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.36" ORDER="674" SD_1="7.5" SD_2="7.5" SE="0.784062560233975" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="183" TOTAL_2="183" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0364790999930027" CI_START="-2.0764790999930027" DF="0.0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="1.0" P_Z="0.5125970488353366" STUDIES="1" TAU2="0.0" TOTAL_1="174" TOTAL_2="183" WEIGHT="100.0" Z="0.6547992015860733">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<CONT_DATA CI_END="1.0364790999930027" CI_START="-2.0764790999930027" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="0.36" ORDER="675" SD_1="7.5" SD_2="7.5" SE="0.794136582238404" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="174" TOTAL_2="183" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="15.266848528064447" CI_END="1.9132037216048208" CI_START="1.1754680317085053" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4996365602679222" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="113" I2="41.048737180724274" I2_Q="13.153966285168293" ID="CMP-001.14" LOG_CI_END="0.28176121699966805" LOG_CI_START="0.07021082245170104" LOG_EFFECT_SIZE="0.1759860197256845" METHOD="PETO" NO="14" P_CHI2="0.08386217314525035" P_Q="0.32475303856212967" P_Z="0.0011104468738733898" Q="9.211704504858403" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1435" TOTAL_2="1256" WEIGHT="900.0" Z="3.2609370564580877">
<NAME>Total number of withdrawals before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.85826601509653" CI_START="1.3752336221464299" DF="0.0" EFFECT_SIZE="3.490298734761513" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.9473487180749347" LOG_CI_START="0.1383764815776047" LOG_EFFECT_SIZE="0.5428625998262696" NO="1" P_CHI2="1.0" P_Z="0.008526531669667924" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.0" Z="2.6304762913004622">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="8.85826601509653" CI_START="1.3752336221464296" EFFECT_SIZE="3.490298734761513" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.9473487180749347" LOG_CI_START="0.13837648157760463" LOG_EFFECT_SIZE="0.5428625998262696" ORDER="676" O_E="5.535580524344569" SE="0.4751942961956857" STUDY_ID="STD-Jann-1999" TOTAL_1="133" TOTAL_2="134" VAR="4.428509307186242" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.157299833376413" CI_START="0.7721207559033326" DF="0.0" EFFECT_SIZE="2.3508083200408736" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.8547492110456213" LOG_CI_START="-0.11231477282320428" LOG_EFFECT_SIZE="0.37121721911120853" NO="2" P_CHI2="1.0" P_Z="0.13240027004192279" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="134" WEIGHT="100.0" Z="1.5047037053088554">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="7.157299833376413" CI_START="0.7721207559033326" EFFECT_SIZE="2.3508083200408736" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8547492110456213" LOG_CI_START="-0.11231477282320428" LOG_EFFECT_SIZE="0.37121721911120853" ORDER="677" O_E="2.648854961832061" SE="0.5680581711684728" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="134" VAR="3.0989486318550417" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.25768243823002" CI_START="0.15955433347179018" DF="0.0" EFFECT_SIZE="3.97957200756393" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="1.9967641306634556" LOG_CI_START="-0.7970913959372319" LOG_EFFECT_SIZE="0.599836367363112" NO="3" P_CHI2="1.0" P_Z="0.40001058646671306" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="0.8416023416067411">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="99.25768243823012" CI_START="0.1595543334717901" EFFECT_SIZE="3.97957200756393" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.996764130663456" LOG_CI_START="-0.7970913959372321" LOG_EFFECT_SIZE="0.599836367363112" ORDER="678" O_E="0.5128205128205128" SE="1.641124566133145" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.3712931243295616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.47769420621917" CI_START="0.4414010917003395" DF="0.0" EFFECT_SIZE="1.4058659647795113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.14.04" LOG_CI_END="0.6510544311174417" LOG_CI_START="-0.3551665970492006" LOG_EFFECT_SIZE="0.14794391703412046" NO="4" P_CHI2="1.0" P_Z="0.5643826598089972" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.00000000000001" Z="0.5763440456953687">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.47769420621917" CI_START="0.4414010917003395" EFFECT_SIZE="1.4058659647795113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6510544311174417" LOG_CI_START="-0.3551665970492006" LOG_EFFECT_SIZE="0.14794391703412046" ORDER="679" O_E="0.9751037344398341" SE="0.5910592128195056" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="2.8624507153802448" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.4679212161738615" CI_START="0.9033715815739516" DF="0.0" EFFECT_SIZE="2.4172166263185217" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.14.05" LOG_CI_END="0.8107647212545648" LOG_CI_START="-0.04413357567383099" LOG_EFFECT_SIZE="0.3833155727903669" NO="5" P_CHI2="1.0" P_Z="0.07881555589728709" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="1.7576002200069571">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="6.4679212161738615" CI_START="0.9033715815739516" EFFECT_SIZE="2.4172166263185217" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8107647212545648" LOG_CI_START="-0.04413357567383099" LOG_EFFECT_SIZE="0.3833155727903669" ORDER="680" O_E="3.5" SE="0.5021714914305593" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="3.9654811715481166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.855942222588511" CI_START="1.0074997945898034" DF="0.0" EFFECT_SIZE="2.62818575846105" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-001.14.06" LOG_CI_END="0.8360671489797976" LOG_CI_START="0.0032449662687063737" LOG_EFFECT_SIZE="0.419656057624252" NO="6" P_CHI2="1.0" P_Z="0.04824121420931206" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="1.9752373937977374">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="6.855942222588511" CI_START="1.0074997945898034" EFFECT_SIZE="2.62818575846105" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8360671489797976" LOG_CI_START="0.0032449662687063737" LOG_EFFECT_SIZE="0.419656057624252" ORDER="681" O_E="4.03765690376569" SE="0.48920387266078685" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="4.178498275590414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.0551440232060445" CI_END="2.0369121303619924" CI_START="0.9295144298337839" DF="1.0" EFFECT_SIZE="1.3759866341919698" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="46" I2="83.48511618934994" ID="CMP-001.14.07" LOG_CI_END="0.3089722945269117" LOG_CI_START="-0.031743863828022585" LOG_EFFECT_SIZE="0.1386142153494446" NO="7" P_CHI2="0.013865903700905124" P_Z="0.1107677278730369" STUDIES="2" TAU2="0.0" TOTAL_1="412" TOTAL_2="325" WEIGHT="100.0" Z="1.5947518963698484">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.4448813797481301" CI_START="0.45965718986728815" EFFECT_SIZE="0.8149540568072506" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" LOG_CI_END="0.1598321943344853" LOG_CI_START="-0.3375659423453421" LOG_EFFECT_SIZE="-0.0888668740054284" ORDER="682" O_E="-2.3970223325062037" SE="0.2921741276462164" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="11.714303936725805" WEIGHT="46.92206887333504"/>
<DICH_DATA CI_END="3.7458080062144914" CI_START="1.276084925557776" EFFECT_SIZE="2.186314051266181" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="16" LOG_CI_END="0.5735455135681924" LOG_CI_START="0.10587957836146415" LOG_EFFECT_SIZE="0.33971254596482825" ORDER="683" O_E="10.365269461077844" SE="0.274709285324147" STUDY_ID="STD-Morris-1998" TOTAL_1="215" TOTAL_2="119" VAR="13.251142425727387" WEIGHT="53.07793112666495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7691694269278024" CI_START="0.5865953709650831" DF="0.0" EFFECT_SIZE="1.0187181142439736" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" I2="0.0" ID="CMP-001.14.08" LOG_CI_END="0.2477694257058886" LOG_CI_START="-0.2316613685158028" LOG_EFFECT_SIZE="0.008054028595042914" NO="8" P_CHI2="1.0" P_Z="0.9474960956130556" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="0.06585144787107881">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.7691694269278024" CI_START="0.5865953709650831" EFFECT_SIZE="1.0187181142439736" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.2477694257058886" LOG_CI_START="-0.2316613685158028" LOG_EFFECT_SIZE="0.008054028595042914" ORDER="684" O_E="0.23383084577114488" SE="0.2816200217465278" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="12.60877644259688" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1844556735192207" CI_START="0.5593540110147975" DF="0.0" EFFECT_SIZE="1.1053886388356844" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" I2="0.0" ID="CMP-001.14.09" LOG_CI_END="0.3393432365295336" LOG_CI_START="-0.2523132433337083" LOG_EFFECT_SIZE="0.04351499659791263" NO="9" P_CHI2="1.0" P_Z="0.7731156985965424" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="0.28830184075396426">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.1844556735192207" CI_START="0.5593540110147975" EFFECT_SIZE="1.1053886388356844" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.3393432365295336" LOG_CI_START="-0.2523132433337083" LOG_EFFECT_SIZE="0.04351499659791263" ORDER="685" O_E="0.8295454545454533" SE="0.3475419450184779" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="8.279146077522546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.155074865781402" CI_END="2.2241477136603756" CI_START="1.1820551756362558" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6214392730878922" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.3471636269285894" LOG_CI_START="0.07263774889303344" LOG_EFFECT_SIZE="0.2099006879108114" METHOD="PETO" NO="15" P_CHI2="0.7243030882502675" P_Q="0.9524922667484027" P_Z="0.0027251547320020896" Q="2.686013518542847" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1492" TOTAL_2="1270" WEIGHT="900.0" Z="2.9971512454799556">
<NAME>Total number of withdrawals due to an adverse event before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.323016390843996" CI_START="0.9889611832857456" DF="0.0" EFFECT_SIZE="3.4909862319319904" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="1.0907170261365695" LOG_CI_START="-0.0048207541213624305" LOG_EFFECT_SIZE="0.5429481360076036" NO="1" P_CHI2="1.0" P_Z="0.05205061329582816" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="1.9427149135788158">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="12.323016390843996" CI_START="0.9889611832857453" EFFECT_SIZE="3.4909862319319904" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.0907170261365695" LOG_CI_START="-0.004820754121362528" LOG_EFFECT_SIZE="0.5429481360076036" ORDER="686" O_E="3.018867924528302" SE="0.6435243151229827" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="2.414738341046636" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.203337421403454" CI_START="0.5586011498450429" DF="0.0" EFFECT_SIZE="2.5016388959436107" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.0493474162228265" LOG_CI_START="-0.2528981746664437" LOG_EFFECT_SIZE="0.3982246207781913" NO="2" P_CHI2="1.0" P_Z="0.2306416411574893" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="1.1987077091186595">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="11.203337421403454" CI_START="0.5586011498450428" EFFECT_SIZE="2.5016388959436107" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0493474162228265" LOG_CI_START="-0.25289817466644376" LOG_EFFECT_SIZE="0.3982246207781913" ORDER="687" O_E="1.5670498084291187" SE="0.7649455063079955" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="1.708987965983606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="341.5371517710299" CI_START="0.043118579725725276" DF="0.0" EFFECT_SIZE="3.83752484134452" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="2.533437952326665" LOG_CI_START="-1.365335552724815" LOG_EFFECT_SIZE="0.5840511998009249" NO="3" P_CHI2="1.0" P_Z="0.5570558173824023" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="0.5872202195147035">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="341.5371517710299" CI_START="0.043118579725725276" EFFECT_SIZE="3.83752484134452" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.533437952326665" LOG_CI_START="-1.365335552724815" LOG_EFFECT_SIZE="0.5840511998009249" ORDER="688" O_E="0.2564102564102564" SE="2.2901588561073436" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.19066403681788296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.008432170117101" CI_START="0.35834235494646327" DF="0.0" EFFECT_SIZE="1.198495316420938" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="0.60297453895172" LOG_CI_START="-0.44570185654949057" LOG_EFFECT_SIZE="0.07863634120111478" NO="4" P_CHI2="1.0" P_Z="0.7688031303526636" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="99.99999999999999" Z="0.2939408139467561">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.008432170117101" CI_START="0.35834235494646327" EFFECT_SIZE="1.198495316420938" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.60297453895172" LOG_CI_START="-0.44570185654949057" LOG_EFFECT_SIZE="0.07863634120111478" ORDER="689" O_E="0.4771784232365146" SE="0.6159977057492887" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="2.635371291816601" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.960446133998462" CI_START="0.5327932962088959" DF="0.0" EFFECT_SIZE="1.6256975261098587" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.15.05" LOG_CI_END="0.6955207379459496" LOG_CI_START="-0.27344124824804156" LOG_EFFECT_SIZE="0.21103974484895394" NO="5" P_CHI2="1.0" P_Z="0.3932382117460469" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.853759600694307">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.960446133998462" CI_START="0.5327932962088959" EFFECT_SIZE="1.6256975261098587" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6955207379459496" LOG_CI_START="-0.27344124824804156" LOG_EFFECT_SIZE="0.21103974484895394" ORDER="690" O_E="1.5" SE="0.569173067129538" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="3.0868200836820083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.005606141706693" CI_START="0.5375001346270736" DF="0.0" EFFECT_SIZE="1.6402786272635064" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.15.06" LOG_CI_END="0.6994566748341944" LOG_CI_START="-0.2696214226350773" LOG_EFFECT_SIZE="0.21491762609955842" NO="6" P_CHI2="1.0" P_Z="0.3846593598653022" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="0.8693433643748962">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.005606141706693" CI_START="0.5375001346270736" EFFECT_SIZE="1.6402786272635064" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6994566748341944" LOG_CI_START="-0.2696214226350773" LOG_EFFECT_SIZE="0.21491762609955842" ORDER="691" O_E="1.527196652719665" SE="0.5692412714673979" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="3.0860804257628547" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.469061347238555" CI_END="2.7994952478911976" CI_START="0.9523971908552116" DF="1.0" EFFECT_SIZE="1.6328598867949726" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" I2="71.17375855010403" ID="CMP-001.15.07" LOG_CI_END="0.4470797346220789" LOG_CI_START="-0.021181894239311987" LOG_EFFECT_SIZE="0.21294892019138345" NO="7" P_CHI2="0.06252689773492792" P_Z="0.0746440481416555" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="341" WEIGHT="99.99999999999999" Z="1.7826453776991042">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.0419059419669217" CI_START="0.36661110095719235" EFFECT_SIZE="0.8652082902027269" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.3100357329391586" LOG_CI_START="-0.43579438876970855" LOG_EFFECT_SIZE="-0.06287932791527495" ORDER="692" O_E="-0.7543424317617866" SE="0.43810430541043355" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="5.210086787521793" WEIGHT="39.4182468339053"/>
<DICH_DATA CI_END="4.934313000795457" CI_START="1.2348468104024826" EFFECT_SIZE="2.4684247346353856" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="6" LOG_CI_END="0.6932266948510836" LOG_CI_START="0.09161308429739583" LOG_EFFECT_SIZE="0.39241988957423973" ORDER="693" O_E="7.235294117647058" SE="0.3533908128746375" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="135" VAR="8.007362505632402" WEIGHT="60.581753166094686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2525330148892206" CI_START="0.7185561738159136" DF="0.0" EFFECT_SIZE="1.5287667181060478" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-001.15.08" LOG_CI_END="0.5122217135691931" LOG_CI_START="-0.1435392748162351" LOG_EFFECT_SIZE="0.18434121937647896" NO="8" P_CHI2="1.0" P_Z="0.2704910644091699" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.1019324334424667">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="3.2525330148892206" CI_START="0.7185561738159136" EFFECT_SIZE="1.5287667181060478" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.5122217135691931" LOG_CI_START="-0.1435392748162351" LOG_EFFECT_SIZE="0.18434121937647896" ORDER="694" O_E="2.8606965174129346" SE="0.38519725064684496" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="6.739592567058875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7519988236356445" CI_START="0.5074599177510113" DF="0.0" EFFECT_SIZE="1.1817483220605915" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" I2="0.0" ID="CMP-001.15.09" LOG_CI_END="0.43964824392079294" LOG_CI_START="-0.29459825526108385" LOG_EFFECT_SIZE="0.07252499432985449" NO="9" P_CHI2="1.0" P_Z="0.6986157031451464" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="0.3871897980415868">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.751998823635644" CI_START="0.5074599177510113" EFFECT_SIZE="1.1817483220605915" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.4396482439207928" LOG_CI_START="-0.29459825526108385" LOG_EFFECT_SIZE="0.07252499432985449" ORDER="695" O_E="0.8977272727272734" SE="0.43130002819822305" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="5.375774302391352" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.270511347811112" CI_END="1.1925254870610693" CI_START="0.8755071482096665" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.021794787784798" ESTIMABLE="YES" EVENTS_1="835" EVENTS_2="662" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.07646766970099635" LOG_CI_START="-0.05774030370350443" LOG_EFFECT_SIZE="0.009363682998745943" METHOD="MH" NO="16" P_CHI2="0.6024323455159546" P_Q="0.0" P_Z="0.7844741490543524" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1519" TOTAL_2="1292" WEIGHT="1000.0" Z="0.27349316101924837">
<NAME>Total number who suffered at least one mild adverse event before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6000897178069022" CI_START="0.6028440662432546" DF="0.0" EFFECT_SIZE="0.9821428571428571" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="56" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.204144334440976" LOG_CI_START="-0.2197950094648891" LOG_EFFECT_SIZE="-0.007825337511956592" NO="1" P_CHI2="1.0" P_Z="0.9423182165436952" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="0.07235648170324493">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="1.6000897178069022" CI_START="0.6028440662432545" EFFECT_SIZE="0.9821428571428571" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="56" LOG_CI_END="0.204144334440976" LOG_CI_START="-0.2197950094648892" LOG_EFFECT_SIZE="-0.007825337511956592" ORDER="696" O_E="0.0" SE="0.24902406914390227" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="0.06201298701298702" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3997806776025925" CI_START="0.5196170339188085" DF="0.0" EFFECT_SIZE="0.8528481012658228" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="56" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.14605999427206026" LOG_CI_START="-0.2843166204633529" LOG_EFFECT_SIZE="-0.06912831309564632" NO="2" P_CHI2="1.0" P_Z="0.5289367248582275" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="0.6296299535827302">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="1.3997806776025925" CI_START="0.5196170339188085" EFFECT_SIZE="0.8528481012658228" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="56" LOG_CI_END="0.14605999427206026" LOG_CI_START="-0.2843166204633529" LOG_EFFECT_SIZE="-0.06912831309564632" ORDER="697" O_E="0.0" SE="0.25280535389418324" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="0.06391054695756324" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.60161737679392" CI_START="0.1341586855719051" DF="0.0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="0.6629105043683917" LOG_CI_START="-0.8723812054084177" LOG_EFFECT_SIZE="-0.104735350520013" NO="3" P_CHI2="1.0" P_Z="0.7891521603801044" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="0.2674117415214152">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="4.60161737679392" CI_START="0.1341586855719051" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.6629105043683917" LOG_CI_START="-0.8723812054084177" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="698" O_E="0.0" SE="0.9018379501394296" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.8133116883116883" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6313736466799162" CI_START="0.1714372761917884" DF="0.0" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-001.16.04" LOG_CI_END="0.21255344240541238" LOG_CI_START="-0.7658947420144854" LOG_EFFECT_SIZE="-0.2766706498045365" NO="4" P_CHI2="1.0" P_Z="0.2676816000415484" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.108417426350856">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.6313736466799167" CI_START="0.17143727619178833" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.21255344240541246" LOG_CI_START="-0.7658947420144855" LOG_EFFECT_SIZE="-0.2766706498045365" ORDER="699" O_E="0.0" SE="0.5747453069248742" STUDY_ID="STD-Becker-1998" TOTAL_1="27" TOTAL_2="23" VAR="0.33033216783216784" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0931071663266718" CI_START="0.39457845266261937" DF="0.0" EFFECT_SIZE="0.6567469332121763" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="71" I2="0.0" ID="CMP-001.16.05" LOG_CI_END="0.038662741513114496" LOG_CI_START="-0.40386663460645716" LOG_EFFECT_SIZE="-0.18260194654667133" NO="5" P_CHI2="1.0" P_Z="0.10577272949979362" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="1.6174891794829955">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.0931071663266718" CI_START="0.39457845266261937" EFFECT_SIZE="0.6567469332121763" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="71" LOG_CI_END="0.038662741513114496" LOG_CI_START="-0.40386663460645716" LOG_EFFECT_SIZE="-0.18260194654667133" ORDER="700" O_E="0.0" SE="0.259943946088377" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="0.06757085510799704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2742804383513083E-31" CI_END="1.5600877363060899" CI_START="0.5588358630247925" DF="0.0" EFFECT_SIZE="0.9337199668599835" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="71" I2="100.0" ID="CMP-001.16.06" LOG_CI_END="0.19314902291994035" LOG_CI_START="-0.25271573102242567" LOG_EFFECT_SIZE="-0.029783354051242647" NO="6" P_CHI2="0.0" P_Z="0.7934389625499811" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.26184757042619417">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.5600877363060897" CI_START="0.5588358630247925" EFFECT_SIZE="0.9337199668599834" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="71" LOG_CI_END="0.1931490229199403" LOG_CI_START="-0.25271573102242567" LOG_EFFECT_SIZE="-0.0297833540512427" ORDER="701" O_E="0.0" SE="0.2619031635318729" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="0.06859326706800295" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.219110523853158" CI_START="0.7768157485745684" DF="0.0" EFFECT_SIZE="1.3129508759876332" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="71" I2="0.0" ID="CMP-001.16.07" LOG_CI_END="0.3461789330135299" LOG_CI_START="-0.1096819784531633" LOG_EFFECT_SIZE="0.11824847728018328" NO="7" P_CHI2="1.0" P_Z="0.3092421889252316" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="1.0168134659766526">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="2.219110523853158" CI_START="0.7768157485745684" EFFECT_SIZE="1.3129508759876332" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="71" LOG_CI_END="0.3461789330135299" LOG_CI_START="-0.1096819784531633" LOG_EFFECT_SIZE="0.11824847728018328" ORDER="702" O_E="0.0" SE="0.2677749559434405" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="0.0717034270305115" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.47852053591057847" CI_END="1.4362317560686624" CI_START="0.7928839331148685" DF="1.0" EFFECT_SIZE="1.067129365923455" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="174" I2="0.0" ID="CMP-001.16.08" LOG_CI_END="0.15722452504601542" LOG_CI_START="-0.10079038253991447" LOG_EFFECT_SIZE="0.02821707125305046" NO="8" P_CHI2="0.4890932582295594" P_Z="0.668147497214151" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="100.0" Z="0.4286918451544175">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.4476799182275422" CI_START="0.6530985313598712" EFFECT_SIZE="0.9723567393058918" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="84" LOG_CI_END="0.16067255004212322" LOG_CI_START="-0.18502129284775798" LOG_EFFECT_SIZE="-0.012174371402817392" ORDER="703" O_E="0.0" SE="0.20306227452563666" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="0.041234287335525026" WEIGHT="58.47055314330835"/>
<DICH_DATA CI_END="1.8742893071239468" CI_START="0.7690117646177755" EFFECT_SIZE="1.20056258790436" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="90" LOG_CI_END="0.27283662752830096" LOG_CI_START="-0.11406701615500665" LOG_EFFECT_SIZE="0.07938480568664716" ORDER="704" O_E="0.0" SE="0.22726911550349915" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="0.05165125086174284" WEIGHT="41.52944685669164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9068596649730316" CI_START="0.8656679384131856" DF="0.0" EFFECT_SIZE="1.284798534798535" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="84" I2="0.0" ID="CMP-001.16.09" LOG_CI_END="0.280318732390286" LOG_CI_START="-0.06264866707100297" LOG_EFFECT_SIZE="0.1088350326596415" NO="9" P_CHI2="1.0" P_Z="0.21352744225845155" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.2439243181958157">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.9068596649730316" CI_START="0.8656679384131856" EFFECT_SIZE="1.284798534798535" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="84" LOG_CI_END="0.280318732390286" LOG_CI_START="-0.06264866707100297" LOG_EFFECT_SIZE="0.1088350326596415" ORDER="705" O_E="0.0" SE="0.20146074815956888" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="0.040586433049013236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2077731354575003" CI_START="0.7305551345363983" DF="0.0" EFFECT_SIZE="1.27" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="58" I2="0.0" ID="CMP-001.16.10" LOG_CI_END="0.3439544444734196" LOG_CI_START="-0.13634700256150584" LOG_EFFECT_SIZE="0.10380372095595687" NO="10" P_CHI2="1.0" P_Z="0.3968932656921339" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="0.8471827673678738">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.2077731354575003" CI_START="0.7305551345363983" EFFECT_SIZE="1.27" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="58" LOG_CI_END="0.3439544444734196" LOG_CI_START="-0.13634700256150584" LOG_EFFECT_SIZE="0.10380372095595687" ORDER="706" O_E="0.0" SE="0.2821314475188223" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="0.07959815367906597" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.86108452780961" CI_END="1.6452613910159841" CI_START="1.1807250131835092" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3937723191388423" ESTIMABLE="YES" EVENTS_1="523" EVENTS_2="348" I2="17.135347055299462" I2_Q="23.691288324304086" ID="CMP-001.17" LOG_CI_END="0.21623490633315468" LOG_CI_START="0.07214876369074977" LOG_EFFECT_SIZE="0.14419183501195224" METHOD="PETO" NO="17" P_CHI2="0.28535140401844583" P_Q="0.2327011774016644" P_Z="8.752457803236604E-5" Q="10.483730919215578" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1492" TOTAL_2="1269" WEIGHT="900.0" Z="3.9228033772762685">
<NAME>Total number who suffered at least one moderate adverse event before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.337520774017145" CI_START="0.9481697387081907" DF="0.0" EFFECT_SIZE="1.7789143318982492" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.5234239775974809" LOG_CI_START="-0.0231139095124929" LOG_EFFECT_SIZE="0.250155034042494" NO="1" P_CHI2="1.0" P_Z="0.07278375190658082" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="1.7941843331934382">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="3.337520774017145" CI_START="0.9481697387081908" EFFECT_SIZE="1.7789143318982492" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.5234239775974809" LOG_CI_START="-0.02311390951249285" LOG_EFFECT_SIZE="0.250155034042494" ORDER="707" O_E="5.588679245283018" SE="0.321039060294572" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="9.702513349946601" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.218837940019993" CI_START="0.8927647086261865" DF="0.0" EFFECT_SIZE="1.6951887551647054" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.5076991116570977" LOG_CI_START="-0.049262985915278355" LOG_EFFECT_SIZE="0.22921806287090968" NO="2" P_CHI2="1.0" P_Z="0.10669051971783501" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="1.613248548837349">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="3.218837940019993" CI_START="0.8927647086261866" EFFECT_SIZE="1.6951887551647054" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.5076991116570977" LOG_CI_START="-0.0492629859152783" LOG_EFFECT_SIZE="0.22921806287090968" ORDER="708" O_E="4.931034482758619" SE="0.3271622931208611" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="9.342723863532425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.36669972042996" CI_START="0.7774147443831894" DF="0.0" EFFECT_SIZE="4.938110452926535" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="1.4964688263609243" LOG_CI_START="-0.10934722683372768" LOG_EFFECT_SIZE="0.6935607997635982" NO="3" P_CHI2="1.0" P_Z="0.09044814208453059" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.6930384846024105">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="31.36669972042996" CI_START="0.7774147443831894" EFFECT_SIZE="4.938110452926535" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.4964688263609243" LOG_CI_START="-0.10934722683372768" LOG_EFFECT_SIZE="0.6935607997635982" ORDER="709" O_E="1.7948717948717947" SE="0.9432642985642002" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="1.123914322294889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5542433915550693" CI_START="0.48138541372612753" DF="0.0" EFFECT_SIZE="0.864979825241512" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" I2="0.0" ID="CMP-001.17.04" LOG_CI_END="0.19151902947929986" LOG_CI_START="-0.31750707325132244" LOG_EFFECT_SIZE="-0.06299402188601132" NO="4" P_CHI2="1.0" P_Z="0.6276005842041203" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="0.48510680876909207">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.5542433915550693" CI_START="0.48138541372612753" EFFECT_SIZE="0.864979825241512" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.19151902947929986" LOG_CI_START="-0.31750707325132244" LOG_EFFECT_SIZE="-0.06299402188601132" ORDER="710" O_E="-1.6224066390041507" SE="0.2990044524638136" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="11.185224083607375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.664873154709561" CI_START="0.8890934776798118" DF="0.0" EFFECT_SIZE="1.5392599977574597" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="31" I2="0.0" ID="CMP-001.17.05" LOG_CI_END="0.4256765418726309" LOG_CI_START="-0.05105257569310529" LOG_EFFECT_SIZE="0.18731198308976274" NO="5" P_CHI2="1.0" P_Z="0.12351605974647299" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="1.5401817392791743">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="2.664873154709561" CI_START="0.889093477679812" EFFECT_SIZE="1.5392599977574597" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="31" LOG_CI_END="0.4256765418726309" LOG_CI_START="-0.05105257569310524" LOG_EFFECT_SIZE="0.18731198308976274" ORDER="711" O_E="5.5" SE="0.28003304350530445" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="12.752092050209203" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.521191762340089" CI_START="0.8330188906454635" DF="0.0" EFFECT_SIZE="1.4492068054522176" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="31" I2="0.0" ID="CMP-001.17.06" LOG_CI_END="0.4016058794562397" LOG_CI_START="-0.07934514984163965" LOG_EFFECT_SIZE="0.16113036480729998" NO="6" P_CHI2="1.0" P_Z="0.18909137759649022" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="1.3132717994143641">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="2.521191762340089" CI_START="0.8330188906454635" EFFECT_SIZE="1.4492068054522176" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="31" LOG_CI_END="0.4016058794562397" LOG_CI_START="-0.07934514984163965" LOG_EFFECT_SIZE="0.16113036480729998" ORDER="712" O_E="4.648535564853553" SE="0.2825130153555655" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="12.529192416099159" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3773536085940319" CI_END="1.591782252243259" CI_START="0.8902493991954968" DF="1.0" EFFECT_SIZE="1.1904130349209119" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="125" I2="0.0" ID="CMP-001.17.07" LOG_CI_END="0.2018836581773889" LOG_CI_START="-0.05048831074684939" LOG_EFFECT_SIZE="0.07569767371526977" NO="7" P_CHI2="0.5390232617911208" P_Z="0.2396899249701423" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="100.00000000000001" Z="1.1757622276975768">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.9357478935782064" CI_START="0.8697522359394836" EFFECT_SIZE="1.2975442415019192" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="74" LOG_CI_END="0.28684879534982216" LOG_CI_START="-0.06060444610445346" LOG_EFFECT_SIZE="0.1131221746226844" ORDER="713" O_E="6.2531017369727095" SE="0.20409575395152524" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="24.006677631551742" WEIGHT="52.758142504957384"/>
<DICH_DATA CI_END="1.6500330566009431" CI_START="0.7084575210578941" EFFECT_SIZE="1.0811930118822837" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="51" LOG_CI_END="0.21749264491425338" LOG_CI_START="-0.1496861848282675" LOG_EFFECT_SIZE="0.033903230042992956" ORDER="714" O_E="1.678132678132684" SE="0.21568266215527734" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="21.4965878204038" WEIGHT="47.24185749504263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9141337301067651" CI_START="0.8586577228456335" DF="0.0" EFFECT_SIZE="1.2820240676038392" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="74" I2="0.0" ID="CMP-001.17.08" LOG_CI_END="0.28197227629274724" LOG_CI_START="-0.06617991964099244" LOG_EFFECT_SIZE="0.10789617832587742" NO="8" P_CHI2="1.0" P_Z="0.22443149023112807" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.2148286069031622">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.9141337301067651" CI_START="0.8586577228456335" EFFECT_SIZE="1.2820240676038392" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="74" LOG_CI_END="0.28197227629274724" LOG_CI_START="-0.06617991964099244" LOG_EFFECT_SIZE="0.10789617832587742" ORDER="715" O_E="5.9402985074626855" SE="0.2045063232726429" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="23.91038220887967" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0200691731870135" CI_START="1.3859189857153358" DF="0.0" EFFECT_SIZE="2.360400430225523" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="20" I2="0.0" ID="CMP-001.17.09" LOG_CI_END="0.6042335260384383" LOG_CI_START="0.1417378442114936" LOG_EFFECT_SIZE="0.37298568512496594" NO="9" P_CHI2="1.0" P_Z="0.0015707897587135084" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="3.1612771246044544">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="4.0200691731870135" CI_START="1.3859189857153358" EFFECT_SIZE="2.360400430225523" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="20" LOG_CI_END="0.6042335260384383" LOG_CI_START="0.1417378442114936" LOG_EFFECT_SIZE="0.37298568512496594" ORDER="716" O_E="11.63636363636364" SE="0.27167225289569524" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="13.549068283945573" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.589059070566925" CI_END="1.6848722696277696" CI_START="0.8786807642354703" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2167435446780392" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="66" I2="56.96393254962088" I2_Q="41.91735175867555" ID="CMP-001.18" LOG_CI_END="0.22656698253764224" LOG_CI_START="-0.05616888091389883" LOG_EFFECT_SIZE="0.08519905081187168" METHOD="PETO" NO="18" P_CHI2="0.017218785426080796" P_Q="0.09886852490244491" P_Z="0.23751411508848697" Q="12.051792078963203" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1492" TOTAL_2="1269" WEIGHT="800.0" Z="1.1812231322177988">
<NAME>Total number who suffered at least one severe adverse event before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.91779426637139" CI_START="1.7428654483953634" DF="0.0" EFFECT_SIZE="7.801090767388649" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="1.5430468018090486" LOG_CI_START="0.2412638602740788" LOG_EFFECT_SIZE="0.8921553310415637" NO="1" P_CHI2="1.0" P_Z="0.007221411984675511" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="2.6864575677955327">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="34.917794266371374" CI_START="1.7428654483953638" EFFECT_SIZE="7.801090767388649" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.5430468018090484" LOG_CI_START="0.24126386027407892" LOG_EFFECT_SIZE="0.8921553310415637" ORDER="717" O_E="3.513207547169811" SE="0.764673743787128" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="1.7102029191883235" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="124.53646212287045" CI_START="0.48155834334110603" DF="0.0" EFFECT_SIZE="7.74413148038254" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="2.09529652396496" LOG_CI_START="-0.3173510882775397" LOG_EFFECT_SIZE="0.8889727178437101" NO="2" P_CHI2="1.0" P_Z="0.14864037975394176" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="1.4443505975519413">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="124.53646212287045" CI_START="0.48155834334110587" EFFECT_SIZE="7.74413148038254" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.09529652396496" LOG_CI_START="-0.3173510882775399" LOG_EFFECT_SIZE="0.8889727178437101" ORDER="718" O_E="1.0191570881226055" SE="1.417201150229536" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="0.4978941318219955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="719" O_E="0.0" SE="0.0" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.47769420621917" CI_START="0.4414010917003395" DF="0.0" EFFECT_SIZE="1.4058659647795113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.6510544311174417" LOG_CI_START="-0.3551665970492006" LOG_EFFECT_SIZE="0.14794391703412046" NO="4" P_CHI2="1.0" P_Z="0.5643826598089972" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.00000000000001" Z="0.5763440456953687">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.47769420621917" CI_START="0.4414010917003395" EFFECT_SIZE="1.4058659647795113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6510544311174417" LOG_CI_START="-0.3551665970492006" LOG_EFFECT_SIZE="0.14794391703412046" ORDER="720" O_E="0.9751037344398341" SE="0.5910592128195056" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="2.8624507153802448" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.960446133998462" CI_START="0.5327932962088959" DF="0.0" EFFECT_SIZE="1.6256975261098587" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.18.05" LOG_CI_END="0.6955207379459496" LOG_CI_START="-0.27344124824804156" LOG_EFFECT_SIZE="0.21103974484895394" NO="5" P_CHI2="1.0" P_Z="0.3932382117460469" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.853759600694307">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.960446133998462" CI_START="0.5327932962088959" EFFECT_SIZE="1.6256975261098587" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6955207379459496" LOG_CI_START="-0.27344124824804156" LOG_EFFECT_SIZE="0.21103974484895394" ORDER="721" O_E="1.5" SE="0.569173067129538" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="3.0868200836820083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.815441652583389" CI_START="0.7217744916510532" DF="0.0" EFFECT_SIZE="2.0487648577910877" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-001.18.06" LOG_CI_END="0.7645827027267744" LOG_CI_START="-0.14159847047676768" LOG_EFFECT_SIZE="0.3114921161250033" NO="6" P_CHI2="1.0" P_Z="0.1778378910093999" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="1.347442094641806">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.815441652583389" CI_START="0.7217744916510532" EFFECT_SIZE="2.0487648577910877" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7645827027267744" LOG_CI_START="-0.14159847047676768" LOG_EFFECT_SIZE="0.3114921161250033" ORDER="722" O_E="2.531380753138075" SE="0.5322953068089119" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="3.5293499763659604" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.537266991603722" CI_END="1.296128641572286" CI_START="0.41478855913323226" DF="1.0" EFFECT_SIZE="0.7332252939506944" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" I2="84.70308767739834" ID="CMP-001.18.07" LOG_CI_END="0.11264810767069522" LOG_CI_START="-0.3821732310048607" LOG_EFFECT_SIZE="-0.13476256166708273" NO="7" P_CHI2="0.010563782442971736" P_Z="0.28571169431709753" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="100.0" Z="1.067576301534662">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="0.7785155365490134" CI_START="0.15447055539746068" EFFECT_SIZE="0.3467819593293143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.10873271595369544" LOG_CI_START="-0.8111542919484819" LOG_EFFECT_SIZE="-0.45994350395108863" ORDER="723" O_E="-6.220843672456576" SE="0.41260591078221576" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="5.8739346387593585" WEIGHT="49.62507240861391"/>
<DICH_DATA CI_END="3.4210933198619973" CI_START="0.6870540259634065" EFFECT_SIZE="1.5331261978740371" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" LOG_CI_END="0.5341649209399153" LOG_CI_START="-0.16300911118607064" LOG_EFFECT_SIZE="0.1855779048769223" ORDER="724" O_E="2.5479115479115464" SE="0.4095234775379213" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="5.962692198564434" WEIGHT="50.37492759138609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.163247810994229" CI_START="0.5779586636356964" DF="0.0" EFFECT_SIZE="1.118153752377136" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" ID="CMP-001.18.08" LOG_CI_END="0.33510627292163253" LOG_CI_START="-0.2381032217816934" LOG_EFFECT_SIZE="0.04850152556996952" NO="8" P_CHI2="1.0" P_Z="0.7401304286559454" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="99.99999999999999" Z="0.33168063052266555">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.163247810994229" CI_START="0.5779586636356964" EFFECT_SIZE="1.118153752377136" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.33510627292163253" LOG_CI_START="-0.2381032217816934" LOG_EFFECT_SIZE="0.04850152556996952" ORDER="725" O_E="0.9850746268656714" SE="0.3367060946214939" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="8.8205983148611" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8804550108192846" CI_START="0.3968168077446582" DF="0.0" EFFECT_SIZE="1.0691178430114303" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" ID="CMP-001.18.09" LOG_CI_END="0.45946109646741845" LOG_CI_START="-0.4014099409630064" LOG_EFFECT_SIZE="0.029025577752206017" NO="9" P_CHI2="1.0" P_Z="0.894852724504413" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="0.1321663397913735">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.8804550108192846" CI_START="0.3968168077446582" EFFECT_SIZE="1.0691178430114303" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.45946109646741845" LOG_CI_START="-0.4014099409630064" LOG_EFFECT_SIZE="0.029025577752206017" ORDER="726" O_E="0.2613636363636367" SE="0.5056799087669935" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="3.9106468788297772" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7116437593777682" CI_END="1.08938863085817" CI_START="0.4643388833082947" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7112281633494519" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="58" I2="63.12199946834215" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.037182838551097594" LOG_CI_START="-0.33316494739312374" LOG_EFFECT_SIZE="-0.14799105442101307" METHOD="MH" NO="19" P_CHI2="0.0996183661682376" P_Q="0.0" P_Z="0.11725405441335282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="412" WEIGHT="200.0" Z="1.5664040542852269">
<NAME>Total number who suffered at least one serious adverse event before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9129346713436668" CI_START="0.23881671920579928" DF="0.0" EFFECT_SIZE="0.46693046919163367" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" I2="0.0" ID="CMP-001.19.06" LOG_CI_END="-0.03956029901560511" LOG_CI_START="-0.6219352721630769" LOG_EFFECT_SIZE="-0.3307477855893409" NO="6" P_CHI2="1.0" P_Z="0.025997990996437785" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="206" WEIGHT="100.0" Z="2.226241777588648">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="0.9129346713436668" CI_START="0.23881671920579928" EFFECT_SIZE="0.46693046919163367" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="-0.03956029901560511" LOG_CI_START="-0.6219352721630769" LOG_EFFECT_SIZE="-0.3307477855893409" ORDER="727" O_E="0.0" SE="0.34208994202943516" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="0.11702552843770232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7155726781541403" CI_START="0.5542370250612736" DF="0.0" EFFECT_SIZE="0.9751071209957152" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" I2="0.0" ID="CMP-001.19.07" LOG_CI_END="0.23440912114049253" LOG_CI_START="-0.25630446512416377" LOG_EFFECT_SIZE="-0.01094767199183568" NO="7" P_CHI2="1.0" P_Z="0.9303119119247678" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="0.08745240979320837">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.7155726781541403" CI_START="0.5542370250612736" EFFECT_SIZE="0.9751071209957152" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.23440912114049253" LOG_CI_START="-0.25630446512416377" LOG_EFFECT_SIZE="-0.01094767199183568" ORDER="728" O_E="0.0" SE="0.2882475896432867" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="0.0830866729351646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.980044800350828" CI_END="3.366806082593337" CI_START="1.1088425926209728" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9321640679494216" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" I2="49.87496812268338" I2_Q="49.87496812268338" ID="CMP-001.20" LOG_CI_END="0.5272181031166492" LOG_CI_START="0.044869899613500075" LOG_EFFECT_SIZE="0.28604400136507463" METHOD="PETO" NO="20" P_CHI2="0.09231196968861399" P_Q="0.09231196968861399" P_Z="0.020092776551768124" Q="7.980044800350828" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="564" TOTAL_2="470" WEIGHT="500.0" Z="2.3246108790186963">
<NAME>Total number who suffered at least one adverse event of abdominal pain before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8045907979250675" CI_START="0.0065470569008066175" DF="0.0" EFFECT_SIZE="0.1086957158157001" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.25637873845746695" LOG_CI_START="-2.183953884586031" LOG_EFFECT_SIZE="-0.9637875730642819" NO="1" P_CHI2="1.0" P_Z="0.12158846348307162" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.5481405396264198">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.8045907979250666" CI_START="0.006547056900806623" EFFECT_SIZE="0.1086957158157001" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2563787384574667" LOG_CI_START="-2.1839538845860305" LOG_EFFECT_SIZE="-0.9637875730642819" ORDER="729" O_E="-1.08" SE="1.4334634626170555" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.4866612244897959" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3165462689208525" CI_START="0.16496234905345275" DF="0.0" EFFECT_SIZE="0.7396656428857895" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="0.5206860604906719" LOG_CI_START="-0.7826151676904778" LOG_EFFECT_SIZE="-0.13096455359990286" NO="3" P_CHI2="1.0" P_Z="0.6936541558975349" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="0.3939009689500541">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="3.3165462689208525" CI_START="0.16496234905345283" EFFECT_SIZE="0.7396656428857895" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5206860604906719" LOG_CI_START="-0.7826151676904776" LOG_EFFECT_SIZE="-0.13096455359990286" ORDER="730" O_E="-0.5145228215767634" SE="0.7655655928787343" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="1.706220622923159" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.754037033117041" CI_START="0.3331515794734246" DF="0.0" EFFECT_SIZE="1.2584970983113533" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="0.6770625604833973" LOG_CI_START="-0.4773581233984966" LOG_EFFECT_SIZE="0.09985221854245042" NO="4" P_CHI2="1.0" P_Z="0.7345673849032366" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.3390562120933857">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="4.754037033117041" CI_START="0.3331515794734246" EFFECT_SIZE="1.2584970983113533" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6770625604833973" LOG_CI_START="-0.4773581233984966" LOG_EFFECT_SIZE="0.09985221854245042" ORDER="731" O_E="0.5" SE="0.6781124241867715" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="2.1746861924686187" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.709689861103053" CI_START="1.2799131703722482" DF="0.0" EFFECT_SIZE="3.338809183389107" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" ID="CMP-001.20.05" LOG_CI_END="0.9400026907126435" LOG_CI_START="0.10718050800155221" LOG_EFFECT_SIZE="0.5235915993570979" NO="5" P_CHI2="1.0" P_Z="0.013722705188005838" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="2.4644412664585245">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="8.709689861103053" CI_START="1.2799131703722482" EFFECT_SIZE="3.338809183389107" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9400026907126435" LOG_CI_START="0.10718050800155221" LOG_EFFECT_SIZE="0.5235915993570979" ORDER="732" O_E="5.03765690376569" SE="0.48920387266078685" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="4.178498275590414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.010850634903372" CI_START="1.1035895941167542" DF="0.0" EFFECT_SIZE="2.973330018800967" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-001.20.08" LOG_CI_END="0.90367863424031" LOG_CI_START="0.04280759680988521" LOG_EFFECT_SIZE="0.4732431155250977" NO="8" P_CHI2="1.0" P_Z="0.031170758162816743" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="2.1548859748593476">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="8.010850634903372" CI_START="1.1035895941167542" EFFECT_SIZE="2.973330018800967" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.90367863424031" LOG_CI_START="0.04280759680988521" LOG_EFFECT_SIZE="0.4732431155250977" ORDER="733" O_E="4.261363636363637" SE="0.5056799087669935" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="3.9106468788297772" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.302104480599441" CI_END="6.040729507533169" CI_START="0.7613426888729377" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.1445431322357216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="56.56148500524999" I2_Q="56.56148500524999" ID="CMP-001.21" LOG_CI_END="0.7810893892775843" LOG_CI_START="-0.1184198184108326" LOG_EFFECT_SIZE="0.33133478543337586" METHOD="PETO" NO="21" P_CHI2="0.1291989722418676" P_Q="0.1291989722418676" P_Z="0.14876487116238132" Q="2.302104480599441" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="204" TOTAL_2="110" WEIGHT="200.0" Z="1.4439079460755713">
<NAME>Total number who suffered at least one adverse event of agitation before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="734" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.808854798686656" CI_START="0.9123599545986311" DF="0.0" EFFECT_SIZE="2.6691733569772236" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" ID="CMP-001.21.08" LOG_CI_END="0.8925873474395486" LOG_CI_START="-0.039833785077227346" LOG_EFFECT_SIZE="0.4263767811811607" NO="8" P_CHI2="1.0" P_Z="0.0730526706222517" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="1.7925014906162156">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="7.808854798686656" CI_START="0.9123599545986311" EFFECT_SIZE="2.6691733569772236" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.8925873474395486" LOG_CI_START="-0.039833785077227346" LOG_EFFECT_SIZE="0.4263767811811607" ORDER="735" O_E="3.2727272727272734" SE="0.547708788799399" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="3.3335009270024822" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" METHOD="PETO" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.2785986884808833" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>Total number who suffered at least one adverse event of asthma before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="736" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" METHOD="PETO" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.2785986884808833" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>Total number who suffered at least one adverse event of atrial fibrillation before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="737" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6634603203285216" CI_END="7.42373752976246" CI_START="1.0242321202339082" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.757468119519905" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="18.110208991400395" I2_Q="18.110208991400395" ID="CMP-001.24" LOG_CI_END="0.8706226087669908" LOG_CI_START="0.010398391320295793" LOG_EFFECT_SIZE="0.4405105000436433" METHOD="PETO" NO="24" P_CHI2="0.30017263205492173" P_Q="0.30017263205492173" P_Z="0.04471261320885176" Q="3.6634603203285216" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="387" TOTAL_2="383" WEIGHT="400.0" Z="2.0073480782951143">
<NAME>Total number who suffered at least one adverse event of bloating before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="738" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.94731771466265" CI_START="0.06166998768206231" DF="0.0" EFFECT_SIZE="0.9917010068690967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="1.2026876466608056" LOG_CI_START="-1.2099261383194857" LOG_EFFECT_SIZE="-0.003619245829339992" NO="3" P_CHI2="1.0" P_Z="0.9953081305123697" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="0.005880420248664988">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="15.94731771466265" CI_START="0.06166998768206231" EFFECT_SIZE="0.9917010068690967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2026876466608056" LOG_CI_START="-1.2099261383194857" LOG_EFFECT_SIZE="-0.003619245829339992" ORDER="739" O_E="-0.004149377593360981" SE="1.417181279928267" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="0.49790809386890716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.852445388849784" CI_START="0.5784077963228687" DF="0.0" EFFECT_SIZE="3.3886293968188226" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="1.2978140100146043" LOG_CI_START="-0.23776586184564574" LOG_EFFECT_SIZE="0.5300240740844793" NO="4" P_CHI2="1.0" P_Z="0.17605217153599304" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="1.3530108269605015">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="19.852445388849784" CI_START="0.5784077963228687" EFFECT_SIZE="3.3886293968188226" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2978140100146043" LOG_CI_START="-0.23776586184564574" LOG_EFFECT_SIZE="0.5300240740844793" ORDER="740" O_E="1.5" SE="0.9020072179736678" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="1.2290794979079498" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.31460416250201" CI_START="1.1587543229427906" DF="0.0" EFFECT_SIZE="4.730843589596683" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.24.05" LOG_CI_END="1.2858858120509828" LOG_CI_START="0.06399136736976814" LOG_EFFECT_SIZE="0.6749385897103756" NO="5" P_CHI2="1.0" P_Z="0.030368312832789304" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="2.165253035344993">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="19.31460416250201" CI_START="1.1587543229427906" EFFECT_SIZE="4.730843589596683" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2858858120509828" LOG_CI_START="0.06399136736976814" LOG_EFFECT_SIZE="0.6749385897103756" ORDER="741" O_E="3.01673640167364" SE="0.7177468452807952" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="1.9411424870012781" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0623485420671488" CI_END="6.219642242201064" CI_START="1.1800956358924326" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.7092014814025367" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="5.868934685581549" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.7937654045129401" LOG_CI_START="0.07191720430386264" LOG_EFFECT_SIZE="0.4328413044084013" METHOD="MH" NO="25" P_CHI2="0.3026805359212189" P_Q="0.0" P_Z="0.018748030345394524" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="412" WEIGHT="200.0" Z="2.3505035197596564">
<NAME>Total number who suffered at least one adverse event of bradycardia before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.708644811183936" CI_START="0.44084457445723974" DF="0.0" EFFECT_SIZE="1.5863874345549738" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.25.06" LOG_CI_END="0.7565330222777232" LOG_CI_START="-0.3557144997685682" LOG_EFFECT_SIZE="0.20040926125457745" NO="6" P_CHI2="1.0" P_Z="0.47999631951415167" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="206" WEIGHT="100.0" Z="0.7063084905859692">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="5.708644811183936" CI_START="0.44084457445723974" EFFECT_SIZE="1.5863874345549738" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7565330222777232" LOG_CI_START="-0.3557144997685682" LOG_EFFECT_SIZE="0.20040926125457745" ORDER="742" O_E="0.0" SE="0.6533397001640208" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="0.4268527638104125" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.014679892736929" CI_START="1.255983248918086" DF="0.0" EFFECT_SIZE="3.8846153846153846" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" ID="CMP-001.25.07" LOG_CI_END="1.0797122043808745" LOG_CI_START="0.09898384724277466" LOG_EFFECT_SIZE="0.5893480258118247" NO="7" P_CHI2="1.0" P_Z="0.01849291567245201" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="2.3555980543311743">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="12.014679892736929" CI_START="1.255983248918086" EFFECT_SIZE="3.8846153846153846" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.0797122043808745" LOG_CI_START="0.09898384724277466" LOG_EFFECT_SIZE="0.5893480258118247" ORDER="743" O_E="0.0" SE="0.5760846916665829" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="0.3318735719725819" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" METHOD="PETO" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.2785986884808833" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>Total number who suffered at least one adverse event of chest discomfort before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="744" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.789172150522846" CI_END="2.517845009603654" CI_START="1.4799184073304965" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9303380990172883" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.40102899283078863" LOG_CI_START="0.17023777200107848" LOG_EFFECT_SIZE="0.28563338241593356" METHOD="PETO" NO="27" P_CHI2="0.5555245039945549" P_Q="0.4846503148845931" P_Z="1.2258831380433872E-6" Q="7.491461392885187" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1342" TOTAL_2="1205" WEIGHT="900.0" Z="4.851407608183317">
<NAME>Total number who suffered at least one adverse event of diarrhoea before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.357514599338287" CI_START="0.7631499316701612" DF="0.0" EFFECT_SIZE="1.8235780676287878" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.639238850836864" LOG_CI_START="-0.11739013032787236" LOG_EFFECT_SIZE="0.26092436025449584" NO="1" P_CHI2="1.0" P_Z="0.17644199354590212" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="99.99999999999999" Z="1.3517915954018198">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="4.357514599338287" CI_START="0.7631499316701613" EFFECT_SIZE="1.8235780676287878" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.639238850836864" LOG_CI_START="-0.1173901303278723" LOG_EFFECT_SIZE="0.26092436025449584" ORDER="745" O_E="3.041509433962265" SE="0.4444476089100275" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="5.06242791028836" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.858782896847037" CI_START="0.3794447668756248" DF="0.0" EFFECT_SIZE="1.0415134227853942" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.4561811751965934" LOG_CI_START="-0.42085143238218164" LOG_EFFECT_SIZE="0.0176648714072059" NO="2" P_CHI2="1.0" P_Z="0.9370694010169965" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="0.07895376169704185">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="2.858782896847037" CI_START="0.3794447668756248" EFFECT_SIZE="1.0415134227853942" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4561811751965934" LOG_CI_START="-0.42085143238218164" LOG_EFFECT_SIZE="0.0176648714072059" ORDER="746" O_E="0.15325670498084332" SE="0.5151732950731969" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="3.7678474840583442" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.489172647368978" CI_START="0.4016490635943517" DF="0.0" EFFECT_SIZE="2.3276412014050383" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.27.03" LOG_CI_END="1.129985313222592" LOG_CI_START="-0.39615324121465584" LOG_EFFECT_SIZE="0.366916036003968" NO="3" P_CHI2="1.0" P_Z="0.34597064259907995" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="0.9424337178653581">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="13.489172647368978" CI_START="0.4016490635943517" EFFECT_SIZE="2.3276412014050383" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.129985313222592" LOG_CI_START="-0.39615324121465584" LOG_EFFECT_SIZE="0.366916036003968" ORDER="747" O_E="1.051282051282051" SE="0.8964613413841213" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="1.2443337139693416" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.686627643096455" CI_START="0.44995952529004046" DF="0.0" EFFECT_SIZE="1.0994879257721664" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-001.27.04" LOG_CI_END="0.42920747895479905" LOG_CI_START="-0.3468265500774407" LOG_EFFECT_SIZE="0.041190464438679124" NO="4" P_CHI2="1.0" P_Z="0.8351800932756304" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="0.20806259464411983">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="2.686627643096455" CI_START="0.44995952529004046" EFFECT_SIZE="1.0994879257721664" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.42920747895479905" LOG_CI_START="-0.3468265500774407" LOG_EFFECT_SIZE="0.041190464438679124" ORDER="748" O_E="0.4564315352697097" SE="0.4558462300839351" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="4.81241714157814" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1427922641724337" CI_START="0.5652555670431074" DF="0.0" EFFECT_SIZE="1.3328468866990988" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-001.27.05" LOG_CI_END="0.49731567547980626" LOG_CI_START="-0.24775515171732845" LOG_EFFECT_SIZE="0.12478026188123886" NO="5" P_CHI2="1.0" P_Z="0.511510551615577" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.6564874380835102">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="3.1427922641724337" CI_START="0.5652555670431074" EFFECT_SIZE="1.3328468866990988" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.49731567547980626" LOG_CI_START="-0.24775515171732845" LOG_EFFECT_SIZE="0.12478026188123886" ORDER="749" O_E="1.5" SE="0.43765829205567347" STUDY_ID="STD-Cummings-1996" TOTAL_1="120" TOTAL_2="120" VAR="5.220711297071129" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.224805689783837" CI_START="1.205008094925685" DF="0.0" EFFECT_SIZE="2.509169813026472" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" I2="0.0" ID="CMP-001.27.06" LOG_CI_END="0.7180701436971917" LOG_CI_START="0.08098996439615523" LOG_EFFECT_SIZE="0.3995300540466734" NO="6" P_CHI2="1.0" P_Z="0.013959966254016756" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="2.4582918826071456">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.224805689783838" CI_START="1.205008094925685" EFFECT_SIZE="2.509169813026472" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.7180701436971918" LOG_CI_START="0.08098996439615523" LOG_EFFECT_SIZE="0.3995300540466734" ORDER="750" O_E="6.569037656903767" SE="0.37422405091917693" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="7.1406312914689885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2977107576376601" CI_END="3.749252102518612" CI_START="1.5445194650782574" DF="1.0" EFFECT_SIZE="2.406406626450646" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="21" I2="0.0" ID="CMP-001.27.07" LOG_CI_END="0.5739446436895261" LOG_CI_START="0.18879338594456427" LOG_EFFECT_SIZE="0.38136901481704516" NO="7" P_CHI2="0.5853212283945117" P_Z="1.0384246744408915E-4" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="100.0" Z="3.8814336904276074">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="5.512568706836504" CI_START="1.403767465160265" EFFECT_SIZE="2.781791616947193" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" LOG_CI_END="0.7413540154126769" LOG_CI_START="0.1472951726358853" LOG_EFFECT_SIZE="0.44432459402428104" ORDER="751" O_E="8.40198511166253" SE="0.3489531048857851" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="8.212320047332131" WEIGHT="42.034289507033705"/>
<DICH_DATA CI_END="3.8784236938273358" CI_START="1.2099775555148808" EFFECT_SIZE="2.1662884434691967" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="11" LOG_CI_END="0.5886552513233982" LOG_CI_START="0.0827773144433578" LOG_EFFECT_SIZE="0.33571628288337807" ORDER="752" O_E="8.754299754299751" SE="0.2971552042595095" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="11.324872429676294" WEIGHT="57.965710492966295"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.89842908905901" CI_START="1.156818605313401" DF="0.0" EFFECT_SIZE="2.3804608602184234" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="0.0" ID="CMP-001.27.08" LOG_CI_END="0.6900568254698741" LOG_CI_START="0.06326526483977642" LOG_EFFECT_SIZE="0.37666104515482524" NO="8" P_CHI2="1.0" P_Z="0.01849170978808345" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="2.355622281003709">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="4.89842908905901" CI_START="1.1568186053134009" EFFECT_SIZE="2.3804608602184234" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.6900568254698741" LOG_CI_START="0.06326526483977633" LOG_EFFECT_SIZE="0.37666104515482524" ORDER="753" O_E="6.398009950248756" SE="0.36818046538238375" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="7.376978459274945" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.27.09" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="9" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="754" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" METHOD="PETO" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.2785986884808833" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>Total number who suffered at least one adverse event of dizziness before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804417282573915" CI_START="0.002228458217120792" DF="0.0" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" NO="1" P_CHI2="1.0" P_Z="0.2785986884808833" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.083472677771923">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="5.804417282573915" CI_START="0.002228458217120792" EFFECT_SIZE="0.11373170793120879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7637586265439483" LOG_CI_START="-2.651995504384174" LOG_EFFECT_SIZE="-0.9441184389201128" ORDER="755" O_E="-0.54" SE="2.00643088476282" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.24839999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="109.94374860194002" CI_START="0.39887601045761756" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.3991620826151385" LOG_EFFECT_SIZE="0.8210042289066104" METHOD="PETO" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.18724053701352888" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.318786385607691">
<NAME>Total number who suffered at least one adverse event of headache before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.94374860194002" CI_START="0.39887601045761756" DF="0.0" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.3991620826151385" LOG_EFFECT_SIZE="0.8210042289066104" NO="1" P_CHI2="1.0" P_Z="0.18724053701352888" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.318786385607691">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="109.94374860194002" CI_START="0.3988760104576178" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.39916208261513825" LOG_EFFECT_SIZE="0.8210042289066104" ORDER="756" O_E="0.9199999999999999" SE="1.4334634626170555" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.4866612244897959" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.501212150451733" CI_END="5.507957023863499" CI_START="2.253415468567024" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.5230264770189277" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.7409905429916126" LOG_CI_START="0.3528412712051092" LOG_EFFECT_SIZE="0.5469159070983609" METHOD="PETO" NO="30" P_CHI2="0.6091776979348785" P_Q="0.5207841282803884" P_Z="3.326612436943242E-8" Q="4.201505259313082" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1132" TOTAL_2="909" WEIGHT="600.0" Z="5.523315684974135">
<NAME>Total number who suffered at least one adverse event of leg cramps before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.47742536591266" CI_START="1.0236176184492352" DF="0.0" EFFECT_SIZE="3.1146845076324974" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.30.01" LOG_CI_END="0.9766903730721025" LOG_CI_START="0.01013775233182696" LOG_EFFECT_SIZE="0.49341406270196486" NO="1" P_CHI2="1.0" P_Z="0.04538394025335504" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="99.99999999999999" Z="2.0010784133423885">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="9.47742536591266" CI_START="1.0236176184492352" EFFECT_SIZE="3.1146845076324974" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9766903730721025" LOG_CI_START="0.01013775233182696" LOG_EFFECT_SIZE="0.49341406270196486" ORDER="757" O_E="3.524528301886792" SE="0.5677577939354742" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="3.102228551085796" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.053334628726447" CI_START="0.11830562541275766" DF="0.0" EFFECT_SIZE="0.6924826988876113" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.30.02" LOG_CI_END="0.6078124590119529" LOG_CI_START="-0.9269946042509031" LOG_EFFECT_SIZE="-0.15959107261947514" NO="2" P_CHI2="1.0" P_Z="0.6835682503221268" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="0.4075987947609774">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="4.053334628726447" CI_START="0.11830562541275766" EFFECT_SIZE="0.6924826988876113" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6078124590119529" LOG_CI_START="-0.9269946042509031" LOG_EFFECT_SIZE="-0.15959107261947514" ORDER="758" O_E="-0.4521072796934864" SE="0.9015532663780944" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="1.2303175458149695" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.26771793801864" CI_START="0.28852189237298975" DF="0.0" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.30.03" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" NO="3" P_CHI2="1.0" P_Z="0.2960386808739228" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.044966039155582">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="59.26771793801864" CI_START="0.28852189237298975" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" ORDER="759" O_E="0.7692307692307692" SE="1.3584558509022568" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.5418872625350358" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29970689113865046" CI_END="9.180175848060083" CI_START="2.4004379965569154" DF="1.0" EFFECT_SIZE="4.69429898075927" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="2" I2="0.0" ID="CMP-001.30.04" LOG_CI_END="0.9628510002764824" LOG_CI_START="0.38029049260013964" LOG_EFFECT_SIZE="0.6715707464383109" NO="4" P_CHI2="0.5840663215798222" P_Z="6.217370087123743E-6" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="99.99999999999999" Z="4.5188592729703245">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="18.090347324554752" CI_START="1.988229091322518" EFFECT_SIZE="5.997312299923045" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.2574469051511081" LOG_CI_START="0.2984664240074789" LOG_EFFECT_SIZE="0.7779566645792936" ORDER="760" O_E="5.645161290322581" SE="0.5633098816537085" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="3.151412552223275" WEIGHT="36.90307404728425"/>
<DICH_DATA CI_END="9.463377883163423" CI_START="1.7484486414893872" EFFECT_SIZE="4.067705766610683" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9760461822971955" LOG_CI_START="0.24265287997077603" LOG_EFFECT_SIZE="0.6093495311339858" ORDER="761" O_E="7.560196560196559" SE="0.4307988561419349" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="5.388289447088058" WEIGHT="63.096925952715736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.98482531787151" CI_START="1.0084773959244941" DF="0.0" EFFECT_SIZE="4.489347903044824" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.30.05" LOG_CI_END="1.3007003565582933" LOG_CI_START="0.003666168354161174" LOG_EFFECT_SIZE="0.6521832624562272" NO="5" P_CHI2="1.0" P_Z="0.04871884702017502" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.9710439668578148">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="19.98482531787151" CI_START="1.0084773959244941" EFFECT_SIZE="4.489347903044824" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3007003565582933" LOG_CI_START="0.003666168354161174" LOG_EFFECT_SIZE="0.6521832624562272" ORDER="762" O_E="2.5870646766169156" SE="0.7618843025738861" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="1.722748770261421" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.067315914982101" CI_START="1.163960155491658" DF="0.0" EFFECT_SIZE="3.064316283741431" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" I2="0.0" ID="CMP-001.30.06" LOG_CI_END="0.9067290641881696" LOG_CI_START="0.06593811386517388" LOG_EFFECT_SIZE="0.48633358902667173" NO="6" P_CHI2="1.0" P_Z="0.023367018335713315" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="2.2673800630185275">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="8.067315914982101" CI_START="1.163960155491658" EFFECT_SIZE="3.064316283741431" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="0.9067290641881696" LOG_CI_START="0.06593811386517388" LOG_EFFECT_SIZE="0.48633358902667173" ORDER="763" O_E="4.590909090909092" SE="0.49388476620205535" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="4.099668478773214" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.631749325502533" CI_END="1.993427560374469" CI_START="1.0921004557845981" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.475473872102972" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="71" I2="58.3944882839894" I2_Q="62.15836415266283" ID="CMP-001.31" LOG_CI_END="0.29960045835745475" LOG_CI_START="0.03826258835622147" LOG_EFFECT_SIZE="0.16893152335683817" METHOD="PETO" NO="31" P_CHI2="0.010122286556115911" P_Q="0.006782835990133185" P_Z="0.011280661458985722" Q="21.14073512116137" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1343" TOTAL_2="1205" WEIGHT="900.0" Z="2.5338823005737914">
<NAME>Total number who suffered at least one adverse event of nausea before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.820229305180977" CI_START="1.145182485354342" DF="0.0" EFFECT_SIZE="3.35349885976672" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.9921216288065098" LOG_CI_START="0.05887469721532314" LOG_EFFECT_SIZE="0.5254981630109165" NO="1" P_CHI2="1.0" P_Z="0.02729617509475615" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="133" WEIGHT="100.0" Z="2.207256061774083">
<NAME>metrifonate 50mg/day with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="9.820229305180977" CI_START="1.1451824853543422" EFFECT_SIZE="3.35349885976672" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9921216288065098" LOG_CI_START="0.05887469721532322" LOG_EFFECT_SIZE="0.5254981630109165" ORDER="764" O_E="4.026415094339622" SE="0.548193867263479" STUDY_ID="STD-Jann-1999" TOTAL_1="132" TOTAL_2="133" VAR="3.3276041295834817" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.089499963426164" CI_START="0.4266496369214993" DF="0.0" EFFECT_SIZE="1.739175835087055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.31.02" LOG_CI_END="0.8506156046071764" LOG_CI_START="-0.3699286196154429" LOG_EFFECT_SIZE="0.24034349249586676" NO="2" P_CHI2="1.0" P_Z="0.4401779869800577" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="133" WEIGHT="100.0" Z="0.7718927014062091">
<NAME>metrifonate 50mg/day with no initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="7.089499963426164" CI_START="0.4266496369214993" EFFECT_SIZE="1.739175835087055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8506156046071764" LOG_CI_START="-0.3699286196154429" LOG_EFFECT_SIZE="0.24034349249586676" ORDER="765" O_E="1.0766283524904217" SE="0.7169537190997172" STUDY_ID="STD-Jann-1999" TOTAL_1="128" TOTAL_2="133" VAR="1.9454396193199206" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.26771793801864" CI_START="0.28852189237298975" DF="0.0" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.31.03" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" NO="3" P_CHI2="1.0" P_Z="0.2960386808739228" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.044966039155582">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="59.26771793801864" CI_START="0.28852189237298975" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" ORDER="766" O_E="0.7692307692307692" SE="1.3584558509022568" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.5418872625350358" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8694738930737749" CI_START="0.10082820096234639" DF="0.0" EFFECT_SIZE="0.29608696091242565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" ID="CMP-001.31.04" LOG_CI_END="-0.060743453643116695" LOG_CI_START="-0.9964179816861549" LOG_EFFECT_SIZE="-0.5285807176646358" NO="4" P_CHI2="1.0" P_Z="0.026798288078964904" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="2.2144434597611875">
<NAME>metrifonate 9-17 mg/day (0.2 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="0.8694738930737749" CI_START="0.10082820096234639" EFFECT_SIZE="0.29608696091242565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.060743453643116695" LOG_CI_START="-0.9964179816861549" LOG_EFFECT_SIZE="-0.5285807176646358" ORDER="767" O_E="-4.029045643153527" SE="0.549619849436093" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="3.3103596701158726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.18254353831819" CI_START="0.36553493259476616" DF="0.0" EFFECT_SIZE="0.8931942146948121" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-001.31.05" LOG_CI_END="0.3389629159573292" LOG_CI_START="-0.4370711130749105" LOG_EFFECT_SIZE="-0.0490540985587906" NO="5" P_CHI2="1.0" P_Z="0.8043018174232262" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="120" WEIGHT="100.0" Z="0.2477836354398153">
<NAME>metrifonate 13-26 mg/day (0.3 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="2.18254353831819" CI_START="0.36553493259476616" EFFECT_SIZE="0.8931942146948121" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3389629159573292" LOG_CI_START="-0.4370711130749105" LOG_EFFECT_SIZE="-0.0490540985587906" ORDER="768" O_E="-0.5435684647302903" SE="0.4558462300839351" STUDY_ID="STD-Cummings-1996" TOTAL_1="121" TOTAL_2="120" VAR="4.81241714157814" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.977291018552006" CI_START="0.8634255394186545" DF="0.0" EFFECT_SIZE="1.853131037762369" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-001.31.06" LOG_CI_END="0.5995873694942168" LOG_CI_START="-0.06377510941550468" LOG_EFFECT_SIZE="0.267906130039356" NO="6" P_CHI2="1.0" P_Z="0.11339743969116349" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="1.5831054146374246">
<NAME>metrifonate 30-55 mg/day (0.65 mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="3.977291018552006" CI_START="0.8634255394186545" EFFECT_SIZE="1.853131037762369" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5995873694942168" LOG_CI_START="-0.06377510941550468" LOG_EFFECT_SIZE="0.267906130039356" ORDER="769" O_E="4.06276150627615" SE="0.38966240380879974" STUDY_ID="STD-Cummings-1996" TOTAL_1="119" TOTAL_2="120" VAR="6.586019152325765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.49101420434116105" CI_END="2.454245348562652" CI_START="0.8686127737534011" DF="1.0" EFFECT_SIZE="1.4600646765422371" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="21" I2="0.0" ID="CMP-001.31.07" LOG_CI_END="0.389917976565679" LOG_CI_START="-0.06117378822520117" LOG_EFFECT_SIZE="0.1643720941702389" NO="7" P_CHI2="0.48347528652676586" P_Z="0.15318486309122717" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="340" WEIGHT="100.0" Z="1.4283718293391805">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="4.400090842077622" CI_START="0.7900080580459315" EFFECT_SIZE="1.8644321444813778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6434616428056824" LOG_CI_START="-0.10236847890318486" LOG_EFFECT_SIZE="0.27054658195124875" ORDER="770" O_E="3.2456575682382134" SE="0.43810430541043355" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="5.210086787521793" WEIGHT="36.5805270878056"/>
<DICH_DATA CI_END="2.434165717057651" CI_START="0.6605574140328198" EFFECT_SIZE="1.2680324173249462" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="13" LOG_CI_END="0.386350141500371" LOG_CI_START="-0.1800894285960415" LOG_EFFECT_SIZE="0.10313035645216476" ORDER="771" O_E="2.144963144963146" SE="0.3327294073957257" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="9.032700843765827" WEIGHT="63.41947291219441"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.071825430441074" CI_START="1.3731382448982679" DF="0.0" EFFECT_SIZE="2.88746527509588" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="0.0" ID="CMP-001.31.08" LOG_CI_END="0.7833192767731284" LOG_CI_START="0.1377142633649872" LOG_EFFECT_SIZE="0.4605167700690578" NO="8" P_CHI2="1.0" P_Z="0.005171933082868884" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="2.7961253858524775">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="6.071825430441074" CI_START="1.3731382448982679" EFFECT_SIZE="2.88746527509588" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7833192767731284" LOG_CI_START="0.1377142633649872" LOG_EFFECT_SIZE="0.4605167700690578" ORDER="772" O_E="7.3731343283582085" SE="0.3792315806722996" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="6.953300642357127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.05319957334089" CI_START="0.010207089955003915" DF="0.0" EFFECT_SIZE="0.10368270244193198" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.31.09" LOG_CI_END="0.02251067449808807" LOG_CI_START="-1.9910980577783235" LOG_EFFECT_SIZE="-0.9842936916401177" NO="9" P_CHI2="1.0" P_Z="0.055347016713697406" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.00000000000001" Z="1.916142053718292">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="1.05319957334089" CI_START="0.010207089955003915" EFFECT_SIZE="0.10368270244193198" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.02251067449808807" LOG_CI_START="-1.9910980577783235" LOG_EFFECT_SIZE="-0.9842936916401177" ORDER="773" O_E="-1.62" SE="1.182803736863143" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.7147836734693876" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006980622048682229" CI_END="13.469844450277085" CI_START="1.6605423873462117" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.729402463382158" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="1.1293625805205816" LOG_CI_START="0.22024996596608698" LOG_EFFECT_SIZE="0.6748062732433343" METHOD="MH" NO="32" P_CHI2="0.9334141292804607" P_Q="0.0" P_Z="0.003618433035660216" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="450" TOTAL_2="221" WEIGHT="200.0" Z="2.9096417119825375">
<NAME>Total number who suffered at least one adverse event of rhinitis before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.517777311625775" CI_START="1.1327399849483768" DF="0.0" EFFECT_SIZE="4.937007874015748" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" ID="CMP-001.32.01" LOG_CI_END="1.3327974086695462" LOG_CI_START="0.054130231079973175" LOG_EFFECT_SIZE="0.6934638198747596" NO="1" P_CHI2="1.0" P_Z="0.03351095706142311" STUDIES="1" TAU2="0.0" TOTAL_1="273" TOTAL_2="134" WEIGHT="100.0" Z="2.125907562745566">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="21.517777311625775" CI_START="1.1327399849483768" EFFECT_SIZE="4.937007874015748" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="1.3327974086695462" LOG_CI_START="0.054130231079973175" LOG_EFFECT_SIZE="0.6934638198747596" ORDER="774" O_E="0.0" SE="0.7510954296207252" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="0.5641443443971418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.00802916889652" CI_START="1.019134316953297" DF="0.0" EFFECT_SIZE="4.515625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-001.32.08" LOG_CI_END="1.3012043118632681" LOG_CI_START="0.00823142568205311" LOG_EFFECT_SIZE="0.6547178687726607" NO="8" P_CHI2="1.0" P_Z="0.04715344647610784" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="100.0" Z="1.984919338284388">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="20.00802916889652" CI_START="1.019134316953297" EFFECT_SIZE="4.515625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.3012043118632681" LOG_CI_START="0.00823142568205311" LOG_EFFECT_SIZE="0.6547178687726607" ORDER="775" O_E="0.0" SE="0.7594986736618554" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="0.5768382352941176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="109.94374860194002" CI_START="0.39887601045761756" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.3991620826151385" LOG_EFFECT_SIZE="0.8210042289066104" METHOD="PETO" NO="33" P_CHI2="1.0" P_Q="1.0" P_Z="0.18724053701352888" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.318786385607691">
<NAME>Total number who suffered at least one adverse event of upset stomach before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.94374860194002" CI_START="0.39887601045761756" DF="0.0" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.33.01" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.3991620826151385" LOG_EFFECT_SIZE="0.8210042289066104" NO="1" P_CHI2="1.0" P_Z="0.18724053701352888" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.318786385607691">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="109.94374860194002" CI_START="0.3988760104576178" EFFECT_SIZE="6.6222295201161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.041170540428359" LOG_CI_START="-0.39916208261513825" LOG_EFFECT_SIZE="0.8210042289066104" ORDER="776" O_E="0.9199999999999999" SE="1.4334634626170555" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.4866612244897959" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.593182893520066" CI_END="2.5337526672640536" CI_START="0.5067912545128173" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1331741670493316" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="84.83281874399657" I2_Q="84.83281874399657" ID="CMP-001.34" LOG_CI_END="0.403764218880128" LOG_CI_START="-0.29517088816427917" LOG_EFFECT_SIZE="0.05429666535792439" METHOD="PETO" NO="34" P_CHI2="0.010237033505384963" P_Q="0.010237033505384963" P_Z="0.7607325231189487" Q="6.593182893520066" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="300" TOTAL_2="157" WEIGHT="200.0" Z="0.30451899614020694">
<NAME>Total number who suffered at least one adverse event of vomiting before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7510229237296792" CI_START="0.012970718841585849" DF="0.0" EFFECT_SIZE="0.0986980607068013" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.34.01" LOG_CI_END="-0.1243468066744429" LOG_CI_START="-1.8870359545031883" LOG_EFFECT_SIZE="-1.0056913805888157" NO="1" P_CHI2="1.0" P_Z="0.025319650094114025" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="2.2364906347150755">
<NAME>metrifonate 95-180 mg/week (2.1mg/kg body weight) with initial loading at 12 weeks</NAME>
<DICH_DATA CI_END="0.7510229237296788" CI_START="0.012970718841585849" EFFECT_SIZE="0.0986980607068013" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.12434680667444312" LOG_CI_START="-1.8870359545031883" LOG_EFFECT_SIZE="-1.0056913805888157" ORDER="777" O_E="-2.16" SE="1.035412330886609" STUDY_ID="STD-Becker-1996" TOTAL_1="27" TOTAL_2="23" VAR="0.9327673469387755" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.292562466281756" CI_START="0.7436564282753173" DF="0.0" EFFECT_SIZE="1.7866705549215773" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" ID="CMP-001.34.06" LOG_CI_END="0.6327166238245857" LOG_CI_START="-0.12862766360320504" LOG_EFFECT_SIZE="0.2520444801106903" NO="6" P_CHI2="1.0" P_Z="0.1943905677337362" STUDIES="1" TAU2="0.0" TOTAL_1="273" TOTAL_2="134" WEIGHT="100.0" Z="1.2976996391161024">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="4.292562466281755" CI_START="0.7436564282753174" EFFECT_SIZE="1.7866705549215773" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.6327166238245856" LOG_CI_START="-0.128627663603205" LOG_EFFECT_SIZE="0.2520444801106903" ORDER="778" O_E="2.9017199017199005" SE="0.447217403150088" STUDY_ID="STD-Morris-1998" TOTAL_1="273" TOTAL_2="134" VAR="4.999914859442098" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="59.26771793801864" CI_START="0.28852189237298975" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" METHOD="PETO" NO="35" P_CHI2="1.0" P_Q="1.0" P_Z="0.2960386808739228" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.044966039155582">
<NAME>Total number who suffered at least one adverse event of accidental injury before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.26771793801864" CI_START="0.28852189237298975" DF="0.0" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.35.01" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" NO="1" P_CHI2="1.0" P_Z="0.2960386808739228" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.044966039155582">
<NAME>metrifonate 45-85 mg/day (1.0 mg/kg body weight) with initial loading at 6 weeks</NAME>
<DICH_DATA CI_END="59.26771793801864" CI_START="0.28852189237298975" EFFECT_SIZE="4.135218753114002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.772818205356005" LOG_CI_START="-0.5398212279984974" LOG_EFFECT_SIZE="0.6164984886787539" ORDER="779" O_E="0.7692307692307692" SE="1.3584558509022568" STUDY_ID="STD-Blass-2000" TOTAL_1="29" TOTAL_2="10" VAR="0.5418872625350358" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5445048206914072" CI_END="4.9076740216497985" CI_START="0.6370055046531637" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7681106772015862" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="35.254329633471535" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="0.6908757082317553" LOG_CI_START="-0.195856814713057" LOG_EFFECT_SIZE="0.24750944675934916" METHOD="MH" NO="36" P_CHI2="0.2139489834243511" P_Q="0.0" P_Z="0.2738888114136875" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="412" WEIGHT="200.0" Z="1.094150916830532">
<NAME>Total number who suffered at least one serious adverse event possibly related to bradycardia before end treatm</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.198370887173553" CI_START="0.1147253874733771" DF="0.0" EFFECT_SIZE="0.694017094017094" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.36.06" LOG_CI_END="0.623080801835225" LOG_CI_START="-0.9403404668451977" LOG_EFFECT_SIZE="-0.15862983250498633" NO="6" P_CHI2="1.0" P_Z="0.6908301764263047" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="206" WEIGHT="100.0" Z="0.3977287053870149">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="4.198370887173553" CI_START="0.1147253874733771" EFFECT_SIZE="0.694017094017094" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.623080801835225" LOG_CI_START="-0.9403404668451977" LOG_EFFECT_SIZE="-0.15862983250498633" ORDER="780" O_E="0.0" SE="0.9183613922829741" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="0.8433876468359226" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.01484057699242" CI_START="0.7527237619877464" DF="0.0" EFFECT_SIZE="2.879432624113475" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-001.36.07" LOG_CI_END="1.0419782157824264" LOG_CI_START="-0.1233643739387981" LOG_EFFECT_SIZE="0.45930692092181424" NO="7" P_CHI2="1.0" P_Z="0.12234714663091352" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.5449963483649833">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="11.01484057699242" CI_START="0.7527237619877465" EFFECT_SIZE="2.879432624113475" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0419782157824264" LOG_CI_START="-0.12336437393879802" LOG_EFFECT_SIZE="0.45930692092181424" ORDER="781" O_E="0.0" SE="0.6845280057411002" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="0.46857859064388774" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.25999555424122156" CI_END="1.1325413289983608" CI_START="0.08450384403559424" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.30936078586262694" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="0.05405405936339281" LOG_CI_START="-1.0731235347724948" LOG_EFFECT_SIZE="-0.5095347377045509" METHOD="MH" NO="37" P_CHI2="0.6101232507692568" P_Q="0.0" P_Z="0.0763973888305296" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="412" WEIGHT="200.0" Z="1.771982942117616">
<NAME>Total number of deaths before the end of treatment</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7714199634524295" CI_START="0.023747529109379245" DF="0.0" EFFECT_SIZE="0.20510204081632652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.37.06" LOG_CI_END="0.2483215347577078" LOG_CI_START="-1.6243815713017196" LOG_EFFECT_SIZE="-0.688030018272006" NO="6" P_CHI2="1.0" P_Z="0.149816698644952" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="206" WEIGHT="100.0" Z="1.4401792272701812">
<NAME>metrifonate 30-55 mg/day (approx 0.65 mg/kg body weight) with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="1.7714199634524295" CI_START="0.023747529109379245" EFFECT_SIZE="0.20510204081632652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2483215347577078" LOG_CI_START="-1.6243815713017196" LOG_EFFECT_SIZE="-0.688030018272006" ORDER="782" O_E="0.0" SE="1.1000350745291878" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="1.210077165194436" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1614989445167665" CI_START="0.07946092380923553" DF="0.0" EFFECT_SIZE="0.4144329896907217" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.37.07" LOG_CI_END="0.33475502779904553" LOG_CI_START="-1.099846390162595" LOG_EFFECT_SIZE="-0.3825456811817748" NO="7" P_CHI2="1.0" P_Z="0.29589638110125416" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="206" WEIGHT="100.0" Z="1.0452739669293545">
<NAME>metrifonate 60-80 mg/day with initial loading at 26 weeks</NAME>
<DICH_DATA CI_END="2.161498944516766" CI_START="0.07946092380923556" EFFECT_SIZE="0.4144329896907217" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3347550277990454" LOG_CI_START="-1.099846390162595" LOG_EFFECT_SIZE="-0.3825456811817748" ORDER="783" O_E="0.0" SE="0.8426919743022162" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="196" TOTAL_2="206" VAR="0.7101297635533671" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-3.454448981025526" CI_START="-8.785551018974473" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-6.12" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="38" P_CHI2="1.0" P_Q="1.0" P_Z="6.79534624929015E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.5">
<NAME>heart rate bpm (change from baseline) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-3.454448981025526" CI_START="-8.785551018974473" DF="0.0" EFFECT_SIZE="-6.12" ESTIMABLE="YES" I2="0.0" ID="CMP-001.38.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="6.79534624929015E-6" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.5">
<NAME>metrifonate 50mg/day fixed dose with no initial loading at 26 weeks</NAME>
<IV_DATA CI_END="-3.454448981025526" CI_START="-8.785551018974473" EFFECT_SIZE="-6.12" ESTIMABLE="YES" ESTIMATE="-6.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="784" SE="1.36" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Metrifonate 30-55mg/day (approx 0.65 mg/kg body weight) vs placebo</NAME>
<IV_OUTCOME CHI2="8.788652852262004" CI_END="1.2916439543193752" CI_START="0.4214908646951201" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.8565674095072476" ESTIMABLE="YES" I2="77.24338378565898" I2_Q="88.61818963409618" ID="CMP-002.01" LOG_CI_END="0.11114281552873954" LOG_CI_START="-0.37521183374503714" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.06723845356824139" NO="1" P_CHI2="0.012347240397735382" P_Q="0.003035617818917591" P_Z="1.1397953282222623E-4" Q="8.785948525338927" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="99.99999999999999" Z="3.858726224117473">
<NAME>MMSE (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.002704326923076918" CI_END="0.9426215860422307" CI_START="-0.10108312450376927" DF="1.0" EFFECT_SIZE="0.42076923076923073" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.025662619115226926" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.37595602597340605" NO="1" P_CHI2="0.9585262089475444" P_Z="0.11403411772750764" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="69.50820062651118" Z="1.5803177465375016">
<NAME>metrifonate 30-55 mg/day with initial loading</NAME>
<IV_DATA CI_END="1.340782712579226" CI_START="-0.5407827125792259" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="785" SE="0.48" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.387138654311133"/>
<IV_DATA CI_END="1.0571884750528173" CI_START="-0.1971884750528174" EFFECT_SIZE="0.43" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="786" SE="0.32" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="48.12106197220005"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.637905521785102" CI_START="1.0620944782148982" DF="0.0" EFFECT_SIZE="1.85" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.4212592369638858" LOG_CI_START="0.026163150966138887" LOG_EFFECT_SIZE="0.2671717284030138" NO="2" P_CHI2="1.0" P_Z="4.1847320083090594E-6" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="30.491799373488803" Z="4.601990049751244">
<NAME>metrifonate 50 mg/day fixed dose with no initial loading</NAME>
<IV_DATA CI_END="2.637905521785102" CI_START="1.0620944782148982" EFFECT_SIZE="1.85" ESTIMABLE="YES" ESTIMATE="1.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="787" SE="0.402" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="30.491799373488803"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4407303674403786" CI_END="4.832878578573634" CI_START="1.217100871050468" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="3.0249897248120514" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.6842058840447612" LOG_CI_START="0.08532657323844624" LOG_DATA="NO" LOG_EFFECT_SIZE="0.48072390379344454" NO="2" P_CHI2="0.8022259163890801" P_Q="0.5376215797078912" P_Z="0.001040117162503843" Q="0.3799663224965584" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.00000000000001" Z="3.2794443651220297">
<NAME>Disability assessment in Dementia DAD (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metrifonate</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.06076404494382022" CI_END="4.773793249127436" CI_START="0.6574552901984059" DF="1.0" EFFECT_SIZE="2.7156242696629214" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.6788636059762544" LOG_CI_START="-0.18213377573604755" LOG_EFFECT_SIZE="0.43386968133008397" NO="1" P_CHI2="0.8052923891722334" P_Z="0.009708313718511196" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="77.15807746553946" Z="2.5860489674015996">
<NAME>metrifonate 30-55 mg/day with initial loading</NAME>
<IV_DATA CI_END="6.057543815882484" CI_START="-0.057543815882484584" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="788" SE="1.56" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="34.96214548348624"/>
<IV_DATA CI_END="5.263148858046877" CI_START="-0.30314885804687686" EFFECT_SIZE="2.48" ESTIMABLE="YES" ESTIMATE="2.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="789" SE="1.42" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="42.19593198205322"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="7.852730490162305" CI_START="0.2872695098376954" DF="0.0" EFFECT_SIZE="4.07" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.8950206924932169" LOG_CI_START="-0.5417104666357571" LOG_EFFECT_SIZE="0.6095944092252201" NO="2" P_CHI2="1.0" P_Z="0.034961132746079905" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="22.84192253446055" Z="2.1088082901554404">
<NAME>metrifonate 50 mg/day fixed dose with no initial loading</NAME>
<IV_DATA CI_END="7.852730490162305" CI_START="0.28726950983769584" EFFECT_SIZE="4.07" ESTIMABLE="YES" ESTIMATE="4.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="790" SE="1.93" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="22.84192253446055"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.401798078093019" CI_END="-0.8602998866709641" CI_START="-3.613371487375956" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="-2.23683568702346" ESTIMABLE="YES" I2="16.72905319384879" I2_Q="3.1103523536016446" ID="CMP-002.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.30092361094168896" P_Q="0.30966579391454974" P_Z="0.0014480821157407198" Q="1.0321020091326265" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.00000000000001" Z="3.1848916568513723">
<NAME>Neuropsychiatric Inventory NPI (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.3696960689603925" CI_END="-0.1990812618538198" CI_START="-3.41401972647939" DF="1.0" EFFECT_SIZE="-1.8065504941666048" ESTIMABLE="YES" I2="26.991102430555564" ID="CMP-002.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.24186429240844387" P_Z="0.02761583767232687" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="73.33135054421182" Z="2.2027008876090335">
<NAME>metrifonate 30-55 mg/day with initial loading</NAME>
<IV_DATA CI_END="1.4631578619118635" CI_START="-3.1231578619118636" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="791" SE="1.17" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="36.033555433870895"/>
<IV_DATA CI_END="-0.4960414177789376" CI_START="-5.003958582221062" EFFECT_SIZE="-2.75" ESTIMABLE="YES" ESTIMATE="-2.75" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="792" SE="1.15" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="37.29779511034092"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.7544489810255257" CI_START="-6.085551018974474" DF="0.0" EFFECT_SIZE="-3.42" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.011913172206124908" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.6686494557882" Z="2.514705882352941">
<NAME>metrifonate 50 mg/day fixed dose with no initial loading</NAME>
<IV_DATA CI_END="-0.7544489810255257" CI_START="-6.085551018974474" EFFECT_SIZE="-3.42" ESTIMABLE="YES" ESTIMATE="-3.42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="793" SE="1.36" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.6686494557882"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.33006152007236594" CI_END="-0.10673269395283803" CI_START="-0.3494890905734468" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="-0.2281108922631424" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="0.847867647610147" P_Q="0.7065240796121546" P_Z="2.3010878553199449E-4" Q="0.14177378567334947" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.0" Z="3.6834385379000976">
<NAME>CIBIC-plus (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>treatment effect</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.18828773439901647" CI_END="-0.08975164410972325" CI_START="-0.40515459628375977" DF="1.0" EFFECT_SIZE="-0.2474531201967415" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.6643455656798788" P_Z="0.0021020215589894007" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="59.23929163476317" Z="3.0754258963312195">
<NAME>metrifonate 30-55 mg/day with initial loading</NAME>
<IV_DATA CI_END="0.021275750175726388" CI_START="-0.4412757501757264" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="794" SE="0.118" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="1" TOTAL_2="1" WEIGHT="27.543630063811648"/>
<IV_DATA CI_END="-0.06440396170059406" CI_START="-0.495596038299406" EFFECT_SIZE="-0.28" ESTIMABLE="YES" ESTIMATE="-0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="795" SE="0.11" STUDY_ID="STD-Morris-1998" TOTAL_1="1" TOTAL_2="1" WEIGHT="31.695661570951522"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.009883493499614732" CI_START="-0.3901165065003853" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.03922147907844517" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="40.76070836523684" Z="2.061855670103093">
<NAME>metrifonate 50 mg/day fixed dose with no initial loading</NAME>
<IV_DATA CI_END="-0.009883493499614732" CI_START="-0.3901165065003853" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="796" SE="0.097" STUDY_ID="STD-Raskind-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="40.76070836523684"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="6.561789825954467" CI_END="1.8597357439683466" CI_START="0.9264655222157661" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.312623726442182" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="60" I2="69.52051112504074" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.26945123825574635" LOG_CI_START="-0.03317073801810264" LOG_EFFECT_SIZE="0.11814025011882184" METHOD="MH" NO="5" P_CHI2="0.037594674104178605" P_Q="0.0" P_Z="0.1259434199669325" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="589" TOTAL_2="412" WEIGHT="100.00000000000001" Z="1.530296234321791">
<NAME>Total number of withdrawals before end of treatment at 26 weeks</NAME>
<GROUP_LABEL_1>Metrifonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metrifonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.323962092143192" CI_END="2.0808580124736564" CI_START="0.9293295700219601" DF="1.0" EFFECT_SIZE="1.3906124125754429" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="46" I2="84.18712848955266" ID="CMP-002.05.01" LOG_CI_END="0.3182424471011127" LOG_CI_START="-0.03183024396155892" LOG_EFFECT_SIZE="0.1432061015697769" NO="1" P_CHI2="0.011911737501618225" P_Z="0.10881420000300758" STUDIES="2" TAU2="0.0" TOTAL_1="412" TOTAL_2="325" WEIGHT="72.48780878276433" Z="1.6035458269602596">
<NAME>metrifonate 30-55 mg/day with initial loading</NAME>
<DICH_DATA CI_END="1.448263813705998" CI_START="0.4573676294340799" EFFECT_SIZE="0.8138728323699422" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" LOG_CI_END="0.1608476795413201" LOG_CI_START="-0.33973457618672404" LOG_EFFECT_SIZE="-0.08944344832270198" ORDER="797" O_E="0.0" SE="0.29404449493678236" STUDY_ID="STD-MALT-Study-Group" TOTAL_1="197" TOTAL_2="206" VAR="0.08646216500262742" WEIGHT="45.7625828767216"/>
<DICH_DATA CI_END="4.362472884055763" CI_START="1.2964579222040211" EFFECT_SIZE="2.3781847133757963" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="16" LOG_CI_END="0.639732740519316" LOG_CI_START="0.11275842588658605" LOG_EFFECT_SIZE="0.376245583202951" ORDER="798" O_E="0.0" SE="0.3095473209801934" STUDY_ID="STD-Morris-1998" TOTAL_1="215" TOTAL_2="119" VAR="0.09581954392601486" WEIGHT="26.725225906042734"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.209154260798406" CI_START="0.5548572717956998" DF="0.0" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.34422604284038816" LOG_CI_START="-0.2558187178562811" LOG_EFFECT_SIZE="0.044203662492053486" NO="2" P_CHI2="1.0" P_Z="0.7727570758947728" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="87" WEIGHT="27.512191217235678" Z="0.28877041228924377">
<NAME>metrifonate 50 mg/day fixed dose with no initial loading</NAME>
<DICH_DATA CI_END="2.209154260798406" CI_START="0.5548572717956998" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.34422604284038816" LOG_CI_START="-0.2558187178562811" LOG_EFFECT_SIZE="0.044203662492053486" ORDER="799" O_E="0.0" SE="0.35246926270269285" STUDY_ID="STD-Raskind-1999" TOTAL_1="177" TOTAL_2="87" VAR="0.1242345811501799" WEIGHT="27.512191217235678"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>